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1  Introduction 
 
1.1  Lipoxygenases 
 
Lipoxygenases (LOs) are oxidoreductases which catalyse the conversion of 
polyunsaturated fatty acids to hydroperoxy fatty acids. In mammals, the main substrate 
of LOs is arachidonic acid (20:4) (AA), in plants linoleic (18:2) and linoleinic (18:3) 
acid. To date four human LOs are described, the 5-, 8-, 12-, and 15-LO. The denotation 
indicates the carbon atom of arachidonic acid where molecular oxygen is inserted. Thus, 
5-LO synthesizes 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid 
(5-HpETE) whereas 15-LO produces 15(S)-hydroperoxy-5,8,11,13-eicosatetraenoic 
acid (15-HpETE). Some lipoxygenases are known to convert different substrates or to 
oxydate at varying positions. Their main substrates determine the terms they are given 
(Brash, 1999; Ford-Hutchinson et al., 1994). 
Lipoxydase, a 15-LO, was the first LO to be characerized and was isolated from 
soybean (Theorell, 1947). The first mammalian LO was identified in 1974 in human 
platelets  (Hamberg, 1974). Shortly afterwards the first mammalian 5 -LO was 
discovered in rabbit leukocytes (Borgeat et al., 1976). LOs are widespread in animals, 
including some lower marine organisms, plants and fungi, but are not expressed in 
bacteria and yeast (Brash, 1999). 
 
 
1.2  5-LO protein structure 
 
The molecular mass of the monomeric LOs in mammals and plants was determined as 
75-80 kDa and 94-104 kDa, respectively. 5-LO copy desoxyribonucleic acids (cDNAs) 
have been cloned from human, mouse, rat and hamster and the human cDNA codes for 
a protein with 673 amino acids (aa) and a molecular weight of 77,839 kD (Matsumoto 
et al., 1988). Since no crystal structure for 5-LO is available so far, a model of 5-LO 
based on experimental data and the structure of reticulocyte 15-LO has been proposed 
(Hemak, 2002). 5-LO like other LOs consists of a C-terminal catalytic domain (aa 115-
673) and an N-terminal b-barrel domain (aa 1-114) (Hammarberg et al., 2000; Hemak, 
2002). Ca
2+-binding to the 5 -LO  b-barrel domain mediates nuclear membrane Introduction 
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translocation (Chen and Funk, 2001). The human LOs (5-, 12-, 15-LO) share a 60 % 
sequence similarity (plant LOs: 25 %) (Ford-Hutchinson et al., 1994). All LOs contain a 
characteristical iron centre in which a non-heme, non-sulfur iron is liganded by 
conserved histidine (His) residues and a C-terminal isoleucine (Ile) (Hammarberg et al., 
1995). Two or three possible adenosine triphosphate (ATP) binding sites have been 
proposed  (Hemak, 2002; Zhang et al., 2000), that deviate from typical nucleotide 
binding sites, though. In 5-LO, an src homology SH3 binding motif that interacts with 
the src homology domain of growth factor receptor-bound protein 2 (Grb2) and 
cytoskeletal proteins has been identified (Lepley and Fitzpatrick, 1994). A characteristic 
feature of 5-LO is its temporary nuclear localization. Some putative nuclear localization 
signal (NLS) sequences as determinants for nuclear import have been supposed so far 
(Chen, 1998; Healy, 1999; Jones, 2003; Jones et al., 2002). 
 
 
1.3  The 5-LO enzyme 
 
5-LO catalyzes the two initial steps in the biosynthesis of leukotrienes, the oxygenation 
of arachidonic acid to 5 -HpETE and the further reaction to the allylic epoxide 
leukotriene A 4 (5(S)-6-oxido-7,9,11-trans-14-cis-eicosatetraenoic acid, LTA4)  (Ford-
Hutchinson et al., 1994; Samuelsson, 1983). LTA4 then can be converted into either 
LTB4 or the cysteinyl leukotrienes LTC4, LTD4 and LTE4 (fig. 2, chapter 1.6). 
Isolated LOs are usually in the inactive form, in which the iron in the active site is in the 
ferrous state (Fe
2+). For catalysis, it needs to be restored into the active, ferric form 
(Fe
3+) by r edox reaction with fatty acid hydroperoxides  (Hammarberg et al., 2001; 
Riendeau et al., 1989; Rouzer and Samuelsson, 1986). The exact chemical mechanism 
of the lipoxygenase reaction is not yet clarified but a radical mechanism is supposed (de 
Groot, 1975). 
Several factors stimulating 5-LO enzyme activity have been identified. Ca
2+ binding to 
the b-barrel C2 domain has been shown (Hammarberg et al., 2000) with a stoichiometry 
of binding of two Ca
2+/5-LO (Hammarberg and Rådmark, 1999). Ca
2+ increases the 
hydrophobicity of 5-LO (Hammarberg and Rådmark, 1999) and promotes membrane 
association. Also, translocation to the nuclear envelope is stimulated  (Rouzer and 
Kargman, 1988). Ca
2+ can significantly increase 5 -LO product formation  in vitro Introduction 
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(Hammarberg and Rådmark, 1999). Similar to Ca
2+, but less efficient, Mg
2+ binding to 
5-LO and activation of the enzyme has been demonstrated (Reddy et al., 2000). Another 
well known factor for 5-LO catalytic activity is ATP, for which a binding site was 
identified in 5-LO (Noguchi et al., 1996; Rouzer and Samuelsson, 1985). This binding 
ability is used for 5-LO purification by affinity chromatography using an ATP-agarose 
column (for review, see (Werz, 2002a)). Cellular membrane fractions stabilize purified 
5-LO and upregulate enzyme activity. Synthetic phosphatidylcholine vesicles alone 
could also stimulate 5 -LO activity  (Rouzer and Samuelsson, 1985). As mentioned 
above, activation of resting 5-LO requires oxidation of the ferrous iron in the active site 
to its ferric form. 5 -HpETE, 12-HpETE and 13-hydroperoxyoctadecaenoic acid 
(13-HpODE) have been shown to act as redox partners in this reaction (Rouzer and 
Samuelsson, 1986). Reducing agents, such as glutathione, can inhibit 5-LO activity by 
acting as a substrate and blocking the oxidation of its iron. In intact cells, glutathione 
peroxidases (GPxs) regulate 5 -LO  activity by reducing lipid hydroperoxides 
(Hatzelmann and Ullrich, 1987; Weitzel and Wendel, 1993). 
Fig. 1 . Activation of 5-LO and leukotriene synthesis in the cell 
 
In resting cells 5 -LO is localized in the cytosol or the soluble compartment of the 
nucleus depending on the cell type. Upon stimulation, the enzyme translocates to the 
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nuclear envelope, which seems to be prerequisite for LT synthesis ((Werz, 2002a) and 
references therein). 
Protein phosphorylation is a signal transduction pathway, by which extracellular signals 
lead to the activation and redistribution of a variety of cellular enzymes and 
transcription factors. Several phosphorylation motifs have been identified in the primary 
sequence of human 5-LO for protein kinase A (PKA), protein kinase C (PKC), Ca
2+-
calmodulin-dependent kinase (CaMK II), mitogen-activated protein kinase-activated 
protein kinase (MAPKAPK, MK) -2 and -3, ribosomal S6 kinase, extracellular signal-
regulated kinases1/2 (ERK1/2) and cyclin dependent kinase (Cdk1,Cdc2) (Lepley and 
Fitzpatrick, 1996). Several known stimuli of 5 -LO product formation activate p38 
mitogen-activated protein kinase (MAPK)  (Werz, 2002b) and ERK1/2  (Werz et al., 
2002). Phosphorylation of 5-LO and activation of LT formation by MK2 and ERK1/2 
has been shown in vitro (Werz et al., 2002; Werz, 2002b). 
A current model for 5-LO activation is shown in fig. 1. 
 
 
1.4  Other proteins involved in leukotriene formation 
 
1.4.1  5-Lipoxygenase-activating protein 
5-Lipoxygenase-activating protein (FLAP) is an 18 kDa membrane-bound protein that 
is a member of the membrane-associated proteins in eicosanoid and glutathione 
metabolism (MAPEG) family (Miller et al., 1990). In intact cells, FLAP expression has 
been shown to be prerequisite for LT synthesis upon stimulation with ionophore 
A23187, wheras in cell homogenates FLAP is not required for 5-LO activity (Dixon et 
al., 1990). A model was proposed, suggesting a heteromerization of 5-LO with AA-
binding FLAP and thereby facilitating the utilization of AA by 5-LO (Abramovitz et al., 
1993; Ford-Hutchinson, 1994). The cellular distribution and regulation of 5-LO and 
FLAP appear to be similar (Silverman and Drazen, 1999). 
Recently, a variant of the gene encoding FLAP has been associated to  the pathogenesis 
of myocardial infarction and stroke by increasing LT production and inflammation in 
the arterial wall (Helgadottir et al., 2004). Thus, a role of the 5-lipoxygenase pathway in 
the development of cardiovascular diseases is indicated. 
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1.4.2  Cytosolic phospholipase A2 
A critical parameter for LT synthesis is the availability of the precursor, free AA. The 
key enzyme in the release of AA is the 85 kDa cytosolic Ca
2+-dependent 
phospholipase A2 (cPLA2). The phospholipase A2 superfamily  consists of a broad range 
of enzymes all specifically catalyzing the cleavage of the sn-2 ester bond of substrate 
phospholipids thus yielding free fatty acids and lysophospholipids (Qiu et al., 1998). 
The different PLA2s are classified in three main types according to their molecular and 
biological properties: the secretory (s)PLA2, the cPLA2 and the intracellular Ca
2+-
independent (i)PLA2. cPLA2 contains a C2 Ca
2+-binding domain and requires Ca
2+ for 
translocation to the nuclear membrane. It can be phosphorylated at five different serine 
(Ser) residues (de Carvalho, 1996). Phosphorylation at Ser505 and Ser727 by ERK or 
p38 MAPK, depending on the cell type, is essential for full enzyme activation (Qiu et 
al., 1998). The activation of cPLA2 bears a resemblance to the activation of 5-LO. 
 
1.4.3  Leukotriene A4 hydrolase and leukotriene C4 synthase 
Leukotriene A4 hydrolase is a 69 kDa protein catalyzing the stereospecific hydrolysis of 
the instable epoxide LTA4 to LTB4 (Haeggström, 2002). LTA4 hydrolase is expressed in 
almost all tissues and blood cells. 
LTC4 synthase is a glutathione-S-transferase catalyzing the conversion of LTA4 to 
cysLTs. The 18 kDa membrane protein displays sequence homology to FLAP, both 
belonging to the MAPEG family (Jakobsson et al., 2000). 
 
 
1.5  Proteins related to 5-LO 
 
The 16 kDa coactosin-like protein (CLP) was shown to bind to F-actin filaments and to 
promote actin polymerization by counteracting capping of actin filaments, thus 
displaying profound similarity to coactosin (Rådmark, 2002). Binding of 5-LO to CLP 
has been shown in yeast two-hybrid-system and coimmunoprecipitation experiments. 
5-LO and F -actin compete for CLP binding, and 5 -LO interferes with actin 
polymerization. 5-LO activity is not affected by CLP binding, though (Provost et al., 
2001). 
The 96 kDa transforming growth factor b (TGFb)-receptor-I-associated protein 1 
(TRAP-1) is a cytosolic protein that has been shown to bind to TGFb receptors (TbR). Introduction 
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Controversal studies have been published concerning the primary binding partner for 
TRAP-1. In one publication yeast two-hybrid assays were used to show binding of 
TRAP-1 to only activated T bRI  (Charng et al., 1998). In another study 
immunoprecipitation experiments identified the inactivated T bRII as the primary 
binding partner for TRAP-1 (Wurthner et al., 2001). Also, TRAP-1 has been described 
as Sma and Mad related protein4 (Smad4) chaperone that facilitates interaction of 
Smad4 with Smad2/3 proteins by binding to Smad4 in the vicinity of the activated 
receptor and mediating its transfer to the phosphorylated Smad2/3. Beforehand, the 
activation of  TbRII leads to dissociation of TRAP-1 from the receptor (Wurthner et al., 
2001). Interaction of TRAP-1 with 5-LO has been shown in a yeast two-hybrid system 
(Provost et al., 1999).  However, speculations, that TRAP-1 mediates the effects of 
TGFb on 5-LO activity, have not been confirmed so far. 
In the two-hybrid screening system with 5-LO as bait a novel human protein, containing 
ribonuclease III motifs, a double-stranded ribonucleic acid (RNA)-binding domain and 
helicase motifs, was identified. The C -terminus of this protein shows significant 
homology to a hypothetical helicase from  Caenorrhabditis elegans  (Provost et al., 
1999). Highly homologous proteins of Drosophila (dicers) are involved in RNA 
interference. Thus, dicers cleave long double stranded RNA into 2 1-25-nucleotide 
sequences (small interfering (si) RNAs) which subsequently assemble with protein 
components into an RNA-induced silencing complex (RISC). RISC in turn binds to 
messenger RNA (mRNA) sequences complementary to the siRNAs and digests the 
bound mRNA. The consequent degradation by exonucleases results in gene silencing 
(Provost, 2002). The possible impact of 5-LO in RNA interference is of considerable 
interest, but the relevance of the 5-LO-dicer complex remains to be elucidated. 
A C-terminal proline-rich region enables 5-LO to bind to the SH3 domain of Grb2, an 
"adaptor" protein for tyrosine kinase-mediated cell signalling. This interaction could be 
inhibited by a synthetic peptide containing the SH3-binding motif of 5 -LO. The 
competitor also interfered with translocation of 5-LO from the cytosol to the nucleus in 
intact human neutrophils (Lepley and Fitzpatrick, 1994). Novel functional implications 
of 5-LO in tyrosine kinase signalling are indicated. 
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1.6  Biological functions of 5-LO products 
 
Fig. 2 gives an overview of products derived from the LO pathway. LOs convert the 
substrate AA to hydroxyeicosatetraenoic acids (HETEs) and HpETEs. 12-HETE and 
12-HpETE inhibit platelet aggregation, affect endocrine functions and may be second 
messengers in neurotransmission (Yamamoto et al., 1997). In addition 12-HETE has 
been shown to stimulate leukocyte chemotaxis (Turner, 1975) and to have modulatory 
effects on tumor metastasis  (Tang, 1999). 15-HETE suppresses platelet 12-LO and 
neutrophil 5 -LO  (Vanderhoek, 1980). Specific receptors for HETEs remain to be 
identified. 5-HETE and 12-HETE have been shown to increase cell proliferation in 
various malignant cells (Avis et al., 2001; Ding et al., 1999). Cyclooxigenase-2 (COX2) 
and 5-LO are overexpressed in some cancer cells where 5-LO and FLAP inhibitors 
induce massive and rapid apoptosis  (Ghosh, 1998; Gupta et al., 2001; Öhd, 2000; 
Yoshimura et al., 2004; Yoshimura et al., 2003). 5-HETE has been reported to induce 
anti-apoptotic signals in malignant mesothelial cells (Romano et al., 2001). 
5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE) stimulates chemotaxis, actin 
polymerization and Ca
2+ mobilization in eosinophils and expression of CD11b/CD18 on 
polymorphonuclear leukocyte (PMNL) cell surface (Powell et al., 1999). 
Lipoxins (lipoxygenase interacting products) (LX) are lipid mediators, synthesized from 
12- and 15-HETE or LTA4, serving as a substrate for 5 -LO or 12- and 15-LOs, 
respectively. LXs exhibit anti-inflammatory effects and support repair and wound 
healing (Serhan et al., 1999). 
5-LO further dehydrates its product 5 -HpETE to the unstable epoxide LTA4. In 
subsequent catalytic steps LTA4 is converted to the biologically active LTs B4, C4, D4 
and E 4  (Samuelsson, 1983). LTs convey messages by interacting with specific 
membrane G -protein-coupled leukotriene receptors  (Izumi et al., 2002) and can 
probably regulate transcription by binding to an intranuclear orphan receptor (Devchand 
et al., 1999).  The proinflammatory LTB4 stimulates chemotaxis and secretion of 
neutrophils and the adherence of leukocytes to the endothelium of venules 
(Haeggström, 2002). In addition, phagocyte aggregation, lysosomal enzyme release and 
superoxide formation can be stimulated  (Samuelsson et al., 1987). In lymphocytes, 
LTB4 stimulates the secretion of IgE, IgG and IgM (see (Werz, 2002a) and references 
therein). Thus, a major impact of LTB4 in the pathogenesis of inflammatory diseases, Introduction 
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such as arthritis, psoriasis, inflammatory bowel disease and asthma, is indicated. LTA4 
synthase catalyzes the conjugation of LTA4  with glutathione (GSH), forming the 
cysteinyl leukotriene (cysLT) LTC4. Subsequent extracellular metabolism leads to 
LTD4 and E4 (Funk, 2001). CysLTs lead to smooth muscle contraction, thus promoting 
bronchoconstriction (Samuelsson, 1983). Furthermore, cysLTs increase mucus secretion 
and vascular permeability, causing swelling during acute inflammation. CysLTs have 
also been described to induce hypotension by leading to constriction of arterioles and 
subsequent decrease of coronary blood flow and myocardial contractility (Samuelsson 
et al., 1987). The synthesis and actions of LTs are summarized in figs. 2 and 3. 
 
Fig. 2 . The arachidonic acid cascade with emphasis on 5-LO pathways. 
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Recent data suggest that 5 -LO products play a role in the development of 
atherosclerosis  (Mehrabian and Allayee, 2003) (for further information, see chapter 
1.12). 
In the arachidonic acid cascade 5-LO and COX1-3 are the key enzymes. The effects of 
the COX products prostaglandins, prostacyclins and thromboxanes comprise relaxation 
and contraction of smooth muscle, regulation of platelet activity, effects on the mucus 
layer in gastric mucosa, stimulation or inhibition of neurotransmitter release, 
temperature control, pain and inflammatory responses (Funk, 2001). 
 
 
1.7  Endogenous inhibitors of 5-LO activity 
 
GPxs are selenoproteins involved in the regulation of cellular peroxide levels. Fatty acid 
hydroperoxides, which are generated by the lipoxygenases, serve as redox partners in 
the oxidation of 5-LO active site iron from the ferrous to its active, ferric form (Ford-
Hutchinson et al., 1994; Rouzer and Samuelsson, 1986). Glutathione-dependent 
peroxidase(s) suppress 5-LO activity by reducing lipid hydroperoxides (Straif et al., 
2000). To date the four GPxs, classical cytosolic (c)GPx (GPx-1), gastro-
intestinal (GI-) GPx (GPx-2), plasma (p)GPx (GPx-3), and phospholipid hydroperoxide 
(PH-) GPx (GPx-4) are known. Their substrates are soluble hydroperoxides like H2O2 or 
organic compounds like cumene or fatty acid hydroperoxides or even cholesterol 
hydroperoxides. Beside the predominantly utilized reducing agent GSH, other thiols 
like dithiothreitol (DTT), b-mercaptoethanol, thioredoxin, glutaredoxin or cysteine are 
used as cosubstrates. The four isoforms differ in their primary substrates and 
cosubstrates and their locations (for review on GPxs see (Arthur, 2000)). 
Binding of adenosine to A 2a receptors leads to elevated intracellular cyclo AMP 
(cAMP) levels, which subsequently inhibit AA release. Thus, LTB4 synthesis and 5-LO 
translocation are repressed (Surette et al., 1999). Also, several leukocyte functions like 
superoxide formation, phagocytosis and adherence are inhibited (Flamand et al., 2000; 
Krump et al., 1997). 
Nitric oxide (NO) is a reducing agent that was shown to inactivate LOs by converting 
the active site iron to the ferrous form (Maccarrone et al., 1996). It is involved in the 
regulation of inflammatory processes (Coffey et al., 2000). Introduction 
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1.8  Pharmacological 5-LO inhibitors 
 
The pathophysiological properties of LTs to cause allergic and inflammatory diseases 
gave reason to pharmacological intervention with the biosynthesis or the action of LTs. 
Although glucocorticoids have been shown to inhibit phospholipases and eicosanoid 
formation in many experimental systems, high dose glucocorticoid therapy did not 
significantly suppress generation of LTs  (Claesson and Dahlen, 1999). LT receptor 
antagonists such as montelukast a re established in asthma therapy (for review, see 
(Brooks and Summers, 1996)). Direct 5-LO inhibitors are divided into three groups: 
redox inhibitors, iron ligand inhibitors, and non-redox inhibitors. Redox inhibitors act 
by reducing the active site iron, thus keeping the enzyme in its inactive ferrous form. 
Compounds like nordihydroguaretic acid, caffeic acid, flavonoids, coumarins, AA-861, 
BW755C, or ZM-207968 efficiently inhibit 5-LO. However, unspecificity and severe 
side effects prevented bringing them onto the market (Ford-Hutchinson et al., 1994). 
Iron ligand inhibitors contain a hydroxamic acid or N-hydroxyurea group chelating the 
active-site iron. Zileuton is available in the USA for the treatment of asthma. ABT-761 
and LDP-977 with improved potency and oral half-lives presently undergo clinical 
trials. Non-redox inhibitors with methoxyalkylthiazol or methoxytetrahydropyran 
structures compete with AA for binding at the active site of 5 -LO. They seem to 
potently suppress various acute inflammatory responses but fail t o inhibit chronic 
inflammation (Turner et al., 1996). A low cellular hydroperoxide level promotes  non-
competitive properties of these compounds, whereas high peroxide levels lead to a 
reduced efficacy (Werz et al., 1998). 
3-Acetyl-11-keto boswellic acid (AKBA), the most potent 11-keto-BA was reported as 
the active principle of Boswellia serrata extracts, that have been traditionally used to 
cure inflammatory and arthritic diseases. BAs have been described as direct-type 5-LO 
inhibitors, without reducing or iron-chelating properties, that probably act by binding to 
a second regulatory binding site for AA which is distinct from the catalytic AA-binding 
site  (Sailer et al., 1998). However, recently it has been found, that BAs in 
concentrations £ 10 µM potently enhanced the formation of reactive oxygen species 
(ROS), the release of AA and 5-LO product synthesis in PMNL (Altmann et al., 2004). 
Higher concentrations were required for the anti-inflammatory effects. Introduction 
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New compounds exhibiting dual acitivity towards COX a nd 5 -LO like hyperforin 
(Albert, 2002) or ML3000 have been described. ML3000 entered clinical trials in 
osteoarthritis (Werz, 2002a). 
Also, several FLAP inhibitors like MK886, Bay X1005, MK-0591 have been developed 
and have considerable potency in reducing LT synthesis in isolated neutrophils. 
However, in whole blood, their inhibitory potencies are low and in vivo they have no 
beneficial effect (Werz, 2002a). 
 
 
1.9  The 5-LO gene organization 
 
The human 5-LO gene was first characterized by Funk et al. (Funk, 1989) and Hoshiko 
et al. (Hoshiko, 1990) and has been cloned from bacteriophage and cosmid genomic 
libraries. It is located on chromosome 10q11.21 whereas all other LOs are clustered on 
chromosome 17p13 (Sun, 1998). The structure of the gene has been defined: it spans 
more than 84 kilobasepairs (kbp) and consists of a 6.1 kbp promoter and 14 exons 
divided by 13 introns (Funk, 1989). The sequences of the 5’-untranslated region (UTR), 
the promoter, the coding region and the 3’-UTR have been published some years ago 
(Dixon et al., 1988; Hoshiko, 1990; Matsumoto et al., 1988). Recently, with data from 
the human genome project (HUGO), even the intron sequences have become available. 
According to this data, the intron/exon structure published in (Funk, 1989) has been 
confirmed (fig. 4). 
 
Fig. 4. Intron/exon structure of the 5-LO gene 
 
For most introns the sizes reported by Funk are supported by the HUGO, only the size 
of intron C is significantly smaller (16.254 kbp instead of > 26 kbp) (tab. 1). Probably, 
sequencing is still not complete (18.02.04). Conspiciously, the first introns (A-D) are 
very large, whereas the last introns (H-M) are of minor length. 
1 4 2 3 56 7 89 10-14
A B C D E F G H I J-M
exons
introns
1 4 2 3 56 7 89 10-14
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Tab.1. Exon (numbers) and intron (capitals) sizes reported by (Funk, 1989) and from recent 
data of the human genome project (http://www.ncbi.nlm.nih.gov). 
 
Transcription leads to a 2.7 kb mature mRNA. However, one group reported the 
expression of multiple 5-LO transcripts (2.7, 3.1, 4.8, 6.4, and 8.6 kb) in various brain 
tumors and in the differentiated promyelocytic leukemic HL-60 cells. The use of 
potential minor transcriptional initiation sites or aberrant splicing of the primary 5-LO 
transcript have been hypothesized to account for this observation (Boado et al., 1992). 
Interestingly, in silico analysis revealed that some of the authentic 5’ splice sites differ 
from the consensus vertebrate 5’ splice site (tab. 2). Hence, these splice sites seem to be 
rather weak. Since weak splice sites might establish the possibility for alternative 
splicing reactions, the sequence was further analized for putative cryptic 5’ splice sites. 
As illustrated in figs. 5 and 6, several sequences with at least 85.7 % homology to the 
consensus vertebrate 5’ splice site can be identified on both strands. Most of these are 
found in intronic regions but some are also detected in exons 2, 8, and 10. It is not 
known, if these sites are of any relevance, though. Some of the accurate splice sites 
display a homology of less than 87.5 %, and thus have not been detected in this 
analysis. Moreover, a sequence element displaying high homology (85 %) to a 
Exon/ 
Intron 
bp 
(HUGO) 
 
  Exon/ 
Intron 
bp 
(HUGO) 
  Exon/ 
Intron 
bp 
(HUGO) 
1 
 
217    6  173    11  122 
A 
 
8000 (8053)    F  4000 (3485)    K  200 (190) 
2 
 
199    7  147    12  101 
B 
 
13000 (13173)    G  11000 (11665)    L  300 (287) 
3 
 
82    8  204    13  171 
C 
 
>26000 (16254)    H  1000 (710)    M  1300 (1221) 
4 
 
123    9  87    14  613 
D 
 
12000 (11727)    I  1700 (1607)       
5 
 
107    10  179       
E  800 (812) 
 
  J  200 (198)       
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published purine-rich splicing enhancer (Yeakley et al., 1996) has been identified in 
exon 14. 
 
Intron 
 
5’ splice site (exon  intron) 
A  AGC  GUGGCG 
B  CG  GUGAGC 
C  CG  GUGAGU 
D  AGC  GUAAGU 
E  TG  GUGAGU 
F  AG  GUAGGG 
G  AG  GUAGGC 
H  AG  GUACAG 
I  AG  GUGGGU 
J  AC  GUGAGC 
K  AG  GUAGGG 
L  AG  GUAGGC 
M  AG  GUGAAG 
   
consensus  AG  GURAGU 
 
Tab. 2. Functional 5’ splice sites. The functional 5-LO 5’ splice sites in comparison with the 
consensus vertebrate 5’ splice site (R = A/G). 
 
 
 
 
 
 
 
Fig. 5. Schematic representation of putative 5’ splice sites in the 5-LO coding sequence. Limit 
for detection was at least 85.7 % homology to the consensus vertebrate 5’ splice site 
(G GURAGU; R = A/G). 
Exon 1 2 3 4 5 6 7 8 9 10 11 12 13 14
cryptic 5‘ splice sites ?
Exon 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Exon 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1 2 3 4 5 6 7 8 9 10 11 12 13 14
cryptic 5‘ splice sites ? cryptic 5‘ splice sites ?Introduction 
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Fig. 6.  Schematic representation of putative 5’ splice sites in the 5 -LO gene.  Limit for 
detection was at least 87.5 % homology to the consensus vertebrate 5’ splice site                   
(AG GURAGU; R = A/G). 
 
By sequence analysis multiple putative response elements (REs) can be identified on the 
direct as well as on the complementary strand. A remarkable cluster of consensus and 
nonconsenus serum protein1 (Sp1) binding sites is located in intron B. Also, various 
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putative Smad binding elements (SBEs) are detectable in some introns. In addition, 
several putative responsive elements for the vitamin D receptor (VDR), TGFb, p53, 
Pu.1, early-growth response factor (Egr-1) and nuclear factor of k-light polypeptide 
gene enhancer in B cells (NFkB) can be found throughout the whole coding and intron 
regions. Funk et al. (Funk, 1989) have proposed a putative mRNA processing signal 
(TGTGTTAT), located in the 3’-UTR. Interestingly, three additional identical 
sequences can be identified in intron C. The impact of some of these sequences has 
been investigated in this work. 
Exon 11 represents a region of characteristically high sequence homology between all 
lipoxygenases. Thus, importance of the coded amino acids for protein functions such as 
subcellular localization, enzyme activity and substrate specificity is suggested. 
 
 
1.10 The 5-LO promoter 
 
The human 5-LO gene promoter was first characterized by Hoshiko et al. (Hoshiko, 
1990). It is highly G+C rich and lacks TATAA or CCAAT boxes which is characteristic 
for house-keeping genes. Multiple transcriptional start sites have been reported and the 
major transcriptional start site was found to be located 65 bp upstream of the ATG. 
Deletion analysis revealed a core promoter region, comprising 292 bp upstream of the 
translational start site. By convention, all positions in the 5 -LO gene are given in 
relation to the transcriptional start site. Two important cis-elements have been 
characterized in the promoter region: five overlapping tandem Sp1/Egr-1 consensus-
binding sites (GGGCGG and GCG(T/G)GGGCG, respectively) between  -210 and 
-244 bp and a c-Myb consensus site located between -1840 and -1852 bp (Hoshiko, 
1990; Silverman et al., 1998). The transcription factor Sp1 is required for basal 5-LO 
transcription  (Hoshiko, 1990), whereas the myb protein downregulates 5 -LO gene 
expression and inhibits macrophage differentiation (Habenicht et al., 1989). In reporter 
gene experiments with HeLa and Drosophila SL2 cells it was found that overexpression 
of Sp1 and Egr-1 enhanced reporter gene activity. In SL2 cells, stimulation by Egr-1 
seems to be mediated predominantly via the GC-box, whereas Sp1 transactivation 
mainly utilizes a solitary consensus binding site at -48 bp (Silverman et al., 1998). Egr 
family members are rapidly and transiently induced by a large number of growth Introduction 
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factors, cytokines, and injurious stimuli. Recently, Silverman and Drazen proposed a 
model, in which Egr-1, increased in inflammation, displaces Sp1 from the 5 -LO 
promoter and further enhances transcription by recruiting the transcriptional 
coactivators CREB binding protein (CBP)/p300  (Silverman and Drazen, 2000). In 
addition, Hoshiko et al. have identified two positive regulatory regions between -3635 
and  –5835 bp and from -789 to  -866 bp, and two negative regulatory regions from 
-1492 to -3335 bp and between -227 and -662 bp. 
 
Fig. 7. The 5-LO promoter sequence from –780 to +65 bp with selected responsive elements 
(http://www.ncbi.nlm.nih.gov).  Transcription factor binding sites and response elements 
(putative REs with grey line) within the 5-LO promoter region. The plasmid pN10 comprises 
nucleotides –780 to +53 bp. All positions are defined in relation to the transcriptional start site. 
 -780  GCGCGCGAAA CCTTCTCCAC ACCCTTCCAG GCATTTGCCC GCCGCGATTC 
   
 -730  AGAGAGCCGA CCCGTGACCC CTGGCCTCCC CTAGACAGCC CCGCATGTCC 
   
 -680  AGATGTGCCG TCCCGCCTGC CTCCCGCGAC CACTGGCCAT CTCTGGGCCT 
   
 -630  GGGCGCGGTC TCGGCGCCCG CCTGCCCCCG CCAGGAGCCG CAGGTCCAGC 
   
 -580  CAGTGAAGAA GCCCGCGCTG AAGGAGCCTC TGTGCTCCAG AATCCATCCT 
   
 -530  CAGTATCAGC GCTGGGGTGG CCTCCTCCAG GAAGCCCTTC TGATTCTCTC 
   
 -480  ATGGGTCGCT CTTCCTCTGC AGACTCCCGG AGCACCCCTG CTCCAAGTAC 
   
 -430  CGCAAGTGGC ACTGAGAACT TGGGGAGAGC AGAGGCTGTG CCTAGATTTG 
   
 -380  TAGGGAGTCC CCGCAGCTCC ACCCCAGGGC CTACAGGAGC CTGGCCTTGG 
   
 -330  GCGAAGCCGA GGCAGGCAGG CAGGGCAAAG GGTGGAAGCA ATTCAGGAGA 
   
 -280  GAACGAGTGA ACGAATGGAT GAGGGGTGGC AGCCGAGGTT GCCCCAGTCC 
   
 -230  CCTGGCTGCA GGAACAGACA CCTCGCTGAG GAGAGACCCA GGAGCGAGGC 
   
 -180  CCCTGCCCCG CCCGAGGCGA GGTCCCGCCC AGTCGGCGCC GCGTGAAGAG 
   
 -130  TGGGAGAGAA GTACTGCGGG GGCGGGGGCG GGGGCGGGGG CGGGGGCGGG 
   
  -80  GGCAGCCGGG AGCCTGGAGC CAGACCGGGG CGGGGCCGGG ACCGGGGCCA 
   
  -30  GGGACCAGTG GTGGGAGGAG GCTGCGGCGC TAGATGCGGA CACCTGGACC 
   
  +21  GCCGCGCCGA GGCTCCCGGC GCTCGCTGCT CCCGCGGCCC GCGCCATG 
     
   
 
transcription initiation site 
REP III 
REP II 
REP IV  REP V 
REP VI 
inverted repeat 
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Moreover, the promoter contains numerous consensus-binding sites for transcription 
factors such as NFkB (involved in macrophage differentiation), glucocorticoid receptors 
(GRs), GATA, activating protein-2 (AP-2) and AP-1 family members. Six repeated 
sequences (REP I -VI) weakly homologous to the silencer regions I and II of the 
e-globin gene and the chicken lysozyme gene have been found from –850 to –130 bp. 
Important gene regulatory sequences are often conserved across species. Interestingly, 
5-LO and the rabbit erythroid cell-specific 15-LO show an identical intron/exon 
organization and both gene promoters are G+C-rich and contain GC boxes (O'Prey et 
al., 1989). 
Recently, the mouse 5-LO promoter has been cloned and analysed (Silverman et al., 
2002). The human and mouse promoter sequences differ dramatically, although, there 
are some  significant similarities. Both sequences lack TATAA motifs, transcription 
factor IIB (TFIIB) recognition elements, initiator sequences, and downstream core 
promoter elements. Both promoters have multiple transcriptional start sites and a major 
start site i n similar regions. Also, the core promoter regions are of similar size 
(~300 bp). Finally, three highly homologous regions containing consensus-binding sites 
for transcription factors implicated in 5 -LO regulation or leukocyte-specific gene 
expression (Sp1/Sp3, Ets/Pu.1/Spi-1, and GATA/GGAGA) have been detected. Binding 
to the indicated GC boxes of the human and mouse promoters and response to 
overexpression has been demonstrated for Sp1/Egr-1 and Sp1/Sp3, respectively 
(Hoshiko, 1990; Silverman et al., 2002). Sp1 is a transcriptional activator, whereas Sp3 
is regarded as a suppressor of Sp1-mediated transcription (for review, see  (Suske, 
1999)). Binding of Pu.1 to the consensus-binding motif (GGAA/T) has been shown by 
electrophoretic mobility shift assays (EMSAs)  (Silverman et al., 2002). The 
transcription factor Pu.1 is primarily expressed in hematopoietic cells and has been 
shown to regulate the expression of a variety of genes involved in inflammation, 
adaptive and innate immunity, and cell differentiation and proliferation. Thus, the 
conserved binding site may play a role in tissue-specific expression of 5-LO (Silverman 
et al., 2002). Although conserved in human and mouse, no binding of the transcription 
factors GATA/GGAGA to the respective consensus binding sites has been 
demonstrated so far (Silverman et al., 2002). 
Furthermore, sequence analysis using consensus binding sites from databases and from 
the literature, reveals the existence of several putative REs for the nuclear receptors Introduction 
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(NRs) VDR, retinoid Z receptor a (RZRa) as well as the retinoic acid related orphan 
receptor  a (RORa), TGFb, Smads, AP-2, ATF-2, retinoblastoma control element 
(RBCE), hFast-1, Oct-1 and p53. In the 5-LO core promoter region, a binding site for 
VDR has been proposed previously (Carlberg, 1995). Binding of RORa1 and RZRa to 
a putative RZR RE in the 5-LO promoter (-1448 bp) has been demonstrated before, thus 
identifying human 5-LO as the first natural responding gene for RZRa. Also, 5-LO 
promoter activity has been shown to be repressed by the pineal gland hormone 
melatonin, the ligand for RZRa. The NRs RZRa and RORa are expressed in B 
lymphocytes, but not in granulocytes (Steinhilber et al., 1995). 
 
 
1.11 5-LO promoter polymorphisms 
 
A series of naturally occurring mutations in the 5-LO core promoter has been found, 
resulting in a variable number of two to eight Sp1/Sp3/Egr-1 consensus sites in the GC-
box  (Drazen and Silverman, 1999; Dwyer et al., 2004; In et al., 1997). Slight 
differences in Sp1/Sp3/Egr-1 binding affinity have been detected and promoter response 
of the mutant forms to transcription factor overexpression was significantly altered (In 
et al., 1997; Silverman et al., 1998). Interestingly, reporter gene assays in HeLa cells 
suggested, that every mutation decreases promoter activity, whereas experiments in 
Schneider Cells, which do not naturally express Sp1 or Egr-1, indicated, that promoter 
activity is proportional to the number of Sp1/Egr-1 binding sites  (Silverman and 
Drazen, 2000). The polymorphisms are of particular interest, as asthma patients with 
sequence variants in the 5-LO gene promoter show a diminished response to treatment 
with 5-LO inhibitors (Drazen et al., 1999). Genotyping data and genetic association 
analyses performed for a Caucasian population indicated, that these polymorphisms do 
not constitute a genetic risk factor for the development of asthma, though (Sayers et al., 
2003). 
Very recently, the 5-LO promoter polymorphisms have been related to atherosclerosis 
susceptibility. In carriers of two variant 5-LO promoter alleles a profound increase in 
carotid intima-media thickness as compared to carriers of the wild type allele was 
detected. Moreover, the increased dietary intake of n-6 fatty acids enhanced the severity 
of atherosclerosis of carriers of two variant alleles, whereas the increased intake of Introduction 
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n-3 fatty acids blunted the atherogenic effect of the variant genotypes (Dwyer et al., 
2004).  These results are consistent with data obtained with 5-LO null mice, which were 
resistant to atherosclerosis (Mehrabian, 2002) and with the fact, that 5-LO is abundantly 
present in macrophages, foam cells, dendritic cells, and artery wall cells from 
atherosclerotic lesions (Spanbroek et al., 2003). Taken together, LT-mediated vascular 
inflammation in atherosclerosis is strongly suggested. However, the above mentioned 
reduced 5-LO gene expression of all naturally occuring mutants (Drazen and Silverman, 
1999; Drazen et al., 1999; In et al., 1997; Silverman and Drazen, 2000) does not support 
this hypothesis, although nonhuman cells (Schneider) and tumor cells that do not 
express 5 -LO (HeLa) might not be the right system for investigations on vascular 
inflammation. 
Recently, it was hypothesized, that the decreased expression of 5-LO in the brain of 
carriers of variant promoter genotypes leads to reduced susceptibility and delayed onset 
of Alzheimer’s disease (Manev, 2000). Aging has been reported to be associated with 
induced 5-LO gene expression in the brain and neuroprotection could be obtained by 
inhibition of the 5-LO pathway. Hence, a role of neuronal 5-LO in neurodegeneration is 
suggested and antiinflammatory treatment is likely to exert beneficial effects in aging-
associated neurodegenerative diseases such as Alzheimer’s (Manev et al., 2000). 
 
 
1.12 5-LO gene expression 
 
1.12.1  Cell type specificity 
5-LO is mainly expressed in immune competent cells from myeloid origin including 
granulocytes, monocytes and macrophages, mast cells and B-lymphocytes (Steinhilber, 
1999). Also, it is found in dendritic cells (Steinhilber, 1999) and epidermal Langerhans 
cells (Spanbroek et al., 1998). 5-LO expression often coincides with FLAP expression. 
Although T-cells express FLAP, they are negative for 5-LO. Interestingly, both, 5-LO 
and FLAP have been found in a number of non-hematopoetic cell types like 
differentiated human skin keratinocytes (Janssen-Timmen et al., 1995) and in neurons in 
various regions of the rat brain (Lammers et al., 1996). 
The mechanisms involved in the cell type specific 5-LO upregulation in response to 
differentiation signals and inflammatory stimuli have not been  clarified yet. In the Introduction 
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human myeloid cell lines Mono Mac 6 (MM6) and HL-60, differentiation with 
1,25-dihydroxyvitamin D 3 (1,25(OH)2D3) and TGFb leads to a significant increase in 
5-LO gene expression and activity (Brungs et al., 1994; Brungs et al., 1995; Janssen-
Timmen et al., 1995). In contrast, U937 cells and HL-60TB cells express FLAP but not 
5-LO (Claesson et al., 1993; Kargman et al., 1993). Silencing of tissue-specific genes is 
often due to strong methylation of their promoters and has been proved to be true for 
5-LO  (Chan et al., 2000; Uhl et al., 2002) (for more details, see chapter 1.12.2). 
Speculations about the impact of Pu.1 binding to its binding site in the 5-LO promoter 
in tissue-specific expression have already been mentioned in chapter 1.10 (Silverman et 
al., 2002). 
 
1.12.2  Epigenetic mechanisms 
Beside transcriptional and posttranscriptional modulation, epigenetic mechanisms are 
known to be involved in the regulation of gene expression. Epigenetic mechanisms are 
not related to genetic information encoded by the genetic code but refer to epigenetic, 
extrakaryotic information. 
 
Fig. 8 . Chromatin organization. 
(from http://www.accessexcellence.org). 
In eukaryotes, DNA t ypically is arranged  in 
vivo as a repeating array of nucleosomes, in 
which 146 bp of DNA are wound around a 
histone (H) octamer. The histone octamer 
consists of an (H3, H4)2 tetramer and two 
dimers of (H2A, H2B). Extended chains of 
nucleosomes are compacted to form a 
chromatin fiber which in turn is folded into a 
chromosome (fig. 8). The nucleosomal 
organization of DNA seems to be prerequisite 
for functional synergism by enabling a 
coordinate binding of transactivating factors to 
otherwise distant sites  (Beato et al., 1996). 
Chromatin can be divided into the decondensed, transcriptionally active euchromatin 
and the condensed, transcriptionally silent heterochromatin. Chromatin organization is Introduction 
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critical for many cellular processes such as transcription, replication, repair, 
recombination and chromosome segregation. The assembly of a gene into chromatin 
generally represses transcription. ATP-utilizing chromatin remodeling factors facilitate 
the binding and function of key components of the transcriptional apparatus by 
disruption and subsequent re-formation of histone-DNA contacts. Chromatin 
remodeling factors comprise ATPases from the SWI/SNF (mating type switch/sucrose 
non-fermenter), Mi-2/CHD and ISWI (imitation switch) family (Tyler and Kadonaga, 
1999). The human homologs of components of the yeast SWI/SNF complex, human 
brahma (hbrm) and brahma related product 1 (BRG1), have been shown to interact with 
other factors of the transcriptional machinery including the GR and estrogen receptor 
(ER) in transient cotransfection assays. Posttranslational, covalent modifications of the 
histone tails, the so-called histone code, lead to dynamic changes in the chromatin 
structure due to altered interactions with DNA or chromatin-associated proteins. 
Histone modifications include acetylation of lysines, phosphorylation of serines and 
threonines, poly(ADP-ribosylation) of glutamic acids, ubiquitination of lysines, 
sumolation of lysines and methylation of lysines and arginines (Khorasanizadeh, 2004; 
Rice and Allis, 2001; Wolffe and Guschin, 2000). 
 
Histone acetylation is a very dynamic, reversible process, that is regulated by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). Although at low level 
rather global, acetylation of the core histones occurs locally on target promoters at 
specific lysines in particular histones. Acetylated N-terminal histone tails bind DNA 
and other histones with reduced affinity, thus leading to less tightly wrapped 
nucleosomes. This effect might be enhanced by other chromatin remodelling factors or 
components of the transcriptional machinery. Hence, access and binding of transcription 
factors to their recognition sites is facilitated and transcription is activated (Wolffe and 
Guschin, 2000). Moreover, histone acetylation specifically can regulate DNA 
replication, histone deposition, and DNA repair by recruiting regulatory proteins that 
contain an acetyllysine binding bromodomain (Khorasanizadeh, 2004). 
HATs are widely spread and can be found among proteins with other known functions 
in trancription, such as transcription initiation factors (e.g. TFIIIC), transcript 
elongation factors (e.g. Elp3), general transcription factors (e.g. TATA-binding protein 
(TBP)-associated factor (TAFII250)), coactivators (e.g. p300/CBP, p300/CBP-
associated factor (PCAF)) and NR coactivators (e.g. steroid receptor coactivator-1 Introduction 
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(SRC-1)/NCoA1, ACTR). Multiple interactions between HATs and regulatory proteins, 
the transcription apparatus and/or other HATs modulate their influence on transcription. 
HATs transfer an acetyl group from acetyl-coenzyme A to the e-amino group of the 
lysine (Sterner and Berger, 2000). Several nuclear HATs contain a bromodomain, thus 
they bind to already acetylated lysines. 
HDACs as well as HATs occur in multi-protein complexes, and among these proteins 
are those that regulate substrate specificity and others functioning in recruitment, 
corepression or chromatin remodeling. To date, 13 classical HDAC are known and can 
be divided into the phylogenetic classes I and II. HDAC function seems to be regulated 
by its intrinsic features, abundance, cellular compartmentalization and association with 
cofactors. Beside an essential Zn
2+ ion, other cofactors are required for HDAC activity, 
including histone binding proteins, recruiters (e.g. Sp1/3, NFkB, methyl-CpG-binding 
protein (MeCP2), GATA-2, other HDACs), nuclear hormone receptor binding proteins 
(e.g. NCoR, silencing mediator for retinoic acid and thyroid hormone receptors 
(SMRT)), chromatin remodeling factors (e.g. Mi-2) and others (Ballestar and Wolffe, 
2001; de Ruijter et al., 2003). 
Inhibition of HDACs by compounds such as trichostatin A (TsA), trapoxin, valproate or 
butyrate by displacing the Zn
2+ ion and/or blocking access to the active site leads to a 
general hyperacetylation of histones, which is followed by transcriptional activation. 
Since histone hypoacetylation has been linked to the pathogenesis of certain types of 
cancer, HDAC inhibitors (HDACis) have great potential for the treatment of malignant 
disease. Some HDACis entered clinical trials. Recently, HDACis have been suggested 
to prevent oxidative neuronal death and may t herefore be useful in the therapy of 
neurological diseases like Parkinson’s disease and stroke (Ryu et al., 2003). Increased 
histone acetylation is suggested to lead to re-expression of silenced genes and/or the 
silencing of downstream genes due to the regained acess of their promoters to other 
regulatory factors. General effects of HDAC inhibition are apoptosis, necrosis, 
differentiation, inhibition of proliferation and cytostasis. Interestingly, Sp1 sites in the 
promoter seem to be essential for full efficiency of HDACis. Possible explanations are 
the ability of Sp1 to bind HDAC1/2 and to protect DNA against methylation (Choi et 
al., 2002; de Ruijter et al., 2003; Doetzlhofer et al., 1999; Jung, 2001; Nakano et al., 
1997). 
Hormone receptors recognize their REs in chromatin, while the access of many other 
transcription factors to promoters is hindered by its nucleosomal organization. Introduction 
24 
Unliganded nuclear hormone receptors such as the thyroid hormone and retinoic acid 
receptor  (RAR)  have been shown to bind the nuclear corepressor (NCoR) which 
interacts with the transcriptionally repressive Sin3 (SWI independent) and recruits 
HDAC. Binding of the ligand to the chromatin-bound receptor leads to recruiting of 
coactivators and displacement or rearrangement of the nucleosome and enables free 
access of transcription factors to their binding sites (Beato et al., 1996; Wolffe and 
Guschin, 2000). In consensus with these reports, hormone treatment led to increased 
histone acetylation and selective changes in the chromatin structure in the promoters of 
ER, GR, RAR and VDR target genes (Chen et al., 1999; Shen et al., 2002). Further 
more, HDACis have been shown to synergistically enhance cell differentiation by 
1,25(OH)2D3  (Gaschott et al., 2001; Kosugi et al., 1999) and the VDR has been 
identified as mediator of butyrate-induced differentiation (Gaschott et al., 2001). 
An involvement of chromatin structure and histone acetylation in the regulation of 5-LO 
expression has been discussed for some time. In HL-60  cells, differentiation with 
dimethyl sulfoxide (DMSO) led to changes of the repressive chromatin conformation 
alongside with transcriptional activation of the 5-LO gene (Ponton et al., 1996). Also, 
15-LO-1 mRNA expression and 5-LO mRNA and protein expression are induced in 
Caco-2 cells following butyrate-induced cell differentiation  (Kamitani et al., 2000; 
Wächtershäuser et al., 2000).  The underlying mechanism, possibly being histone 
acetylation, has not been investigated in these studies, though. Recently, valproate has 
been reported to significantly increase histone acetylation and 5 -LO protein in the 
mouse hippocampus,  in vivo  (Yildirim et al., 2003). For further information, see 
paper IV/chapter 4.5. 
 
Methylation of cytosines within the CpG dinucleotide is the most prevalent epigenetic 
modification of DNA in mammalian genomes. In vertebrates, the genomes of somatic 
cells are globally methylated. However, discrete regions, including most repetitive and 
parasitic DNA, are hypermethylated, whereas the GC-rich CpG islands are 
hypomethylated. CpG islands contain promoters and binding sites for proteins involved 
in transcription and are typically found in house-keeping genes and widely expressed 
genes. Both methylated and unmethylated DNA is assembled into nucleosomes. 
Methylated DNA is generally associated with transcriptionally silent heterochromatin. 
DNA methylation is involved in many processes such as transcription, chromatin 
structure modulation, genomic stability, differentiation, genomic imprinting, Introduction 
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X chromosome inactivation, ageing and the silencing of parasitic DNA elements. DNA 
methylation outside of promoter regions probably contributes to the silencing of cryptic 
transcriptional start sites. Aberrant DNA methylation patterns play a role in the 
pathogenesis of diseases like cancer, ICF (immunodeficiency, centromere instability, 
facial anomalies), Rett, ATRX (X-linked, a-thalassemia mental retardation) and Fragile 
X syndromes (Leonhardt and Cardoso, 2000; Robertson, 2002). 
(Cytosine-5) DNA methyltransferases (DNMTs) catalyze the transfer of a methyl group 
from S-adenosylmethionine (SAM) to the 5’ position of cytosine. Currently, the five 
mammalian DNMTs DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L are 
known but only DNMT1, DNMT3A and DNMT3B have been shown to be catalytically 
active. Due to its preference for hemimethylated double-strand DNA, DNMT1 is 
commonly termed maintenance methyltransferase. It is suggested, that DNMT1 is 
required to maintain methylation patterns following replication and for genomic 
imprinting and X chromosome inactivation. Targeted disruption of the DNMT1 gene 
indicated the contribution of other methyltransferases to the homeostasis of DNA 
methylation patterns, though. Alternative splice variants of DNMT1 have been reported 
that might exert tissue-specific roles. DNMT3A and DNMT3B are capable of 
methylating unmethylated and hemimethylated DNA in vitro. Since they are essential 
for  de novo methylation  in vivo, they are usually referred to as  de novo 
methyltransferases. They presumably have independent, but overlapping functions in 
the establishment of cellular DNA methylation patterns during embryonic development. 
Several DNMT inhibitors are known, including 5 -azacytidine (AC), 5 -aza-2’-
deoxycytidine (AdC), S -adenosylhomocysteine (SAH), dibutyryl-cyclo-AMP 
(dbcAMP) and sodiumarsenite (Attwood et al., 2002; Robertson, 2002). 
Since DNMTs do not seem to have any sequence specificity, other mechanisms must 
exist to target DNA methylation to certain DNA sequences. Several different proteins 
have been reported to interact with the catalytically active DNMTs. Among these 
proteins are chromatin remodeling enzymes (SNF2-like proteins), histone deacetylases 
(HDAC1/2), the presumably catalytically inactive DNMT3L, methyl-CpG binding 
proteins (MBD2/3), proliferating cell nuclear antigen (PCNA), a transcription 
elongation factor (E2F1), a trancriptional repressor (RP58), corepressors (DNMT1-
associated protein (DMAPI), TSG101), an oncogenic transcription factor (PML-RAR 
fusion protein) and a tumor suppressor (retinoblastoma protein (pRb)). Methylcytosine 
binding proteins are components of macromolecular repressor complexes like MeCP1 Introduction 
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and Mi-2/nucleosome remodeling histone deacetylase complex (NuRD), which can 
preferentially bind, remodel, and deacetylate methylated DNA-containing nucleosomes 
in vitro. Thus, chromatin remodeling, histone acetylation (and possibly other histone 
modifications), DNA methylation and transcription are tightly connected. In fig. 9 a 
proposed model depicts the reliance of these activities on each other. 
 
Fig. 9. Model for how HDACs, ATP-dependent chromatin remodeling enzymes, and DNA 
methyltransferases may cooperate to set up region-specific DNA methylation patterns. The 
histones within a transcribed or transcriptionally competent region destined for silencing (top) 
may first be deacetylated (and potentially methylated) and this likely initiates transcriptional 
silencing. The chromatin remodeler can now recognize the chromatin and mobilize 
nucleosomes in an ATP-dependent manner to allow the DNMT access to its target DNA sites or 
create a particular chromatin signature or 'epitope' that is recognized by the DNMT or DNMT-
containing complex. Once the region is methylated, the methylated cytosines will recruit methyl-
CpG binding proteins (MBD) and their associated co-repressors to further reinforce 
transcriptional silencing and chromatin compaction (Robertson, 2002). 
 
Histone deacetylation of a transcriptionally active region may lead to transcriptional 
shutdown and enables chromatin remodeling enzymes to bind and modulate chromatin 
structure, which in turn facilitates either the access of DNMTs to the nuclesosomal 
DNA or the recognition of the region by DNMTs. Methylated CG dinucleotides may 
directly interfere with the binding of transcription factors to their binding sites. The 
gene silencing exhibited by DNA methylation is further reinforced by the recruitment of Introduction 
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competing methylcytosine binding proteins and their associated repressive activities. 
This model is supported by the fact that the HDACi TsA leads to cytosine 
hypomethylation at specific sequences. CpG islands are thought to be protected from 
methylation through binding of Sp1 to sites in or near these regions of DNA, and also 
through the action of an embryo-specific factor (Attwood et al., 2002; Ballestar and 
Wolffe, 2001; Newell-Price et al., 2000; Richards and Elgin, 2002; Robertson, 2002). 
 
5-LO gene expression has been shown to be regulated by DNA methylation. The 5-LO 
promoter was heavily methylated in the 5-LO-negative myeloid cell lines U937 and 
HL-60TB, whereas it was completely unmethylated in the 5 -LO-positive cell line 
HL-60. Furthermore, reporter gene assays with a 5-LO promoter plasmid revealed an 
almost complete loss of transcriptional activity by methylation of the GC-rich core 
region by  SssI methylase. Treatment of U937 and HL-60TB cells with the DNMT 
inhibitor AdC led to a prominent promoter hypomethylation and a correlating induction 
of 5-LO pre-mRNA and mature mRNA (Uhl et al., 2002). Further, it was found that 
incubation of rat cerebellar neurons with AdC or valproate induced 5-LO mRNA. Both 
agents have also been reported to induce 5 -LO mRNA and to decrease DNA 
methylation in human NT2 and NT2-N cells. It can be speculated, that aging-altered 
DNA-methylation may cause aging-associated 5-LO upregulation in the brain (Manev 
and Uz, 2002; Zhang et al., 2004). 
 
1.12.3  Gene regulation by 1,25(OH)2D3 
The nuclear hormone vitamin D is a major component in the maintenance of calcium 
and phosphate homeostasis, bone formation, small lipophilic compound metabolism, 
and cellular growth. Further, the hormone can induce growth inhibition, differentiation 
and apoptosis of a number of cell types and also has immune-suppressive effects. 
Vitamin D3 (cholecalciferol) can either be derived from dietary sources or synthesized 
in the skin from 7-dehydrocholesterol by exposure to ultraviolet light. The functionally 
active compound, the seco-steroid 1,25(OH)2D3 (calcitriol), is generated by 
25-hydroxylation in the liver and subsequent 1a-hydroxylation in the kidney. Like other 
nuclear hormones, 1,25(OH)2D3 is a lipophilic compound that easily passes biological 
membranes and enters the nucleus. Most of the known biological effects of  
1,25(OH)2D3 are “genomic” effects that are mediated through specific and high affinity 
binding to its NR VDR. Also, rapid, “non-genomic” actions of 1,25(OH)2D3 are known Introduction 
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that have been suggested to be mediated via putative membrane receptors. They have 
been reported to involve activation of Ca
2+ channels, G-protein coupled receptors, and 
downstream PKC and MAPK pathways (Carlberg and Polly, 1998; Issa et al., 1998). 
Most primary 1,25(OH)2D3 target genes are involved in calcium endocrinology or bone 
formation such as osteocalcin, osteopontin, human parathyroid hormone (PTH), CYP24 
(cytochrome P450, subfamily XXIV, vitamin D 24-hydroxylase), CYP1a, and the 
calbindin genes. However, VDREs have also been identified in other genes like 5-LO, 
b3 integrin, fibronectin, atrial natriuretic factor (ANF), tumor necrosis factor a (TNFa), 
c-fos or p21
WAF1/CIP1. 
The 52-60 kD protein VDR is a member of the NR superfamily of transcription factors. 
According to amino acid sequence homology and RE preference, the VDR can be 
classified together with the T3R and RAR into the second subclass of this family. The 
first subclass contains the steroid hormone receptors ER, progesterone receptor (PR), 
GR, mineralocorticoid receptor (MR), and androgen receptor (AR). Orphan receptors, 
for which no ligand was known at the time of their discovery, form the third subclass of 
the NR superfamily. According to their function, VDR, RAR, T3R, ER, PR, AR, GR, 
and MR form the classical endocrine receptor subgroup of the NR superfamily. The 
ligand-bound VDR predominantly resides within the nucleus, but substantial amounts of 
unoccupied receptor have been detected in the cytoplasm (Carlberg and Polly, 1998; 
Issa et al., 1998). 
Recently, the three-dimensional structure of the VDR has been solved (Rochel et al., 
2000). For a schematic representation, see fig. 10. Like other NRs it is characterized by 
an N-terminal DNA-binding domain (DBD) and a C-terminal ligand-binding domain 
(LBD). The LBD contributes to ligand binding, dimerization, nuclear import signalling, 
interaction with the transcriptional machinery, and transcriptional activation/inhibition. 
It contains 12  a-helices and two  b-sheets and at least three different dimerization 
interfaces. Ligand binding modifies the orientation of helix 12 containing the activation 
function-2 (AF-2) domain which results in the closing of the ligand binding pocket 
(“mouse trap model”) and the formation of a new binding interface by helices 3, 5, and 
12 that allows interaction with transcriptional cofactor proteins. The AF-2 domain is 
essential for effective receptor-ligand interaction. Corepressors have been suggested to 
interact with regions within helices 1, 10, and 11. The DBD is characterized by two zinc 
fingers, formed by two zinc atoms that are coordinated by eight conserved cysteine Introduction 
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residues. Further, it contains several positively charged amino acids, favouring 
electrostatic interactions with the DNA backbone and two nuclear import regions. The 
hinge region D between DBD and LBD confers flexibility to the protein. Unlike other 
NRs, the VDR lacks a ligand-independent AF-1 motif in its aminoterminal A/B domain. 
Hormone dependent phosphorylation at distinct serine residues has been reported for 
VDR and might be involved in the regulation of DNA binding, ligand binding, nuclear 
localization and gene transactivation (Issa et al., 1998; Polly et al., 2000; Quack and 
Carlberg, 2000; Rachez and Freedman, 2000). 
 
Fig. 10. Modular structure of the VDR. The DNA binding domain (DBD, C) contains two 
potential nuclear transfer signals (N1 and N2). The ligand binding domain (LBD, E) contains 
three putative heterodimerization interfaces (E1, E2, and E3). A TFIIB interface is also 
indicated. The 12 a-helices and 2 b-sheets of the LBD are shown above as tubes and arrows, 
respectively (adapted from (Issa et al., 1998)). 
 
Transcriptional transactivation by a ligand-activated nuclear hormone receptor requires 
the close proximity to the basal transcription machinery, which is achieved through 
specific binding to REs. Thus, primary 1,25(OH)2D3 responding genes contain within 
their promoter region a VDRE. Since VDR monomer affinity to VDREs is rather weak, 
efficient DNA binding requires homo- and/or heterodimerization with an accessory 
partner receptor, being predominantly RXR. In fact, many NRs heterodimerize with 
RXR. In these various heterodimeric complexes, RXR seems to assume different 
conformations and displays an altered sensitivity to its ligand 9-cis retinoic acid (RA). 
VDR-RXR, similarly to T3R-RXR and RAR-RXR, cannot be activated by 9-cis RA to a 
large extent, unless it is already stimulated by 1,25(OH)2D3. The synergistic action 
between VDR and RXR appears to depend on sufficient amounts of RXR, since 
otherwise other competing, RXR interacting receptors can lead to transrepressive 
effects. Moreover, at limiting concentrations of RXR, 9 -cis RA mediates the 
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dissociation of heterodimer complexes and induces homodimerization, thus leading to a 
squelching effect. The VDR bound to a specific VDRE exibits distinct preferences for 
particular RXR isoforms, which influences the positive response to 1,25(OH)2D3 
(Carlberg and Polly, 1998; Carlberg and Saurat, 1996; Thompson et al., 1999). 
Simple REs for a dimerizing NR, like the VDR, are formed by two hexameric core 
binding motifs that are arranged as a direct repeat (DR), a palindrome or an inverted 
palindrome (IP). The VDR consensus core binding motif has the sequence RGKTCA (R 
= A/G, K = G/T). Nevertheless, several natural VDREs carry a rather degenerated 
motif, such as the VDRE identified in the human 5-LO promoter (AGGGCA AAG 
GGTGGA). These class II elements are generally weaker than the perfect or reasonable 
class I VDREs when isolated from their natural promoter context. According to the 
“3-4-5 rule” proposed by Umesono et al, optimal VDREs are direct repeats spaced by 
three nucleotides (DR3)  (Umesono et al., 1991) and the majority of the naturally 
occurring VDREs that have been identified so f ar, are DR3-type elements. VDR 
heterodimers have been shown to adopt a predefined polarity on VDREs. Since the 
receptor, which is in the 3’ position is more easily activated (at lower ligand 
concentrations), the heterodimerization confers a polarity-directed ligand sensitivity. 
The polarity of binding and the optimal distance of core binding motifs are based on the 
spacing requirements of the DBDs and the location of their dimerization interfaces. 
Binding of the first ligand presumably leads to conformational changes in both 
heterodimeric partners and thereby increases the sensitivity to the second ligand, which 
is termed allosteric synergistic ligand interaction. Beside the simple VDREs, several 
natural VDREs are complex VDREs that are composed of more than two core binding 
motifs and/or overlap with binding sites for other transcription factors like AP-1, TBP, 
cAMP-regulated enhancer-binding protein (CREB) or CTF/NF-1  (Carlberg, 1996; 
Carlberg, 2003). 
The VDR has been shown to interact with various compounds of the transcriptional 
machinery. Many coactivators contain three copies of a homologous LXXLL motif 
through which they bind to the AF-2 domains and a lysine residue in helix 3 of the 
LBDs of DNA-bound NRs. They enhance ligand-dependent transcriptional activation 
(fig. 11). The main members of the NR coactivator gene family SRC/p160 
SRC-1/NCoA-1, transcriptional intermediary factor (TIF2)/ GRIP1/ SRC-2/ NCoA-2, 
and receptor associated coactivator 3 (RAC3)/ ACTR/ p300/CBP integrator protein 
(PCIP)/ SRC-3 appear to be interacting with many NRs and binding to the VDR has Introduction 
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already been experimentally proven. In  glutathione S -transferase ( GST) pull-down 
assays VDR did not display any coactivator selectivity (Carlberg, 2003; Carlberg and 
Polly, 1998; Freedman, 1999; Issa et al., 1998; Jones et al., 1998; Rachez and 
Freedman, 2000). 
Further, the corepressor proteins NCoR, RIP13D1, SMRT and Alien can interact with 
VDR and mediate ligand-independent transrepression (fig. 11). NCoR has been shown 
to bind to the hinge region of RAR and T 3R. In COS-1 and yeast cells binding of 
unliganded VDR-RXR heterodimers to rat CYP24 VDREs exerts transcriptional 
repression via interaction with the corepressor RIP13D1, whereas ligand activation leads 
to dissociation of the corepressor and binding of a coactivator. VDR-RXR-Alien 
complexes mediate repression only through DR3-type VDREs and not through IP9-type 
VDREs (Carlberg, 2003; Carlberg and Polly, 1998; Jones et al., 1998; Polly et al., 2000; 
Rachez and Freedman, 2000). 
The third category within the cofactor group are the cointegrator proteins such as 
CBP/p300. They can cooperate with NRs, coactivators, corepressors, and the 
preinitiation complex, thus forming larger coactivator complexes (fig. 11). As already 
mentioned in chapter 1.12.2., coactivators such as SRC-1 and RAC3 and cointegrators 
like CBP/p300 contain intrinsic HAT activities, whereas transcriptional repressive 
complexes include for instance NCoR, Sin3 and HDAC. Thus, a link between NR 
signalling and chromatin organization is provided. Presumably, coactivator function is 
primarily the recruitment of CBP/p300, that appears to be the primary source of HAT 
activity (Carlberg and Polly, 1998; Freedman, 1999; Issa et al., 1998; Jones et al., 1998; 
Rachez and Freedman, 2000). 
Further NR coactivator complexes without HAT activity are VDR interacting proteins 
(DRIP) and the analogous TR associated proteins (TRAP)/SMCC, activator-recruited 
co-factor (ARC), negative regulator of activated transcription (NAT), CRSP and 
mammalian Mediator. They are the target not only of  NRs but also of many other 
transcription factors such as Sp1 and form a bridge from the LBD to the basal 
transcription machinery through a single subunit (DRIP205/TRAP220) (fig. 11). Since 
Mediator binds to the carboxy-terminal repeat domain (CTD) of RNA polymerase II, it 
has been assumed, that this complex targets RNA polymerase II holoenzyme to 
promoters. Since the DRIP-mediated potentiation of ligand-dependent VDR-RXR 
transcription activity depends on the presence of chromatin, it can be assumed, that the 
DRIP complex contains or recruits chromatin-remodelling activities other than HATs. Introduction 
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Ligand-activated VDR-RXR heterodimers seem to change rapidly between coactivators 
of the p160-family and those of the DRIP/TRAP family  (Carlberg, 2003; Freedman, 
1999; Issa et al., 1998; Rachez and Freedman, 2000). 
 
 
 
 
Fig. 11. Model for VDR regulation of gene transcription. The various coregulators (middle 
panel) do not necessarily assemble at the same time; in fact, a cyclic association and 
dissociation has been reported for some cofactors (adapted from (Issa et al., 1998)) 
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TAFII135, TAFII55, and TAFII28 have been reported. Ligand binding causes 
dissociation of corepressors and TFIIB, thereby relieving repression (fig. 11) (Carlberg 
and Polly, 1998; Issa et al., 1998; Jones et al., 1998; Masuyama et al., 1997; Rachez and 
Freedman, 2000). 
Recently, the coregulator Ski-interacting protein/Nuclear coactivator-62 kDa 
(SKIP/NCoA62) whose primary sequence is unrelated to other NR coactivators has 
been described to interact with the VDR. Like DRIP/TRAP it appears to lack chromatin 
modifying activity. SKIP/NCoA62 binds the VDR ligand-independently via a helix 10 
interface that is functionally and physically distinct from the region bound by the AF-2-
dependent p160 coactivators. The interaction is required for full VDR transactivation 
activity and the interface contains residues that are also involved in TFIIB and RXR 
binding. It was suggested, that SKIP/NCoA62 may regulate the exchange between 
TFIIB and RXR at the VDR helix 10 interface. SKIP/NCoA62 preferentially interacts 
with the VDR-RXR heterodimer as compared with the VDR monomer or homodimer 
and addition of ligand leads to a profound stabilization of the complex. GRIP1 and 
SKIP/NCoA62 form a ternary c omplex with VDR  in vitro  and in vivo (chromatin 
immunoprecipitation assays), SKIP/NCoA62 entering last, and synergistically enhance 
ligand-dependent VDR transcriptional activity in transient reporter gene assays. 
SKIP/NcoA62 also interacts with  the Ski (Sloan-Kettering-Institute) oncoprotein and 
with other nuclear proteins such as the NRs RAR, ER, and GR, the repressor CBF-1, 
and the coregulators SMRT, Sin3A, HDAC2, and SRC-1. Further, it enhances TGFb-
dependent transactivation by interacting with Smad proteins. Thus, via specific 
interactions with corepressors or coactivators in a ligand-dependent mode, 
SKIP/NCoA62 might mediate a switch from transcriptional repression to activation. In 
addition, SKIP/NCoA62 has been shown to interact with components of the splicing 
machinery like pre-mRNA processing factor 8 (Prp8), U5 snRNP 200-kDa helicase, and 
Prp28, and with putative components of the nuclear matrix like matrin 3 and 
tubulin b 5. Expression of a dominant negative SKIP/NCoA62 led to a 1,25(OH)2D3-
dependent transient accumulation of unspliced growth hormone mRNAs transcribed 
from a VDRE-driven reporter gene cassette containing five exons and introns, each. 
Thus, SKIP/NCoA62 seems to be required for correct mRNA processing and might 
provide a functional link between VDR-mediated transcription and RNA splicing 
(Barry et al., 2003; Leong et al., 2001; Makarov et al., 2002; Zhang et al., 2001; Zhang 
et al., 2003). Introduction 
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To further complicate the complex network of regulatory mechanisms, the 
transcriptional regulator Yin-Yan-1 (YY1), that is located in the nuclear matrix, has 
been described to competitively block the binding of VDR-RXR heterodimers to the 
VDRE from the rat osteocalcin gene. Dependent on the cellular protein context, YY1 
can activate or repress transcription via interactions with compounds of the basal 
transcription machinery, such as TFIIB, transcription factors like Sp1, CREB, and 
CBP/p300, and HDACs (Carlberg and Polly, 1998; Doetzlhofer et al., 1999; Issa et al., 
1998; Yang et al., 1997). 
Beside VDREs conferring transcriptional activation upon ligand stimulation, also 
repressor VDREs have been described for instance for the IL-2 and PTH and PTH-
related peptide (PTHrP) gene promoters. In the case of the repression of IL-2 gene 
expression the VDR is suggested to act as a DNA-independent modulator of nuclear 
signalling pathways (Issa et al., 1998; Jones et al., 1998; Quack and Carlberg, 2000). 
1,25(OH)2D3 has not only been described to augment transcription of target genes but 
also to enhance mRNA stability as reported for the epidermal growth factor receptor 
(EGFR) (González et al., 2002). 
Because of its above described effects, 1,25(OH)2D3 has been identified as a potential 
therapeutic in diseases like osteoporosis, psoriasis, multiple sclerosis, cancer, 
rheumatoid arthritis, diabetes, hyperparathyroidism, and in transplantation. However, 
severe side effects led to the development of several analogs aiming to dissociate 
antiproliferative and calcemic activities (fig. 12). The first generation of compounds 
contains the prodrugs 1 -OH-D3 and 1 -OH-D2 that are currently used to treat 
osteoporosis. The main target for structure modification was the C17 side chain, 
attempting to increase the metabolic clearance rate by decreasing interactions with the 
serum protein vitamin D-binding protein (DBP). Only those analogs are VDR agonists 
that cause both an efficient dissociation of corepressors from the receptor as well as a 
specific binding of coactivators. All agonists show an identical mode of action (EC50 
values of about 0.1 nM), but interestingly some superagonists display a RE-type 
selectivity. Among the most potent agonists are the antipsoriatic drugs calcipotriol 
(MC903) and 22-oxacalcitriol or the highly antiproliferative seocalcitol (EB1089). 
Limited protease digestion assays with various 1,25(OH)2D3 analogs led to the 
differentiation of an agonistic, an antagonistic and a non-agonistic conformation of the 
VDR. They differ in the orientation of helix 12. Antagonists bind to the LBD of VDR 
with sufficient affinity and stabilize the VDR in the antagonistic conformation, in which Introduction 
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the association of coactivators is blocked. VDR antagonists (i.e. ZK159222) have 
relatively bulky ring structures in their side chains. However, corepressor dissociation 
seems not to be prevented. The differentiation of the analogs into agonists and 
antagonists is somewhat difficult, though, as many of them are partial agonists and/or 
function as agonists in certain tissues and antagonists in others. This is possibly due to 
different expression levels of coactivator and corepressor proteins. Therefore, the term 
selective VDR modulator has been proposed. Analogs with two side chains at C20 such 
as Gemini stabilize the VDR in a conformation, in which corepressors do not dissociate 
from the receptor, thus blocking interaction with coactivators. These compounds are 
referred to as non-agonists. In the case of exposure of DNA-bound VDR-RXR 
heterodimers to low corepressor levels versus an excess of coactivator proteins, non-
agonists turn into agonists or even superagonists (Berg and Haug, 1999; Carlberg, 2003; 
Issa et al., 1998; Jones et al., 1998). 
 
Fig. 12. Structure of 1,25(OH)2D3 and selected analogs. 
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5-LO activity, protein expression and mRNA strongly increase upon differentiation of 
myeloid cell lines such as MM6 and HL-60 with 1,25(OH)2D3/TGFb (Brungs et al., 
1994; Brungs et al., 1995). In MM6 cells, treatment with 1,25(OH)2D3 and TGFb led to 
an up to 5 -fold increase in primary transcripts, a 64-fold increase in mature 5 -LO 
mRNA, a 128-fold increase in protein expression, and a more than 500-fold increase in 
5-LO activity. No significant induction of 5-LO transcription was found in nuclear run-
off assays, though (Härle et al., 1999). Both 1,25(OH)2D3 and TGFb were required for 
these profound responses. Either agent alone induced small amounts of 5-LO protein 
and mRNA but only very low 5-LO activities (Härle et al., 1998). As will be further 
discussed in chapter 1.12.4, the regulation of 5 -LO gene expression by 
1,25(OH)2D3/TGFb is but one example for several lines of evidence for an interplay 
between the 1,25(OH)2D3 and TGFb signalling pathways. 
The induction of 5 -LO activity in MM6 cells by 1,25(OH)2D3/TGFb could be 
suppressed by 75 to 85 % when the 1,25(OH)2D3 antagonist ZK191732 was added 
(Gaschott et al., 2001). In contrast, three new potent VDR agonists have been identified 
due to their induction of 5-LO activity in MM6 cells (Werz et al., 2000).  
 
1.12.4  The TGFb b/Smad signalling system 
As mentioned above (chapter 1.12.3), 5-LO activity, protein expression and mRNA 
strongly increase upon incubation of myeloid cell lines with TGFb/1,25(OH)2D3 
(Brungs et al., 1994; Brungs et al., 1995). Hence, transcriptional control by the 
TGFb/Smad signalling system is of particular interest. 
The TGFb superfamily of secretory peptides is composed of many multifunctional 
cytokines including various forms of TGFb, the bone morphogenetic proteins (BMPs), 
the nodals, the activins, the inhibins, the anti-Müllerian hormone (AMH), myostatin and 
many others. These factors regulate cell migration, adhesion, multiplication, 
differentiation and death and their effects differ depending on the type and state of the 
cell. The highly similar isoforms TGFb1, TGFb2, and TGFb3 potently inhibit cellular 
proliferation of many cell types, whereas they stimulate growth of most mesenchymal 
cells. In addition, TGFbs strongly induce extracellular matrix synthesis and integrin 
expression, inhibit hematopoietic functions and modulate immune responses (Massagué 
and Wotton, 2000; Piek et al., 1999). Thus, disruptions of TGFb signalling pathways Introduction 
37 
underlie many human disorders such as cancer, fibrotic or inflammatory disorders 
(Massagué, 1998). 
TGFb is synthesized as a prohormone. After cleavage, the mature hormone remains 
bound to the propeptide latency-associated protein (LAP). Recognition by the signalling 
receptors requires a multistep activation process that is currently poorly understood. The 
bioactive forms of TGFb and related factors are dimers. 
Smad proteins are the downstream effectors of TGFb signalling and can be divided into 
three groups. The receptor-regulated Smads (R-Smads) comprise the human members 
Smad1, 2, 3, 5 and 8 and their cooperating Smad (or common-partner/collaborating/co-
mediator Smad, Co-Smad) is Smad4. The human inhibitory Smads (I-Smad/Anti-
Smads) are Smad6 and 7. Smads1, 5 and 8 transmit signalling by BMP receptors, while 
Smads2 and 3 mediate signalling by TGFb and activin receptors  (Massagué and 
Wotton, 2000). 
 
 
Fig. 13. The TGFb b/Smad signalling pathway. The two-step transcriptional activation process  
involves two  families of membrane receptor protein kinases and their substrates, the Smad 
proteins. The Smad complex acts as transcription factor. (Adapted from (Massagué and Wotton, 
2000)). 
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Binding of the ligand TGFb to its type II receptor (facilitated by betaglycan (BG)/TGFb 
type III receptor) leads to assembly with the type I receptor, both of which are 
transmembrane protein serine/threonine kinases. In this ligand-induced complex, the 
constitutively active TGFb receptor II (TbRII) activates the TbRI by phosphorylation of 
its GS region (the complex containing two TbRIIs and TbRIs, each). The immunophilin 
FKBP12 suppresses receptor phosphorylation by binding to the unphosphorylated GS 
regions of TbRIs. BMP exerts negative-feedback control through the protein BMP and 
activin membrane-bound inhibitor (BAMBI) that forms heterodimers with type I 
receptors and interferes with their activation. TbRIs specifically phosphorylate R-Smads 
in their SSxS (x = M/V) motif, leading to activation, complex formation with Co-Smads 
and nuclear accumulation. The membrane associated protein Smad anchor for receptor 
activation (SARA) promotes the interaction of Co-Smads with the activated T bRs, 
whereas the inhibitory Smads Smad6 and Smad7 block activated Smad1 and the 
activated receptors, respectively. Basal levels of Smad1 and Smad5 are regulated by the 
E3 ubiquitin ligase Smad ubiquitination regulatory factor-1 (Smurf1), administering 
them to ubiquitination and degradation. Following translocation to the nucleus, the 
heteromeric Smad complex binds to DNA via SBEs (CAGAC or even AGAC) and 
certain G/C-rich sequences, recruits transcriptional coactivators (CBP/p300, PCAF) and 
activates transcription (Itoh et al., 2000). Phosphorylation of R-Smads by Ras-activated 
ERKs attenuates nuclear accumulation (Fig. 13, (Massagué and Chen, 2000; Massagué 
and Wotton, 2000)). 
Because of the weak affinity of Smad MH1 domains to SBEs, probably additional DNA 
contacts via transcriptional partners are required. These cofactors bind to their 
corresponding cognate sequences located at specific distances from the SBEs and to the 
Smad MH2 transactivation domains. They determine the choice of target genes and 
comprise DNA-binding adaptors (e.g. forkhead activin transducers (FAST-1/-2), olf-
associated zink finger (OAZ)), constitutive (e.g. transcription factor binding to 
immunoglobulin heavy constant µ enhancer 3 (TFE3), core-binding factor A (CBFA)) 
and signal-regulated (e.g. AP-1) transcription factors (Massagué and Wotton, 2000). 
Among the transcription factors reported to interact with Smad proteins are some of 
which binding sites have been identified in the 5-LO promoter, such as Sp1 (Feng et al., 
2000; Moustakas and Kardassis, 1998; Pardali et al., 2000), Sp3 (Lai et al., 2000), AP-1 
(Brodin et al., 2000; Takeshita et al., 1998; Wong et al., 1999), AP-2, NFkB (López-Introduction 
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Rovira et al., 2000) and the VDR. The VDR has been shown to  physically and 
functionally interact with Smad3 and Smad7  in vitro and  in vivo, thus crosslinking 
TGFb and 1,25(OH)2D3 signalling (Aschenbrenner et al., 2001; Yanagi et al., 1999; 
Yang et al., 2001b). At least one member of the SRC-1/TIF2 protein family has been 
shown to be required for the interaction (Yanagi et al., 1999; Yanagisawa et al., 1999). 
The spacing between VDRE and SBE significantly affects the synergistic 
transcriptional activation by TGFb and 1,25(OH)2D3 (Subramaniam et al., 2001). In one 
study, multiple mechanisms responsible for TGFb/1,25(OH)2D3 crosstalk have been 
reported. Thus, ligand-binding to the VDR induces TGFb mRNA expression, the VDR 
enhances T bRII expression in certain cell types, Smad3 activates the VDR and the 
crosstalk is dependent on the PI 3-kinase pathway (Yang et al., 2001b). 
Also, negative regulation of TGFb signalling by interactions with transcription factors 
such as the GR (Song et al., 1999), Smad interacting protein 1 (SIP1) or Evi-1 has been 
reported (Watanabe and Whitman, 1999). 
In addition, Smad proteins are suggested to activate transcription by relieving the action 
of transcriptional repressors. Furthermore, suppression of transcription by the 
recruitment of corepressors (e.g. TG3-interacting factor (TGIF), the proto-oncogene 
cSKI, Ski-related novel  gene N (SnoN)), has also been described  (Massagué and 
Wotton, 2000). The nuclear hormone receptor-interacting cofactor SKIP has been 
described to associate with Ski and Sno and to act as coactivator of TGFb-dependent 
transcription. Thus, SKIP appears to modulate both TGFb and NR signalling pathways 
(Leong et al., 2001) (also see chapter 1.12.3). 
Recently, two proteins that are involved in RNA metabolism have been identified as 
Smad binding proteins by yeast two-hybrid and GST pull-down assays. Splicing factor 
3b subunit 2 (SF3b2) is involved in the excision of introns from pre-mRNA. The role of 
eukaryotic translation initiation factor 4E nuclear import factor 1 (4-ET) is the 
nucleocytoplasmic shuttling of eukaryotic translation initiation factor 4E (eIF4E). These 
interactions may provide a functional link between TGFb signalling and RNA 
processing (Warner et al., 2003). 
Cell type specificity of Smad-mediated gene responses are probably due to different 
expression patterns of Smad-interacting proteins. 
For the relevance of TRAP1 in TGFb signalling and as a protein binding to 5-LO, see 
chapter 1.5. Introduction 
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Finally, a crosstalk between the TGFb and the kinase pathways is suggested. 
Antagonistic as well as cooperative interactions between TGFb and Ras signalling have 
been described (Massagué and Chen, 2000). In addition, TGFb and BMP can probably 
activate various MAPK signalling pathways. TGFb can enhance the activity of AP-1 (a 
dimer of c-Jun and c-Fos) complexes through phosphorylation of c-Jun by c-jun NH2-
terminal kinase (JNK), and as well the activity of CREB complexes through 
phosphorylation of activating-transcription factor (ATF2) by p38. Activated Smads can 
associate with Jun or ATF2,  in vitro. The  mitogen-activated protein kinase kinase 
kinase (MAPKKK) family member TGFb-activated kinase1 (TAK1) likely links the 
receptors with these pathways by direct interaction with MAPK kinases (MKKs) that 
subsequently activate JNK or p38 (Massagué, 2000; Massagué et al., 2000; Massagué 
and Chen, 2000). In addition, without Smad proteins being involved, TGFb can directly 
activate MAPKs, PI 3-K, and other mediators (Engel et al., 1999; Kracklauer et al., 
2003; Yang et al., 2003). 
Recently, based on genome-level analysis, a hierarchical model of gene regulation by 
TGFb has been proposed (fig. 14) (Yang et al., 2003). In this model, Yang and co-
authors suggest, that Smad3 directly activates immediate-early target genes of TGFb, 
encoding regulator proteins including signal transducers and transcriptional regulators. 
As the characteristic Smad3/Smad4 DNA-binding motif repeats are not present in 
secondary gene targets, these are probably regulated through lower affinity SBEs or by 
immediate-early target gene-encoded transcriptional regulators. Smad2 and ERKs might 
predominantly transmodulate immediate-early gene and intermediate gene regulation by 
TGFb/Smad3. 
 
Fig. 14. Hierarchical model of gene regulation after ligand-induced activation of the TGFb b 
receptor complex (TRb bI/II). (Adapted from (Yang et al., 2003)) 
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1.12.5  Other inducers of 5-LO gene transcription 
Depending on the cell type, several cytokines have been shown to be inducers of the 
5-LO pathway. In granulocytes, 5-LO expression and AA liberation are stimulated by 
granulocyte-macrophage colony-stimulating factor (GM-CSF) in response to platelet-
activating factor (PAF) (McColl et al., 1991). IL-3 increases the expression of 5-LO, 
FLAP, cPLA2 and LTC4 synthase in mouse mast cells (Murakami et al., 1995). 
Furthermore, enhanced steady state levels of 5 -LO mRNA have been detected in 
response to differentiation and activation by RA, glucocorticoids, human chorionic 
gonadotropin, dbcAMP, DMSO, phorbol-12-myristate-13-acetate (PMA), okadaic acid, 
oxidized low density lipoproteins or Ca
2+-ionophore in various leukocyte cell lines 
(Bigby, 1999; Silverman and Drazen, 1999; Zhang et al., 1999). In HL-60 cells the 
upregulation is, at least in part, caused by TGFb in serum (Steinhilber et al., 1993). Aims of the present investigation  
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2  Aims of the present investigation 
 
Due to the pharmacological relevance of 5-LO products the regulation of 5-LO gene 
expression is important for the pathogenesis of inflammatory diseases  (Steinhilber, 
1999; Werz, 2002a). Thus, regulatory mechanisms that influence 5-LO expression on 
transcriptional or posttranscriptional levels are of interest (Drazen and Silverman, 1999; 
Drazen et al., 1999; Silverman and Drazen, 2000). 
In this study the contribution of epigenetic mechanisms (Uhl et al., 2002) as well as of 
the signalling pathways of the potent 5-LO stimuli TGFb and 1,25(OH)2D3 (Brungs et 
al., 1994; Brungs et al., 1995) to the induction of 5-LO gene expression should be 
characterised. A previously performed functional analysis of the 5 -LO promoter 
(paper I; dissertation N. Klan) failed to identify sequence elements in the promoter that 
were required for the profound induction of 5-LO mRNA, protein, and activity during 
the differentiation of myeloid cell lines induced by TGFb and 1,25(OH)2D3 (Härle et al., 
1999). Hence, the main aim of this thesis was to identify sequences outside of the 
promoter that might confer the activation of 5 -LO gene expression by  TGFb and 
1,25(OH)2D3. For this purpose, several reporter gene plasmids containing different parts 
of the 5-LO gene were cloned and analysed in reporter gene assays. 
Furthermore, possible crosstalks between the signalling pathways of 5 -LO relevant 
transcription factors, epigenetic mechanisms and posttranscriptional events were 
subjects of the present investigation. Methods  
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3  Methods 
 
The following table lists the methods used in this thesis and indicates in which paper the 
respective method is described. 
Method 
 
Paper 
Cloning of reporter gene plasmids 
(using PCR-methods and restriction enzymes) 
 
II, III 
Transient transfections 
(standard calcium phosphate method) 
 
II, III 
Reporter gene assays 
(luciferase and SEAP assays) 
 
(I), II, III 
RT-PCR 
 
I, II 
SDS-PAGE and Western blot 
 
(I) 
 
 
The following human cell lines have been used:  
Cell line 
 
Paper/ 
chapter 
Mono Mac 6 cells (monocytes/macrophages)  II, 4.2.7, 4.5.2 
U937 cells (lymphoma cells)  4.5.1 
HeLa cells (cervix carcinoma cells)  II, III 
Caco-2 cells (colon carcinoma cells)  4.2.2, 4.2.3, 4.4 
HL-60 cells (promyelocytic leukemia cells)  I 
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4  Results 
 
4.1  Vitamin D -responsive elements within the human 5 -LO gene 
promoter bind VDR, but do not confer vitamin D -dependent 
transcriptional activation 
 
Among the putative VDREs within the 5 -LO promoter, t he sequence located at 
positions -291 bp to -276 bp (AATTCA GGAG AGAACG) shows some homology to 
the DR4-type mouse phosphate intestinal transporter (mPit-1) VDRE (AGTTCA TGAG 
AGTTCA) and the sequence  -309 bp to  -294 bp ( AGGGCA AAG GGTGGA)  was 
previously proposed for possible VDR binding (Carlberg, 1995). DNase I footprinting 
assays and EMSAs that were performed by coauthors, revealed that the purified VDR 
binds to putative VDREs within the 5-LO promoter as a heterodimer together with 
RXR. EMSAs with nuclear extracts from TGFb/1,25(OH)2D3-differentiated MM6 cells 
also indicated binding of additional protein(s) induced by TGFb/1,25(OH)2D3 to the 
VDR/RXR/5LO-56 complex. Interestingly, TGFb and 1,25(OH)2D3 had no effect on 
5-LO promoter activity in transient reporter gene assays in different cell types (also 
performed by coauthors), which is consistent with results obtained by nuclear run-off 
assays using nuclear extracts from MM6 cells  (Härle et al., 1999). Transient 
transfections and subsequent luciferase assays with systematically truncated 5 -LO 
promoter reporter constructs plus expression vectors for VDR and RXR indicated the 
presence of two negative ( -5814 bp to  -5395 bp and  -913 bp to  -778 bp) and two 
positive regulatory regions (-778 bp to -229 bp and -141 bp to -78 bp) in MM6 cells. In 
HeLa cells, the inhibitory region from -913 bp to -778 bp and the positive regulatory 
region from -778 bp to -229 bp were not detected. In both cell lines the pN10 construct 
(-778 bp to +53 bp) caused the most profound induction of transcriptional activity. 
Coexpression of the receptors  VDR and RXR did not significantly affect 5 -LO 
promoter activity when the DNA sequence from -778 bp to -229 bp, which contains the 
putative VDREs, was present, but reduced 5 -LO promoter activity in reporter gene 
constructs that lack the VDREs. 
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4.1.1  Transcription of the stably transfected 5-LO promoter CAT reporter gene 
in HL-60 cells is independent of TGFb b/1,25(OH)2D3 
In order to investigate whether integration of the 5-LO promoter into the genome is 
required for the upregulatory effects of  TGFb and 1,25(OH)2D3,  HL-60 cells were 
stably transfected with 5 -LO promoter-chloramphenicol acetyltransferase (CAT) 
constructs leading to the cell lines HL60-6079-5LO, which contains a stably integrated 
CAT gene under the control of the 5 -LO promoter ( -6079 to +81 bp), HL60-SV40 
(where the CAT reporter gene is under the control of an SV40 promoter), and HL60-
Basic (no promoter). Cells were cultured with or without 1 ng/ml TGFb in combination 
with 50 nM 1,25(OH)2D3 and after 24 h, CAT and endogenous 5-LO mRNA expression 
were determined by RT-PCR. TGFb and 1,25(OH)2D3 did not significantly affect CAT 
expression in HL60-6079-5LO cells and only slightly stimulated CAT mRNA 
expression in HL60-SV40 and in HL60-Basic  cells (1.9- and 1.7-fold, respectively) 
(paper I: fig. 8A). In contrast, TGFb and 1,25(OH)2D3 caused a 13.8-fold, 11.1-fold and 
7.1-fold increase of endogenous 5-LO mRNA in HL60-SV40, HL60-Basic, and HL60-
6079-5LO, respectively (paper I: fig. 8B). 
 
 
4.2  The coding sequence mediates induction of 5-LO expression by 
1,25(OH)2D3 and TGFb b 
 
The results reported in paper I (chapter 4.1) indicated, that the strong increase in 5-LO 
mRNA expression induced  by TGFb and 1,25(OH)2D3  are not mediated by the 
promoter but possibly by REs that are located outside of the 5-LO promoter region. 
Hence, the contribution of the coding region, the 3’-UTR and introns J, K, L and M to 
the induction of 5-LO gene expression was investigated. 
 
4.2.1  1,25(OH)2D3 and TGFb b induce accumulation of mature 5-LO mRNA 
The 5-LO positive human myeloid cell line MM6 was incubated with 1 ng/ml TGFb in 
combination with 50 nM 1,25(OH)2D3 for 24 hours. Subsequently, nuclear and 
cytosolic RNA was isolated and subjected to RT-PCR analysis, using either 
oligo(dT)12-18 or random hexamer primers for cDNA synthesis for the determination of 
mature and pre-mRNA, respectively. The time course experiment revealed a prominent Results  
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increase of mature 5-LO mRNA in the nucleus as well as in the cytosol following 
incubation with 1,25(OH)2D3 and TGFb, whereas pre-mRNA levels were not 
significantly elevated (paper II: fig. 1). 
 
4.2.2  Cotransfection of VDR and RXR induces reporter gene activity when the 
5-LO coding sequence is present 
Reporter gene assays with plasmid constructs containing the 3’-UTR, the coding 
sequence (cds) and the last four introns (introns J, K, L and M) were performed in the 
presence and absence of expression vectors for VDR and RXR. For that purpose, the 
3’-UTR, the cds and the last four introns were cloned into the 5-LO promoter reporter 
gene construct pN10 and in the pGL3 vectors (Promega) in such a way that the 5-LO 
cds was in frame to the luciferase sequence. Thus, in the cell, fusion proteins were 
generated. Two sets of luciferase reporter gene plasmids were constructed, the first 
containing the 5-LO core promoter (-778 to +53 bp) in the plasmid pGL3-Basic plus the 
different parts of the 5-LO gene, and the second containing the 5-LO cds plus the last 
four introns in front of the luciferase gene using the pGL3-Basic, pGL3-Promoter and 
pGL3-Control vector, respectively (paper II: fig. 2). The core promoter-containing 
pN10 construct was chosen for cloning, as it has previously been shown to cause the 
most profound reporter gene activity (chapter 4.1/paper I). 
HeLa cells that do not express endogenous 5-LO were transiently transfected with the 
aforementioned reporter gene plasmids in the presence or absence of VDR and RXR 
expression constructs. Reporter gene activity of constructs containing the 5 -LO 
promoter alone or in combination with the 3’-UTR was not upregulated by 
cotransfection of RXR/VDR (paper II: fig. 3). However, inclusion of the 5-LO cds led 
to an approximately 3-fold induction of luciferase activity by NR overexpression and 
addition of  introns J-M even led to an about 6-fold induction. This upregulation seemed 
to be independent from the 5-LO promoter since it was also observed with plasmids 
containing no promoter, an SV40-promoter or an SV40-promoter plus  -enhancer 
(pGL3-ba-cdsInJM, pGL3-prom-cdsInJM and pGL3-ctrl-cdsInJM, respectively). 
All experiments have been performed using 800 ng reporter gene plasmid and 100 ng 
expression vector for the NRs, each (8/1). Various amounts of expression plasmids have 
been investigated revealing a dose-dependent upregulation (fig. 15). Although 200 ng 
expression vector (4/1) led to an even more profound induction of reporter gene Results  
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activity, 100 ng were considered to ensure the availability of sufficient amounts of VDR 
and RXR and were used for all subsequent experiments. 
 
Fig. 15.  VDR/RXR dose-dependently enhance luciferase activity of a coding sequence-
containing reporter gene construct in transiently transfected HeLa cells. The plasmid 
pN10-cds3UTR was transiently transfected into HeLa cells with or without increasing amounts 
of expression vectors for VDR and RXR. Luciferase activity was measured 24 h after 
transfection. Depicted are the relative light units (RLU) of the respective ratios of reporter to 
NR expression vectors. Each experiment was performed in triplicates and normalization for 
transfection efficiency was performed by cotransfection of pCMV-SEAP. Displayed is one 
representative out of at least three independent experiments (mean ± SE). 
 
Consistent with the data from reporter gene assays, RT-PCR with HeLa cells that were 
transiently transfected with pN10-cdsInJM revealed a 2.2- ( –0.4) fold VDR/RXR-
mediated induction of 5-LO pre-mRNA (random hexamer priming) and 4.6- (–1.8) fold 
induction of mature mRNA (oligo(dT)18-20 priming). 
In the 5-LO positive Caco-2 cells the plasmids pN10, pN10-cdsInJM and p(DR3)4tkluc 
led to 2.5-, 7.7- and 1.0-fold inductions by cotransfection of RXR/VDR, respectively 
(fig. 16). 
In summary, the data show that the 5 -LO cds mediates induction by VDR/RXR. 
Interestingly, in both cell lines no effect of VDR/RXR overexpression was observed 
with the p(DR3)4tkluc plasmid that contains a 4 -times concatemerized rat atrial 
natriuretic factor (rANF) VDRE. 
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Fig. 16.  Effects of VDR/RXR on the transcriptional activity of luciferase reporter gene 
constructs in transiently transfected Caco-2 cells. The indicated plasmids were  transiently 
transfected into Caco-2 cells with or without expression vectors for VDR and RXR. 
p(DR3)4tkluc, containing a four times concatemerized DR3-type VDRE in front of the thymidine 
kinase promoter, was used as positive control. Luciferase activity was measured 24 h after 
transfection. Each experiment was performed in triplicates. Results are presented as mean – SE 
of at least three independent experiments after normalization for transfection efficiency by 
cotransfection of pCMV-SEAP. Inductions are expressed with respect to pSG5-cotransfected 
cells. 
 
 
4.2.3  Induction of reporter gene activity by 1,25(OH)2D3 and TGFb b is also 
mediated by the 5-LO coding sequence 
In order to investigate whether the effect of 1,25(OH)2D3 and TGFb also depends on 
sequences located outside of the promoter like the coding region and 3’-UTR, reporter 
gene assays with the corresponding plasmid constructs (paper II: fig. 2) were 
performed. HeLa and Caco-2 cells were incubated with 1 ng/ml TGFb for 24 hours 
before transfection. After exchange of medium, cells were incubated with 1  ng/ml 
TGFb and/or 50 nM/1 µM of 1,25(OH)2D3 for another 8/22 hours (HeLa and Caco-2 
cells, respectively) before luciferase activity was determined. In both cell lines TGFb 
alone only slightly increased reporter gene activity. However, in HeLa cells the 
combination of both agents revealed a significant synergistic effect with reporter gene 
constructs containing the coding sequence (paper II: fig. 4). The upregulation by 
1,25(OH)2D3 and TGFb varied for the used constructs. With pN10 and pN10-3UTR, 
induction by TGFb and 1,25(OH)2D3 did not differ from the negative control 
pN10 pN10-cdsInJM p(DR3)4tkluc
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pGL3-Basic, whereas the presence of the 5 -LO cds (pN10-cds) led to a 5.1-fold 
induction and inclusion of the cds plus introns J -M (pN10-cdsInJM) t o a 12.4-fold 
upregulation. The reporter gene activity of the promoterless plasmid pGL3-ba-cdsInJM 
was also induced (about 16-fold) and the plasmid p(DR3)4tkluc (containing a 4-times 
concatemerized VDRE) employed as positive control was induced by 9 -fold. 
Interestingly, introduction of the cds plus the introns J -M downstream of the 
translational stop codon of the luciferase gene (pN10-cdsInJM-inv) led to a significant 
reduction of inducibility (3.6-fold). Preincubation with TGFb was required to obtain the 
prominent synergistic effects, indicating that the effect represents a secondary response 
(data not shown). Incubation of the transiently transfected cells with increasing amounts 
of 1,25(OH)2D3 revealed an explicit dose-dependency (fig. 17). Since the concentration 
of 50 nM is the standard concentration used in previous studies, all subsequent 
experiments have been performed with 50 nM 1,25(OH)2D3. 
 
Fig. 17. 1,25(OH)2D3 dose-dependently enhances luciferase activity of a coding sequence-
containing reporter  gene construct in transiently transfected HeLa cells. The plasmid 
pN10-cdsInJM was transiently transfected into HeLa cells with or without expression vectors 
for VDR and RXR. 16 h after transfection 1  ng/ml TGFb and increasing amounts of 
1,25(OH)2D3 (VD3) were added for another 8 h before luciferase activity was determined. Each 
experiment was performed in triplicates and normalization for transfection efficiency was 
performed by cotransfection of pCMV-SEAP. Displayed is one representative out of at least 
three independent experiments – SE (Cells were not preincubated with TGFb!) (RLU: relative 
light units). 
 
In Caco-2 cells (fig. 18) considerably higher amounts of  1,25(OH)2D3 (1 µM) were 
required to obtain significant inducing effects (2.9-fold for pN10-cdsInJM). No 
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synergistic action of TGFb and 1,25(OH)2D3 was observed. Interestingly, 1,25(OH)2D3-
mediated induction of the control plasmid p(DR3)4tkluc was considerably higher than 
in HeLa cells (16.5-fold). 
 
Fig. 18. In Caco-2 cells 1,25(OH)2D3 mediates upregulation of luciferase activity, but no 
synergistic action of 1,25(OH)2D3 and TGFb b can be observed. The indicated plasmids were 
transiently transfected into Caco-2 cells with or without expression vectors for VDR and RXR. 
Before transfection, cells were p reincubated with TGFb (1 ng/ml) for 24 h and 16 h after 
transfection 1,25(OH)2D3 (1 µM) and/or TGFb (1 ng/ml) were added for another 22 h before 
luciferase activity was determined. Each experiment was performed in triplicates. Results are 
presented as mean  – SE of at least three independent experiments after normalization for 
transfection efficiency by cotransfection of pCMV-SEAP. 
 
In agreement with the well-known fact that VDR binds to DNA predominantly as 
heterodimer with RXR, overexpression of both NRs was required for upregulation of 
5-LO expression by TGFb and 1,25(OH)2D3 (fig. 19). 
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Fig. 19. Cotransfection of VDR and RXR is required for full upregulation of pN10-cdsInJM 
by 1,25(OH)2D3 and TGFb b in transiently transfected HeLa cells. pN10-cdsInJM was 
transiently transfected into HeLa cells with or without expression vectors for VDR and/or RXR. 
Before transfection, cells were preincubated with TGFb (1 ng/ml) for 24 h and 16 h after 
transfection  1,25(OH)2D3  (50  nM) and TGFb (1 ng/ml) were added for another 8  h before 
luciferase activity was determined. Each experiment was performed in triplicates. Results are 
presented as mean  – SE of at least three independent experiments after normalization for 
transfection efficiency by cotransfection of pCMV-SEAP (RLU: relative light units). 
 
Taken together, the data show that the 5-LO cds mediates induction of reporter gene 
activity by 1,25(OH)2D3 and TGFb. 
 
4.2.4  1,25(OH)2D3 and TGFb b regulate 5-LO mRNA processing 
In order to determine whether the effects of 1,25(OH)2D3/TGFb occur on the mRNA 
level, HeLa cells were transiently transfected with pN10-cdsInJM, pSG5-VDR and 
pSG5-RXR. The formed mRNA transcripts were subsequently analysed by RT-PCR. 
Cells were preincubated with TGFb (1 ng/ml) for 24 h and after transfection 
1,25(OH)2D3 (50 nM)/TGFb (1 ng/ml) were added together with or without 
cycloheximide (CHX) (10 µM) for 8 h. After extraction of total RNA, RT-PCR analysis 
was performed using either oligo(dT)18-20 or random hexamer priming for cDNA 
synthesis and different sets of primers for PCR reactions (paper II: tab. 1, fig. 5). With 
primer pairs that are located in the beginning or the end of the coding sequence, 28 PCR 
cycles were sufficient to obtain defined PCR products of correct size. In contrast, 35 
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cycles were required when the respective primer pairs were located between exons 8 
and 13 indicating that central parts of the cds are removed during mRNA processing. 
Interestingly, when a primer pair spaning the complete coding region was used 
(cds_start/Asurev), multiple  PCR products were obtained, indicating that mRNA 
processing seems to occur at several sites. The 1,25(OH)2D3/TGFb-mediated induction 
of transcripts varied significantly (given as fold induction, paper II: fig. 5) depending on 
the RNA position that was analysed by PCR. The most prominent increase in 5-LO 
mRNA was observed when primers that span intron M like 5-LO1/Asurev (14.6-fold) 
and InJM_5/Asurev (9.8-fold) or primers that are located within intron M (7.8-fold) 
were used. This increase roughly corresponds to the measured enhancement of 
luciferase activity (12.4-fold). Interestingly, the induction obtained with these primer 
pairs was significantly inhibited when CHX was added together with 1,25(OH)2D3 and 
TGFb, indicating that protein synthesis was required (paper II: figs. 6B and D). 
Strikingly, when using primers cds_start/1883_rev or Ncofor1/Asurev that amplify 
exons 1 to 8 or parts of exon 14 and the luciferase gene, respectively, (paper II: fig. 5) 
only a weak increase in the respective PCR signals (6.0-fold and 2.5-fold, respectively) 
was obtained that was not inhibited by CHX (paper II: figs. 6A and C). These parts of 
the mRNA were prominently expressed since 28 cycles were sufficient to obtain clear 
PCR signals of correct size. 
In summary, the characterization of the transcribed RNA species by RT-PCR leads to 
the suggestion that central parts of the 5-LO cds are removed during mRNA processing 
and that 1,25(OH)2D3 and TGFb induce the inclusion of exon 13 into the mature 
mRNA. 
 
4.2.5  Upregulation of 5-LO mRNA processing by 1,25(OH)2D3/TGFb b does not 
depend on a distinct part of the coding sequence 
In order to identify sequences in the coding region that participate in the 
1,25(OH)2D3/TGFb-mediated regulation of 5-LO expression, deletion constructs of the 
vector pN10-cds were cloned and analyzed in reporter gene assays. The coding region 
was divided into four parts which were subsequently deleted (paper II: fig. 7). 
Domain A ranges from exon 1 to 4, domain B from exon 4 to 10, domain C from 
exon 10 to 14 and domain D represents the last part of exon 14 (paper II: fig. 5). The 
respective deletion of parts A to D reduced induction of reporter gene activity by Results  
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1,25(OH)2D3/TGFb (paper II: figs. 8A and B). A significant decrease in 5 -LO 
upregulation by 1,25(OH)2D3/TGFb could be seen when parts B+C, A+B+C or B+C+D 
were deleted (from 5.1-fold to 2.6-, 2.0- and 2.2-fold, respectively). In constructs in 
which large parts of the cds are deleted (pdcdsABC and pdcdsBCD), the 1,25(OH)2D3-
mediated induction of luciferase activity was completely lost and only the minor TGFb-
mediated enhancement could be measured. 
Sequence analysis revealed the existance of some putative VDREs in the 5-LO coding 
sequence and even in the introns. The two most promising putative VDREs that are 
located in exon 2 and intron J were deleted and the resulting constructs were subjected 
to transient transfection studies as described above. As can be seen in figs. 20 A+B, 
deletion of the putative VDREs does neither significantly affect the VDR/RXR- nor the 
TGFb/1,25(OH)2D3-mediated upregulation of 5-LO expression. 
 
Fig. 20.  Deletion of putative VDREs does neither affect the VDR/RXR- (A) nor the 
TGFb b/1,25(OH)2D3- (B) mediated upregulation of 5-LO expression. The indicated plasmids 
were transiently transfected into HeLa cells with or without expression vectors for VDR and 
RXR. Before transfection, cells were preincubated with TGFb (1 ng/ml) for 24 h and 16 h after 
transfection  1,25(OH)2D3  (50  nM) and TGFb (1 ng/ml) were added for another 8  h before 
luciferase activity was determined. Each experiment was performed in triplicates. Results are 
presented as mean  – SE of at least three independent experiments after normalization for 
transfection efficiency by cotransfection of pCMV-SEAP. Inductions are expressed with respect 
to pSG5-cotransfected (A) or to untreated cells (B). 
 
In summary, the deletion analysis demonstrates that for an almost complete loss of the 
response to  1,25(OH)2D3/TGFb, removal of large parts of the cds is required. This 
suggests that the regulation of the 5-LO mRNA processing by TGFb and 1,25(OH)2D3 
involves multiple parts of the cds rather than being mediated by distinct REs. 
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4.2.6  Inclusion of the 5-LO coding sequence plus introns J-M changes the kinetics 
of 1,25(OH)2D3/TGFb b-mediated upregulation of reporter gene activity 
 
 
Fig. 21.  Long-term kinetics of TGFb b/1,25(OH)2D3-mediated 5 -LO upregulation. The 
indicated plasmids were transiently transfected into HeLa cells with or without expression 
vectors for VDR and RXR. Before transfection, cells were preincubated with TGFb (1 ng/ml) for 
24 h and 16 h after transfection 1,25(OH)2D3 (50 nM) and TGFb (1 ng/ml) were added for the 
indicated times before luciferase activity was determined. Each experiment was performed in 
triplicates. Results are normalized  for transfection efficiency by cotransfection of pCMV-SEAP 
(RLU: relative light units). 
 
To further determine the 5-LO upregulating effect long-term kinetics were measured. 
HeLa cells were preincubated with TGFb (1 ng/ml) for 24 hours and were transfected 
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with the plasmids pN10, pN10-cdsInJM or pGL3-prom-cdsInJM. After change of 
medium, the cells were incubated with TGFb (1 ng/ml) and 1,25(OH)2D3 (50 nM) for 
up to 56 hours. Remarkably, luciferase activity of cells transfected with pN10 decreased 
in a time-dependent manner, independently from cotransfection with VDR/RXR and 
incubation with 1,25(OH)2D3/TGFb (fig. 21 A). In contrast, luciferase activity of cells 
transfected with pN10-cdsInJM (figs. 21 B+C) or pGL3-prom-cdsInJM (figs. 21 D+E) 
scarcely decreased, when the NRs were cotransfected and cells were incubated with 
1,25(OH)2D3/TGFb. Thus, interaction of VDR/RXR heterodimers with the 5-LO cds 
and/or introns J-M seem to prolong the response to 1,25(OH)2D3 and TGFb. 
 
4.2.7  Depending on cell type and assay system,  the 1,25(OH)2D3 analogon 
ZK191732 displays agonistic or antagonistic action on 5-LO expression 
 
 
Fig. 22. Agonistic effect of the 1,25(OH)2D3 analogon ZK191732. The indicated plasmids were 
transiently transfected into HeLa cells with expression vectors for VDR and RXR. 16 h after 
transfection the indicated amount of ZK191732 and/or 1,25(OH)2D3 (50 nM) were added for 
8 h before luciferase activity was determined. Each experiment was performed in triplicates. 
Results are presented as mean  –  SE of at least t hree independent experiments after 
normalization for transfection efficiency by cotransfection of pCMV-SEAP. Inductions are 
expressed with respect to untreated cells. 
 
To antagonize the 1,25(OH)2D3-mediated regulation, HeLa cells were transiently 
transfected with the reporter gene construct containing both 5-LO promoter and cds plus 
introns J-M or the positive control p(DR3)4tkluc and the expression plasmids for VDR 
and RXR and were incubated with the 1,25(OH)2D3-analogon ZK191732 (100/500 nM) 
for 8  hours ( the structure is depicted in fig. 12, chapter 1.12.3). Interestingly, the 
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compound that has previously been determined to act antagonistically on 5-LO activity 
in MM6 cells  (Gaschott et al., 2001), showed an explicit dose-dependent agonistic 
activity in this assay (fig. 22). Strikingly, with p(DR3)4tkluc the effect was rather low 
and no dose-dependency could be observed. Consistent with the above described results 
these data suggest that the pathway of 1,25(OH)2D3-mediated regulation of 5-LO gene 
expression is distinct from the classical 1,25(OH)2D3  signalling pathway through 
VDREs. 
In the previous experiments mentioned above, the antagonistic activity of ZK191732 in 
MM6 cells has been characterized by 5-LO activity assays. To address, whether the 
1,25(OH)2D3 analogon diminishes 5-LO activity by inhibiting the protein expression 
5-LO protein levels have been determined by means of Western blot. MM6 cells were 
grown with or without 1,25(OH)2D3 (50 nM)/TGFb (1 ng/ml) and/or ZK191732 
(500 nM or 1 µM) for 4 days until cells were harvested and subjected to SDS-PAGE 
and Western blot. Fig. 23 illustrates that 1  µM ZK191732 induces 5 -LO protein 
expression (lane 5). However, 500 nM ZK191732 are not sufficient to significantly 
upregulate 5 -LO protein level (lane 3). Interestingly, in combination with 
1,25(OH)2D3/TGFb the analogon dose-dependently reduces the prominent induction of 
5-LO protein mediated by 1,25(OH)2D3/TGFb (lanes 2, 6, and 7). Thus, in MM6 cells 
the 1,25(OH)2D3 analogon ZK191732 displays agonistic as well as antagonistic 
activities. 
Fig. 23. Agonistic and antagonistic effects of the 1,25(OH)2D3 analogon ZK191732. Mono 
Mac 6 cells were grown in the absence of additives (lane 1) or in the presence of 1,25(OH)2D3 
(50 nM)/TGFb (1 ng/ml), ZK191732 (500 nM/1 µM), or their combinations for 4 days. The 
samples (3 x 10
5 cells, solubilized in SDS-PAGE loading buffer) were analysed for 5-LO protein 
by Western blot. Lane 4: protein size marker. 
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4.3  The coding sequence mediates induction of 5-LO expression by 
Smads3/4 
 
Since Smad proteins have been described as downstream effectors of TGFb, the role of 
TGFb/Smad signalling in 5-LO gene regulation was investigated. 
 
4.3.1  Effects of TGFb b on 5-LO reporter gene activity 
HeLa cells were transiently transfected as described above with the above mentioned 
luciferase reporter gene constructs (for overview see paper III: fig. 1) in the absence of 
VDR/RXR and Smad3/Smad4 expression constructs. TGFb (1 ng/ml) led to an about 
1.5-fold induction of reporter gene activity with the control pGL3-Basic (paper III: 
fig. 2). A similar induction was observed with pN10, pN10-3UTR and pN10-cdsINJM-
inv. Interestingly, slightly increased effects (about 2-fold induction) were observed with 
plasmids that contain the 5-LO coding sequence (pN10cds, pN10-cdsInJM, pGL3-ba-
cdsInJM and pGL3-prom-cdsInJM). With all plasmids tested,  1,25(OH)2D3 (50 nM) 
alone did not significantly enhance transcriptional activity under these experimental 
conditions, i.e. in the absence of cotransfected VDR/RXR. A slight induction of 
transcriptional activity was obtained with the p(DR3)4tkluc plasmid when 1,25(OH)2D3 
and TGFb were combined. 
 
4.3.2  Smad3/Smad4 strongly induce reporter gene activity when the 5-LO coding 
sequence is present 
HeLa cells were transiently transfected with luciferase reporter gene constructs 
(paper III: fig. 1) and cotransfected with either pCGN-Smad3 and pCGN-Smad4 or an 
empty cytomegalovirus (CMV) promoter construct as control. In order to determine the 
optimal amount of Smad expression vectors, different amounts were tested. As shown 
in fig. 24, 100 ng of each expression vector per 800 ng reporter gene plasmid (8/1) was 
sufficient for maximal reporter gene activation. Thus, all subsequent experiments were 
performed with these amounts. Results  
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Fig. 24. Determination of optimal amounts of Smad3/4 expression vectors for cotransfection 
in HeLa cells. The plasmids pN10 (A) and pN10-cdsInJM (B) were transiently transfected into 
HeLa cells with or without increasing amounts of expression vectors for Smads3 and 4. 
Luciferase activity was measured 24 h after transfection. Each experiment was performed in 
triplicates and normalization for transfection efficiency was performed by cotransfection of 
pCMV-SEAP. Depicted are the relative light units (RLU) of the respective ratios of reporter to 
Smad expression vectors (mean ± SE). Displayed is one representative out of at least three 
independent experiments. 
 
Coexpression of Smads increased reporter gene activity obtained with pN10 (containing 
the 5 -LO core promoter) by 3.7-fold. Interestingly, the TGFb-responsive plasmid 
p3TP-Lux, carrying three TGFb tetradecanoyl phorbol acetate REs from the 
plasminogen activator inhibitor 1 (PAI-1) gene, was only induced by 1.6-fold  which 
was comparable to the negative control pGL3-Basic (2.2-fold). The effects of the Smad 
proteins on 5-LO gene expression was strongly enhanced by the presence of the cds 
(paper III: fig. 3). Induction of pN10-cds and of pN10-cdsInJM (containing also introns 
J-M) was 17.5-fold and 24.0-fold, respectively. Interestingly, the upregulation of the 
3’-UTR-containing  plasmid pN10-3UTR was significantly higher than with pN10 
(8.8-fold versus 3.7-fold) but inclusion of the 3’-UTR did not further enhance the 
induction of the constructs containing the coding sequence (pN10-cds3UTR and 
pN10-cdsInJM3UTR). When the 5 -LO coding and intronic sequences were inserted 
behind the luciferase stop codon (pN10-cdsInJM-inv) there was a strong reduction of 
the upregulation by cotransfection of Smad3/Smad4 to pN10 levels (3.1-fold). Induction 
of reporter gene activity by Smad3/Smad4 also occurred with pGL3-ba-cdsInJM and 
pGL3-prom-InJM (without promoter and with SV 40 promoter, respectively), which 
suggests that the Smad3/Smad4 effects do not depend on the 5-LO promoter. 
 
16/1 8/1 4/1
R
L
U
0
2
5
0
5
0
0
7
5
0
1
0
0
0
1
2
5
0
+
 
p
C
M
V
 
+
 
S
m
a
d
3
+
4
 
16/1 8/1 4/1
R
L
U
0
5
1
0
1
5
2
0
2
5
+
 
p
C
M
V
 
+
 
S
m
a
d
3
+
4
 
A. B.
16/1 8/1 4/1
R
L
U
0
2
5
0
5
0
0
7
5
0
1
0
0
0
1
2
5
0
+
 
p
C
M
V
 
+
 
S
m
a
d
3
+
4
 
16/1 8/1 4/1
R
L
U
0
5
1
0
1
5
2
0
2
5
+
 
p
C
M
V
 
+
 
S
m
a
d
3
+
4
 
16/1 8/1 4/1
R
L
U
0
2
5
0
5
0
0
7
5
0
1
0
0
0
1
2
5
0
+
 
p
C
M
V
 
+
 
S
m
a
d
3
+
4
 
16/1 8/1 4/1
R
L
U
0
5
1
0
1
5
2
0
2
5
+
 
p
C
M
V
 
+
 
S
m
a
d
3
+
4
 
A. B.Results  
59 
4.3.3  TGFb b effects are only marginally enhanced by Smad3/Smad4 
In the absence of coexpressed Smads, TGFb enhanced reporter gene activity by 1.5- to 
2.7-fold for 5 -LO promoter constructs and up to 4.1-fold for the positive control 
p3TP-Lux (paper III: fig. 4). Interestingly, in cells that were cotransfected with Smad3 
and Smad4 t here was no significantly altered response to TGFb indicating that the 
TGFb effects are independent of Smad overexpression. 
 
4.3.4  Synergism between RXR/VDR and Smad3/Smad4 
Cotransfection of expression plasmids for VDR/RXR and/or Smad proteins 3/4 
profoundly enhanced absolute reporter gene activity (paper III: fig. 5). In cells 
cotransfected with VDR/RXR, addition of TGFb (1 ng/ml) or 1,25(OH)2D3 (50 nM) 
upregulated reporter gene activity and both ligands displayed a synergistic effect. In 
cells cotransfected with Smads3/4 only, TGFb enhanced reporter gene activity whereas 
1,25(OH)2D3 was without effect. The combined cotransfection of Smads3/4 and 
VDR/RXR led to additive effects on absolute reporter gene activity. As expected, 
addition of either 1,25(OH)2D3 or TGFb increased reporter gene activity and 
combination of both agents had a synergistic effect (paper III: fig. 5). Interestingly, 
coexpression of Smads3/4 and VDR/RXR increased reporter gene activity by 12.6-fold, 
whereas the ligand-mediated inductions by 1,25(OH)2D3 or TGFb and the combination 
of both agents were 2.4-, 2.6- and 5.9-fold, respectively, suggesting a remarkable 
constitutive activity of Smads and VDR/RXR, respectively. 
 
4.3.5  Identification of sequence elements with significance for Smad signalling in 
5-LO gene regulation 
In order to identify sequences in the coding region and introns that participate in 
Smad3/4 and TGFb-mediated enhancement of 5-LO expression, the above described 
deletion constructs from the vector pN10-cds were analyzed in reporter gene assays. As 
shown in fig. 6A (paper III) deletion of parts A, B or D reduced Smad3/4-mediated 
induction of 5 -LO expression from 14.7-fold (pN10-cds) to 8.8-, 8.6- and 9.0-fold, 
respectively. A prominent decrease to 3.9-fold was observed, when part C was deleted. 
Comparably, a 3.7-fold upregulation of 5-LO gene expression by Smad3/4 coexpression 
was determined for the 5-LO promoter plasmid pN10. Deletion of two or three parts of 
the cds rather decreased the inhibitory effect (paper III: fig. 6B). In contrast to the Results  
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Smad3/4 mediated effects, transcriptional activation by TGFb was not affected by the 
deletion of parts of the coding region (paper III: figs. 7A+B). 
Sequence analysis revealed the existence of several putative SBEs in the 5-LO coding 
sequence and introns. Deletion of a 286 bp sequence in intron M from the vector 
pN10-cdsInJM comprising 4 putative SBEs (paper III: fig. 8A) led to a construct, which 
is less responsive to coexpression of Smad proteins (pdSBE2 10.4-fold, pN10-cdsInJM 
18.4-fold) (paper III: fig. 8B), suggesting that these SBEs might be involved in the 
regulation of 5 -LO mRNA expression by Smads. The minor TGFb-mediated 
upregulation of 5-LO expression was not altered by the deletion (paper III: fig. 8C). 
Furthermore, the two most promising putative TGFb responsive elements (TREs), 
located in exon 10 and intron J, were deleted from plasmid pN10-cdsInJM (paper III: 
fig. 8A). Deletion of TRE 1 significantly reduced the Smad-mediated enhancement of 
5-LO expression from 16.2- to 6.7-fold (paper III: fig. 8B), whereas deletion of TRE 2 
or of both led to no marked changes. The TGFb-mediated transcriptional activation of 
5-LO was not affected by either deletion (paper III: fig. 8C). 
 
 
4.4  Cotransfection of Sp1 or Ap2a a does not significantly affect 
reporter gene activity 
 
As already mentioned in chapter 1.10, numerous putative and some functional REs for 
various transcription factors have been detected throughout the whole sequence of the 
5-LO gene. One of these is Sp1, for which the characteristic binding sites (GC boxes) 
are known in the promoter and which is required for basal 5-LO expression (Hoshiko, 
1990). Also, putative binding sites for Ap2a can be found in the 5-LO promoter. To 
address, whether both transcriptional regulators influence 5-LO promoter activity and/or 
like VDR and Smads mediate any effect through the cds, cotransfection studies have 
been performed. 
HeLa and Caco-2 cells were transiently transfected with luciferase plasmids as 
described above and cotransfected with an expression vector for either Sp1 or Ap2a. In 
HeLa cells the reporter gene activity of the 5-LO promoter driven construct pN10 was 
not affected by overexpression of either Sp1 or Ap2a. Insertion of the 5-LO cds plus 
introns J -M slightly enhanced the Ap2a-mediated effect from 1.1-fold to 2.1-fold, Results  
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whereas Sp1 inducibility was not significantly changed (1.4-fold and 1.8-fold, 
respectively) (fig. 25 A). Similarly, but to an even lower extent, in Caco-2 cells the 
Ap2a-mediated induction is slightly higher for pN10-cdsInJM compared to pN10 (1.6-
fold versus 1.1-fold) (fig. 25 B). 
 
 
Fig. 25. Cotransfection of Sp1 or Ap2a a. The indicated plasmids were transiently transfected 
into HeLa (A) or Caco-2 (B) cells with or without expression vectors for Sp1 or Ap2a. 24 h 
after transfection luciferase activity was determined. Each experiment was performed in 
triplicates. Results are presented as mean – SE of at least three independent experiments after 
normalization for transfection efficiency by cotransfection of pCMV-SEAP. Inductions are 
expressed with respect to cells cotransfected with empty vector. 
 
 
4.5  TsA and structurally related HDACis induce 5-LO (and 15-LO) 
promoter activity 
 
As reported in chapter 1.12.2 the 5-LO promoter is regulated by DNA methylation. 
Since DNA methylation and histone acetylation are tightly connected processes and 
recent reports indicate an involvement of chromatin remodeling and histone acetylation 
in the regulation of 5 -LO and 15-LO gene expression (for further information, see 
chapter 1.12.2), the impact of histone acetylation on 5-LO and 15-LO promoter activity 
has been investigated. 
 
4.5.1  TsA induces 15-LO mRNA expression in U937 cells 
Since upregulation of 15-LO expression by the HDACi sodium butyrate has already 
been shown in Caco-2 cells  (Kamitani et al., 2000), the effects of the more potent 
HDACi TsA on 15-LO mRNA expression in the myeloid cell line U937 has been 
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investigated. U937 cells were cultured with TGFb (1 ng/ml) and 1,25(OH)2D3 (50 nM) 
for 24 h, with or without TsA (330 nM) for the last 8 h. Following cell harvest, total 
RNA was extracted and reverse transcribed into cDNA. 15-LO and b-actin expression 
were analyzed by PCR employing 35 and 24 cycles, respectively. TsA alone induced 
15-LO mRNA expression by 5.8-fold, whereas 1,25(OH)2D3/TGFb rather decreased 
15-LO mRNA generation. Combination of TsA with 1,25(OH)2D3/TGFb lessened the 
TsA-mediated upregulation (3.2-fold) (fig. 26). Thus, 15-LO mRNA expression is not 
increased by 1,25(OH)2D3/TGFb in U937 cells and in combination with TsA, 
1,25(OH)2D3/TGFb seem to suppress TsA-mediated 15-LO mRNA induction. 
 
Fig. 26. Induction of 15-LO mRNA expression in U937 cells. Cells were cultured for 24 h in 
the presence or absence of TGFb (10 ng/ml) and 1,25(OH)2D3 (VD3) (50 nM).  TsA (330 nM) 
was added after 16 h for another 8 h, before cells were harvested and analyzed by RT-PCR. 35 
and 24 cycles were used for 15-LO and b-actin, respectively (mean ± SE). 
 
 
4.5.2  TsA induces 5-LO mRNA expression in MM6 cells 
In order to study the effects of TsA on 5 -LO mRNA expression, MM6 cells were 
cultured with TsA (330 nM) and/or TGFb (1 ng/ml) and 1,25(OH)2D3 (50 nM) for 24 h. 
Following cell harvest, total RNA was extracted and reverse transcribed into cDNA. 
5-LO and  b-actin expression were analyzed by PCR employing 28 and 24 cycles, 
respectively. TsA alone led to an about 11-fold increase in 5-LO mRNA expression, 
whereas induction by 1,25(OH)2D3/TGFb was 43-fold (paper IV: fig. 1). Interestingly, 
combination of TsA with 1,25(OH)2D3/TGFb did not further increase the effect of 
1,25(OH)2D3/TGFb but rather inhibited (62 %)  the induction mediated by both agents 
and led to an only 16-fold upregulation of 5-LO mRNA compared to the control. Hence, 
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TsA alone strongly increases 5-LO mRNA generation in MM6 cells but diminishes the 
1,25(OH)2D3/TGFb-induced 5-LO mRNA upregulation. 
Experiments performed by coauthors revealed that TsA strongly induces 5-LO promoter 
activity in transiently transfected MM6 and HeLa cells (paper IV). Further, as already 
mentioned above, 5-LO promoter activity was independent from 1,25(OH)2D3/TGFb in 
reporter gene assays. Combination with TsA and/or overexpression of VDR/RXR did 
not alter the response to 1,25(OH)2D3/TGFb. 
Since the involvement of multiple Sp1 binding sites in the transcriptional activation of 
genes such as G ai2 and WAF/Cip1 by HDACis like sodium butyrate, TsA or HC 
(Helminthsporium carbonium) toxin has been suggested recently (Nakano et al., 1997; 
Yang et al., 2001b), the GC boxes have been deleted from the 5-LO promoter reporter 
gene construct pN10. Reporter gene assays with the resulting plasmids indicated that the 
TsA-mediated induction of 5 -LO promoter activity does not depend upon the five 
tandemized Sp1 sites. 
Furthermore, transient transfection experiments with in vitro methylated plasmid DNA 
demonstrated that DNA methylation dominates over histone acetylation in the 
regulation of 5 -LO promoter activity. TsA only partially reversed methylation-
dependent inhibition of 5-LO promoter-driven luciferase activity. 
Finally, a series of recently synthesized HDACis that are structurally related to 
trapoxin B and TsA have been studied in the transient transfection system. Since the 
EC50 values obtained in this model are consistent with reported potencies in other in 
vitro systems, this assay seems to be a useful tool for the screening for and evaluation of 
HDACis. 
 
 
4.6  Interplay of 1,25(OH)2D3/TGFb b signalling and histone acetylation 
in the regulation of 5-LO gene regulation 
 
5-LO has been shown to be induced by HDAis (chapter 4.5/paper IV), HDACis have 
been reported to synergistically enhance cell differentiation by 1,25(OH)2D3 (Gaschott 
et al., 2001), and the VDR interacts with cointegrators containing intrinsic HAT 
activities (chapter 1.12.3). Thus, the possible crosslinking of the 1,25(OH)2D3/TGFb Results  
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signalling pathway and histone acetylation has been further investigated. It was of 
particular interest, if histone acetylation also affects the cds and/or introns J-M. 
 
Fig. 27. Interaction of 1,25(OH)2D3/TGFb b signalling and histone acetylation. The indicated 
plasmids were transiently transfected into HeLa cells, untreated or preincubated for 24 h with 
TGFb (1 ng/ml), and cotransfected with expression vectors for VDR and RXR. 16 h after 
transfection 1,25(OH)2D3 (50 nM)/TGFb (1 ng/ml) and/or TsA (330 nM) were added for 24 h 
before luciferase activity was determined. Each experiment was performed in triplicates. 
Results are presented as mean  – SE of at least three independent experiments after 
normalization for transfection efficiency by cotransfection of pCMV-SEAP. Inductions are 
expressed with respect to untreated cells. 
 
Some of the above described (5-LO promoter) reporter gene plasmids were again 
analyzed in the transient transfection system. HeLa cells, untreated or preincubated with 
TGFb (1 ng/ml), were transiently transfected with luciferase reporter vectors and 
cotransfected with expression plasmids for VDR and RXR. 16 h after transfection, 
medium was changed and 1,25(OH)2D3 (50 nM)/TGFb (1 ng/ml) and/or TsA (330 nM) 
were added for 24 h, until cells were harvested and luciferase activity was measured. As 
displayed in fig. 27, 1,25(OH)2D3/TGFb alone only slightly induced reporter gene 
activity of the 5-LO promoter containing plasmid pN10 or the negative control pGL3-
Basic containing no promoter (2.8- and 4.8-fold, respectively). In contrast, as already 
reported above, the cds (and introns) containing plasmids pN10-cds, pN10-cdsInJM and 
pGL3-ba-cdsInJM (for overview, see paper II: fig. 2) are highly inducible by both 
agents (10.1-, 13.9-, and 27.9-fold, respectively). Consistent with the results reported in 
chapter 4.5/paper IV, the 5-LO core promoter (pN10) is activated by TsA (14.4-fold). 
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Inclusion of the cds and introns J-M suppresses the TsA-mediated upregulation to 3.3-, 
1.2-, and 1.3-fold for the plasmids pN10-cds, pN10-cdsInJM and pGL3-ba-cdsInJM, 
respectively. The combined incubation with 1,25(OH)2D3/TGFb/TsA does not affect the 
TsA-mediated induction of pN10. However, the response of the cds-containing 
plasmids to 1,25(OH)2D3/TGFb/TsA is drastically reduced compared to 
1,25(OH)2D3/TGFb alone (pN10-cds 5.3-fold, pN10-cdsInJM 2.3-fold, and pGL3-ba-
cdsInJM 5.5-fold). Thus, TsA seems to mediate an inhibitory effect on 5 -LO 
upregulation by 1,25(OH)2D3/TGFb through the cds. 
 
 
4.7  Sp1 and Sp4, but not Sp3 synergistically with TsA enhance coding 
sequence-mediated upregulation of 5-LO gene expression 
 
Recent reports indicate a crosslink between chromatin organization and the action of 
transcription factors of the Sp family. For instance, binding of Sp1 and Sp3 to 
HDAC1/2 has been described to be required for HDAC activity and Sp1 sites in 
promoters seem to be essential for full efficiency of HDACis (de Ruijter et al., 2003; 
Nakano et al., 1997; Yang et al., 2001a). The Sp family of transcription factors consists 
of the closely related proteins Sp1, Sp2, Sp3 and Sp4. Sp1, Sp3 and Sp4 can bind to and 
act through GC-boxes (for review, see  (Suske, 1999)). Sp1 is an ubiquitous factor, 
known to be a transcriptional activator of a large number of genes. It belongs to the 
limited list of transcription factors that have been shown to interact with nucleosomal 
DNA ((Li et al., 1994) and references therein) and is required to prevent methylation of 
CpG islands. Its function is severely affected by nucleosome structure (Hodny et al., 
2000). Sp1 interacts with its binding site in the form of multiple stacked tetramers, 
which contain several interacting surfaces for associating proteins (Davie, 2003). Sp2 
function has not been elucidated, yet. Sp3, like Sp1, is ubiquitiously expressed. Its 
action is not fully understood, either, but it seems that dependent on the structure and 
arrangement of the binding sites it can strongly activate transcription or repress Sp1-
mediated activation by competing with Sp1 for their common binding sites. Finally, Sp4 
is a tissue-specifically expressed transcriptional activator. Sp knockout experiments 
indicate that Sp family members have individual as well as overlapping functions. Results  
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Fig. 28. Crosstalk of Sp1/Sp3/Sp4 signalling and histone acetylation. The plasmids pN10 or 
pN10-cdsInJM were transiently transfected into HeLa cells with or without expression vectors 
for Sp1 (A, B, C), Sp3 (D,E,F) or Sp4 (G, H, I). 16 h after transfection TsA (330 nM) was added 
for 24 h before luciferase activity was determined. Each experiment was performed in 
triplicates. Results are presented as mean –  SE of at least three independent experiments after 
normalization for transfection efficiency by cotransfection of pCMV-SEAP. Inductions mediated 
by Sp proteins (A, D, G), TsA (B, E, H) or both (C, F, I)  are expressed with respect to untreated 
cells, cells cotransfected with empty vector and both, respectively. 
 
For information on the relevance of Sp1 for basal 5-LO promoter activity, see chapters 
1.10 and 1.11. Sp1 cotransfection studies have already been described in chapter 4.4. To 
characterize the crosstalk of Sp family members and histone acetylation in the 
regulation of 5-LO gene expression, Sp1/Sp3/Sp4 cotransfections have been combined 
with TsA treatment in transient transfection experiments. To further address, whether 
sequences in the cds and introns are involved in this regulation, not only the 5-LO 
promoter reporter gene plasmid pN10 but also the cds and introns J -M-containing 
construct pN10-cdsInJM was used for transfections. HeLa cells were transiently 
transfected with the reporter gene plasmids and cotransfected with expression vectors 
for the transcription factors Sp1, Sp3 or Sp4. 16 h a fter transfection, medium was 
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changed and cells were incubated with TsA (330 nM) for 24 h. Subsequently, the cells 
were harvested and the luciferase assay was performed. Fig. 28 shows fold inductions 
calculated for TsA-treatment, Sp cotransfection or the combination of both. As already 
mentioned above, the 5-LO promoter is highly responsive to TsA. Independently from 
cotransfection with Sp1 or Sp3, pN10 luciferase activity was induced by about 30-fold 
(figs. 28 A+D). However, overexpression of Sp4 enhanced the TsA-mediated activation 
of pN10 from 39.5- to 72.6-fold (fig. 28 G). Consistent with fig. 27, inclusion of cds 
and introns J -M strongly reduced the TsA-mediated induction. Interestingly, 
cotransfection of Sp1 or Sp4 also increased the TsA-mediated upregulation of pN10-
cdsInJM from 3.2- to 8.9-fold and from 2.9- to 22.8-fold, respectively (figs. 27 A+G) 
(note: Sp1-mediated induction is higher than depicted in fig. 27 due to the prolonged 
incubation time). Consistent with previous results, Sp1 overexpression did not induce 
5-LO promoter activity (fig. 28 B), although the transcription factor is required for basal 
promoter activity. Likewise, Sp3 and Sp4 did not increase pN10 luciferase activity 
(figs. 28 E+H). Interestingly, insertion of the coding sequence and introns J-M increased 
the induction by Sp1 (8.1-fold compared to 1.1-fold for pN10) and Sp4 (4.8-fold 
compared to 1.3-fold for pN10), which was not observed for Sp3 (figs. 28 B+H+E). 
Similar to the above described enhancement of TsA-mediated activation by Sp1 and 
Sp4, Sp1- and Sp4-mediated upregulation of pN10-cdsInJM was prominently increased 
by TsA treatment (figs. 28 B+H: from 8.1- to 20.1-fold and from 4.8- to 40.5-fold, 
respectively). Thus, Sp1/Sp4 and histone hypoacetylation seem to have additive effects 
on the coding sequence-mediated induction, whereas Sp3, independently from histone 
acetylation does not affect luciferase activity. Figs. 28 C+F+I show the total inductions 
mediated by the transcription factor Sp plus TsA. Interestingly, inclusion of the cds and 
introns J-M enhanced the induction mediated by Sp1+TsA from 32.6- to 65.4-fold. 
Since Sp3 did not induce luciferase activity of either plasmid, the total effects 
corresponded to the TsA effects (pN10: 37.7-fold, pN10-csdInJM: 1.7-fold). The very 
high Sp4+TsA-mediated induction was not different for both plasmids (pN10: 113.9-
fold, pN10-csdInJM: 122.6-fold), indicating that the different intensities of the single 
effects compensated each other. Discussion  
68 
5  Discussion 
 
5.1  Functional interaction of the VDR with the 5-LO promoter does 
not mediate induction of 5-LO gene expression by 1,25(OH)2D3 
 
Since the 5-LO promoter contains several putative VDREs (within -313 bp to -258 bp), 
it was reasonable to assume that the prominent upregulatory effects of 1,25(OH)2D3 on 
5-LO mRNA expression in myeloid cell lines during maturation are due to ligand-
dependent transactivation of the VDRE by VDR. In fact, the binding of VDR together 
with RXR to 5 -LO promoter fragments spanning the putative VDREs in vitro with 
similar magnitudes compared to the well-documented VDRE of the mouse osteopontin 
promoter could be shown. Also, differentiation of MM6 cells by 1,25(OH)2D3 and 
TGFb caused markedly enhanced protein binding to VDREs from nuclear extracts 
compared to untreated cells. However, luciferase reporter gene assays failed to 
demonstrate significant transcriptional activation of the 5 -LO promoter upon 
stimulation with 1,25(OH)2D3 (plus TGFb) in various myeloid cell lines. Expression of 
a reporter construct containing a 4-times concatemerized rANF VDRE in front of the 
thymidine kinase promoter (p(DR3)4tkluc) was strongly increased after treatment of 
these cell lines with 1,25(OH)2D3 and TGFb, though. Moreover, in stably transfected 
HL-60 cells endogenous 5-LO mRNA was strongly upregulated by 1,25(OH)2D3 and 
TGFb, whereas the CAT reporter gene driven by the entire 5-LO promoter fragment 
(-6079 to +81 bp), was not responsive. Hence, the simple lack of bridging factors or 
coactivators in transient transfections could be excluded. Taken together, it can be 
concluded that the strong induction of 5-LO mRNA expression by 1,25(OH)2D3 and 
TGFb in myeloid cell lines seems to be mediated by regulatory elements located outside 
of the 5-LO promoter and apparently does not involve the VDR/RXR interaction with 
the VDREs located within the 5-LO promoter. 
By means of reporter gene assays using HeLa and MM6 cells, previous findings that the 
promoter region containing the five tandemized Sp1-sites is essential for basal promoter 
activity  (Silverman et al., 1998) were confirmed. For both cell lines positive and 
negative regulatory regions were identified. In agreement to the presented results, 
Hoshiko  et al. identified a positive regulatory region ( -6079 to  -3635 bp), which 
comprises the sequence between -5814 and -5395 bp that has been reported in paper I. Discussion  
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In HeLa cells the presence of a negative regulatory region at -662 to -227 bp that was 
reported before  (Hoshiko, 1990) could not be confirmed. The reason for this 
discrepancy is unknown but could be due to different transfection protocols, different 
deletion constructs or experimental conditions. In addition, a new inhibitory region 
(from -5395 to -4894 bp), which contains two putative binding sites for the transcription 
factor p53 that match the consensus sequence (GAACATGTCC) to more than 80 % was 
identified.  Using MM6 cells, a positive regulatory region (-778 to -229 bp) that is not 
functional in the 5-LO negative HeLa cells was found. Interestingly, putative VDREs 
are located in that region, but as stated above, in reporter gene experiments 
TGFb/1,25(OH)2D3 did not alter 5-LO promoter activity in any cell type investigated. 
These findings are in agreement with results from nuclear run-off assays (Härle et al., 
1998; Härle et al., 1999) and previous transfections (Uhl et al., 2002) where increased 
transcription of the 5-LO gene could not be demonstrated. 
Of interest, the coexpression of VDR and RXR was found to be essential for high level 
induction of reporter gene activity of the plasmid p(DR3)4tkluc that was used as 
positive control. Low expression of VDR and RXR (no expression vectors added), 
caused only marginal effects o f TGFb/1,25(OH)2D3, except for RBL-1 cells, which 
could be due to a high expression level of VDR and/or VDR related coactivators. 
5-LO promoter deletion studies revealed that coexpression of the receptors VDR and 
RXR does not significantly affect 5-LO promoter activity when the VDREs are present. 
In contrast, it reduces 5-LO promoter activity in reporter gene constructs that lack the 
DNA sequence from -778 to -229 bp, which contains the putative VDREs. One possible 
explanation could be that VDR/RXR recruit coactivators that are required for high 5-LO 
promoter activity. However, the VDR does not bind to 5 -LO promoter constructs 
lacking the VDREs, and instead sequesters coactivators from the 5-LO promoter. This 
conclusion is supported by DNA footprinting and EMSA a nalyses, where a strong 
interaction of VDR/RXR with the VDREs at -309 to -294 bp and at -290 to -275 bp 
with homology to the VDRE of the mPit-1 gene, could be demonstrated. 
In summary, it was strongly suggested that the effects of TGFb/1,25(OH)2D3 on 5-LO 
gene expression are mediated by further regulatory elements outside of the 5 -LO 
promoter, which were absent in transient and stable reporter gene transfections. 
Considered were exons, introns or the 3’UTR which might contain sequences like 
mRNA processing signals, sequences that affect mRNA stability (Dixon et al., 2000; Discussion  
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Lemm and Ross, 2002; Tierney and Medcalf, 2001), or transcription factor binding 
sites. 
 
 
5.2  The upregulation of 5-LO gene expression by 1,25(OH)2D3/TGFb b 
depends upon the coding sequence 
 
In order to investigate, whether sequences in the exons, introns or 3’UTR of the 5-LO 
gene confer the prominent response to 1,25(OH)2D3/TGFb, the above described reporter 
gene constructs were cloned. On the one hand reporter gene assays demonstrated that 
induction of luciferase activity by 1,25(OH)2D3 and TGFb depends on the 5-LO cds. 
This upregulation was independent of the promoter (5-LO, CMV, no promoter) 
indicating that at least under the in vitro conditions of reporter gene assays, the 5-LO 
promoter is not required for the 1,25(OH)2D3 and TGFb effect. On the other hand, the 
induction of reporter gene activity mediated by the cds depended on the coexpression of 
VDR/RXR which indicates that the VDR is involved in this signalling. Coexpression of 
VDR/RXR was also required for 1,25(OH)2D3 signalling in the control experiments, i.e. 
the stimulation of reporter gene activity of the p(DR3)4tkluc plasmid that contains a 
four times concatemerized DR3 VDRE in front of the thymidine kinase promoter. 
However, there was a significant difference in the reporter gene assays between 
classical vitamin D signalling and the induction of reporter gene activity mediated by 
the cds. Whereas coexpression of VDR/RXR did not affect reporter gene activity of the 
p(DR3)4tkluc plasmid in the absence of 1,25(OH)2D3 and TGFb, it led to a 3-fold 
stimulation of luciferase activity of vector constructs containing the 5-LO cds in HeLa 
cells (paper II: fig. 3). This suggests that there is a considerable ligand-independent 
activity of the VDR regarding the induction of reporter gene activity mediated by the 
5-LO cds. Inclusion of the last four introns (J, K, L and M) further enhanced the 
inducibility of the reporter gene constructs. 
In agreement with the fact that 1,25(OH)2D3 predominantly acts by binding to 
VDR/RXR heterodimers, overexpression of both NRs is required for full induction of 
luciferase activity by 1,25(OH)2D3/TGFb (fig. 19). Hence, although 1,25(OH)2D3 action 
through the cds displays evident differences from classical  1,25(OH)2D3 signalling, 
VDR/RXR heterodimers are clearly involved. Discussion  
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Compared to the 5-LO negative cell line HeLa, in the 5-LO permissive Caco-2 cells the 
1,25(OH)2D3/TGFb mediated activation of 5 -LO expression is rather low and non-
synergistic (fig. 18), which might be due to different tissue-specific expression levels of 
1,25(OH)2D3/TGFb and/or required cofactors. 
As it was previously found in MM6 cells, 1,25(OH)2D3 and TGFb  augment 5 -LO 
mRNA expression mainly by posttranscriptional mechanisms (Härle et al., 1998). RT-
PCR data obtained with MM6 cells (paper II: fig. 1) revealed a prominent induction of 
mature 5 -LO mRNA but not pre-mRNA by 1,25(OH)2D3/TGFb, which suggests 
enhanced mRNA processing as mechanism of 5-LO upregulation. This conclusion is 
also supported by the increased inducibility of intron-containing plasmids by 
1,25(OH)2D3/TGFb in reporter gene assays, suggesting that splicing processes are 
involved. Generally, the presence of introns in the transcription unit was shown to 
activate gene expression in yeast and mice (Ares et al., 1999; Fong and Zhou, 2001). 
Another possible mechanism could be transcriptional arrest mediated by the cds that is 
overcome by 1,25(OH)2D3 and TGFb. However, such a mechanism is rather unlikely 
because RT-PCR data show that there is only low expression of the middle part of the 
5-LO cds but not of the 3’-end. Furthermore, inducibility by 1,25(OH)2D3/TGFb was 
rather low with the pN10-cdsInJM-inv plasmid, which contains the 5-LO cds behind the 
luciferase reporter gene. However, a transcriptional stop site should also be operative 
under these conditions. 
It can only be speculated, whether the first (very long) introns of the 5-LO gene also 
participate in its regulation. It was not possible to include these introns in the reporter 
gene vectors because of their huge size. Thus, it is very well possible that these introns 
also participate in the regulation of the 5 -LO gene expression. In consequence, the 
observed 1,25(OH)2D3/TGFb effects on 5 -LO expression in MM6 cells and in the 
reporter gene assays performed in this investigation might be due to slightly different 
mechanisms. 
The partial inhibition of the 1,25(OH)2D3/TGFb effects by CHX suggests that the 
response to both agents requires at least in part protein biosynthesis. Thus, it is possible 
that 1,25(OH)2D3/TGFb induce the biosynthesis of proteins involved in 5-LO mRNA 
splicing and/or other processing reactions. This circumstance would explain the 
observed induction of luciferase activity without concomitant increases in the mRNA 
level in the reporter gene assays. In the constructs, the 5-LO and luciferase coding Discussion  
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sequences are merged in frame so that translation of the transcribed mRNA yields a 
5-LO-luciferase fusion protein. Thus, aberrant RNA processing that leads to a frame 
shift in the 5 -LO coding region prevents correct translation of the luciferase. 
Consequently, induction of correct 5 -LO mRNA processing by 1,25(OH)2D3/TGFb 
generates correctly translated luciferase protein and subsequent activity. 
Taking the existance of some rather weak 5’ splice sites in the 5-LO gene (chapter 1.9, 
tab. 2) into consideration, it appears likely that auxiliary sequences help to specify the 
appropriate splice sites. Usually, the pairing of the correct splice sites is thought to be 
achieved by either exon or  intron definition. Dependent on the sizes of exons and 
introns, bridging factors between the spliceosome components U1 snRNP (bound to the 
5’ splice site) and U2 auxiliary factor (U2AF, bound to the polypyrimidine tract) span 
either the exon or the intron (Berget, 1995). SR proteins belonging to the superfamily of 
arginine and serine rich splicing factors have been suggested to act as exon-bridging 
proteins in constitutive splicing. Their ability to bind exon sequences via their RNA 
binding domains and to interact with U2AF and U1 snRNP through their RS domains 
supports this hypothesis. Interactions between SR proteins bound to neighboring exons 
are also likely to be involved in juxtaposing exons  (Berget, 1995; Fu, 1995). The 
definition of corresponding splice sites across the exon or intron cannot occur on 
terminal exons, but instead is suggested to involve interactions with the 5’ cap structure 
and poly-A site, respectively (Black, 1995). Sequences have been identified that can 
activate the use of weak splice sites independently from exon-bridging interaction. Most 
of these are purine-rich splicing enhancers located in the exon downstream of the 
stimulated intron that are involved in the recruitment of U2AF. Complexes that 
assemble on an exonic splicing enhancer contain U1 snRNP and SR proteins. SR 
proteins play a role in the recognition of splicing enhancers, in stabilizing U1/5’ splice 
site interactions and in defining a functional 5’ splice site. Furthermore, they stimulate 
and/or stabilize U2-U6 interaction at the 3’ splice site and also at later stages of 
spliceosome assembly. Splicing enhancers have been described to be involved in 
constitutive as well as in alternative splicing. In addition, positive-regulatory sequences 
that are not purine-rich exist in introns (Black, 1995; Fu, 1995; Graveley, 2000; Mount, 
2000; Schaal and Maniatis, 1999; Yeakley et al., 1996). Heterogeneous nuclear RNA 
particle (hnRNP) proteins have been proposed to bind to intronic consensus sequences 
(silencers), to affect 5’ splice site recognition antagonistically to SR protein function, 
and to be involved in differential splicing (Berget, 1995; Fu, 1995; Yang et al., 1994). Discussion  
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As already mentioned in chapter 1.9, a sequence highly homologous to an exonic 
splicing enhancer composed of repetitive GAA elements has been detected in exon 14 
of the 5 -LO gene. This splicing enhancer has been reported to be recognized by a 
complex of nuclear proteins including a specific SR protein and a GAA-binding protein 
and to recruit additional SR proteins (Yeakley et al., 1996). It is tempting to speculate 
about the relevance of such a sequence in the 5-LO cds. 
Interestingly, bifunctional proteins displaying features of classical transcription factors 
and coactivators as well as of SR protein splicing factors (e.g. PGC-1, a coactivator of 
many NRs) or of interaction with RNA or RNA-binding proteins (e.g. Pu.1) have been 
discovered (Bentley, 2002; Monsalve et al., 2000). Strikingly, Pu.1-binding to the 5-LO 
promoter has been reported (Silverman et al., 2002) and putative Pu.1 binding sites are 
also located in the 5-LO coding and intron sequences (chapter1.9). 
As already mentioned in chapter 1.12.3, NRs such as VDR have recently been shown to 
be involved in coupling of transcription to  splicing  (Zhang et al., 2003). mRNA 
processing events that have been observed to be affected by steroid hormones include 
intron retention, 5’ splice site selection, exon skipping and inclusion, terminal exon 
selection, and polyadenylation. Ligand-activated steroid hormone receptors have been 
proposed to bind to target DNA REs and recruit cell-specific coregulators. Some of 
these like the hnRNP-like protein coactivator activator (CoAA) are involved both in 
transcriptional and splicing regulation (Auboeuf et al., 2002). CoAA also enhances the 
activity of various transcription factors and in turn CoAA activity may be influenced by 
other promoter-recruited coregulators  (Auboeuf et al., 2004). Interestingly, CoAA 
action has been reported to be not promoter-specific (Iwasaki et al., 2001), which would 
be consistent with the results obtained by reporter gene assays in this study. In chapter 
1.12.3 the NR coactivator SKIP/NCoA62 has already been described as another 
candidate for interconnecting  VDR-mediated transcription and mRNA splicing. The 
binding interface located in VDR helix 10 is thus distinct from the interface in helix 12 
bound by p160 coactivators. Consistent with VDR-SKIP/NCoA62 interactions having 
been described to occur ligand-independently (Barry et al., 2003) a 1,25(OH)2D3/TGFb-
independent effect has also been measured by VDR/RXR cotransfection in reporter 
gene assays with plasmids containing the 5 -LO cds (paper II: fig. 2; fig. 15). 
Alternatively, endogenous 1,25(OH)2D3 and/or low corepressor levels might be 
responsible for this induction. Inhibition of VDR-TFIIB interactions (thereby releasing 
TFIIB into the transcription preinitiation complex) and facilitation of VDR-RXR Discussion  
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interactions by the ligand and the concurrent binding of the coactivator GRIP-1 to the 
AF-2-dependent hydrophobic cleft  (Barry et al., 2003) may account for the 
1,25(OH)2D3/TGFb-mediated effect in our transient transfection experiments (paper II: 
fig. 4; fig.18). Zhang et al reported a 1,25(OH)2D3-induced increase in the interaction of 
endogenous VDR, SRC-1, and SKIP/NCoA62 with the VDREs in the native rat 
24-hydroxylase promoter as determined by ChIP analysis (Zhang et al., 2003). Hence, 
the regulation of 5-LO gene expression seems to differ from classical signalling through 
VDREs at least with respect to the observed promoter-independency. Nevertheless, the 
assembly of VDR and several coregulators in multi-protein complexes presumably 
contributes to 1,25(OH)2D3/TGFb-action in 5 -LO regulation. Interactions of 
SKIP/NCoA62 with key components of the spliceosome that are critical for proper 
excision of introns from pre-mRNA and the accumulation of unspliced transcripts 
following SKIP/NCoA62 disruption indicate an additional role of SKIP/NCoA62 in the 
splicing process (Makarov et al., 2002; Zhang et al., 2003). Thus, a complex containing 
the VDR, other transcription factors like Pu.1, coactivators like SKIP/NCoA62 and 
CoAA, and splicing factors like SR proteins might provide the link between 
transcriptional and posttranscriptional regulation of 5-LO gene expression. In summary, 
our results with the 5 -LO cds clearly support the concept that mRNA 
processing/splicing is involved in the regulation of gene expression by 
1,25(OH)2D3/TGFb. The competitive recruitment of coregulator proteins like CoAA 
and/or SKIP/NCoA62 required for the transcriptional activity of a promoter to VDR 
containing multi-protein complexes built up on the transcript might account for the low 
reporter gene activity of the 1,25(OH)2D3/TGFb responsive 5 -LO cds-containing 
plasmids (Auboeuf et al., 2004). On the other hand, formation of the 5-LO-luciferase 
fusion protein might be the reason for the attenuated basal reporter gene activity. 
Since purified SR proteins have been reported to bind nonspecifically to RNA, it has 
been suggested that  interaction with other nuclear proteins confers RNA-binding 
specificity to these splicing factors (Fu, 1995). The VDR or other transcription factors 
might be such binding proteins. The interface for RNA-binding probably is distinct 
from the DNA-binding interface (DBD). Moreover, 1,25(OH)2D3, RA and TGFb have 
been described as stimuli of alternative splicing events. It has been hypothesized that 
nuclear hormones and their receptors influence alternative splicing by changing the 
conformation of the CTD of the largest subunit of RNA polymerase II, which directs Discussion  
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splicing, capping, and polyadenylation factors to pre-mRNA  (Akker et al., 2001; 
Magnuson et al., 1991). The hyperphosphorylated form of RNA polymerase II CTD has 
been proposed to serve as loading platform for RNA processing factors. In contrast to 
the diffuse distribution of many basic transcription factors in the nucleus, polymerase II 
also colocalizes with splicing factors in their presumable storage compartment, the 
nuclear speckles. Upon activation of transcription, RNA polymerase II and splicing 
factors translocate to the periphery of the speckles, where active mRNA synthesis 
occurs. Phosphorylation of SR proteins is also involved in their release. It has been 
suggested that sequence-specific DNA binding proteins or transcriptional coactivators 
might be involved in the recruitment of distinct processing factors to promoter-bound 
RNA polymerase II (Hirose and Manley, 2000; Monsalve et al., 2000). However, the 
recruitment of splicing factors by 5-LO promoter-bound VDR seems rather unlikely due 
to the observed promoter-independent upregulation of reporter gene activity by 
1,25(OH)2D3 and TGFb. 
RT-PCR analysis of the transcripts generated in the transiently transfected HeLa cells 
was difficult to perform when the region between exon 8 and 13 was amplified. More 
cycles were necessary (paper II: tab. 1) and in some PCR reactions multiple products 
were detected. Although trying several sets of primers, it was not possible to amplify 
the whole cds, at least three definite bands that were smaller than expected were 
obtained. It cannot be ruled out that strong secondary structures of the mRNA in this 
region simply disturbed the RT-PCR reactions, though. Sequencing a 450 bp PCR 
product solely allowed to verify the last 100 bp of exon 14. The sequencing data further 
upstream could not be interpreted due to superimposing of different sequences. Taken 
together, it seems that in untreated HeLa cells, 5-LO mRNA processing occurs that 
removes parts of the cds. RT-PCR data suggest that 1,25(OH)2D3/TGFb induce the 
generation of more complete transcripts. On the other hand, the artificial construction of 
the intron-containing plasmid might be responsible for these observations. In the pN10-
cdsInJM construct the “first” exon, containing exons 1 -10, is extremely large. 
Consequently, exon recognition may be disturbed. Nevertheless, one previous 
publication reporting the occurence of differential 5-LO expression (Boado et al., 1992) 
and 1,25(OH)2D3-induced changes in the alternative splicing of fibronectin pre-mRNA 
(Magnuson et al., 1991) indicate consistency with aberrant splicing of 5-LO pre-mRNA 
that is suppressed by 1,25(OH)2D3/TGFb. Discussion  
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Coding sequence deletion studies (paper II: figs. 7 and 8) revealed that the respective 
deletion  of parts A to D reduced induction of reporter gene activity by 
1,25(OH)2D3/TGFb (paper II: fig. 8). In constructs in which larger parts of the cds are 
deleted (pdcdsABC and pdcdsBCD), the 1,25(OH)2D3-mediated induction of reporter 
gene activity was almost  completely lost and only the minor TGFb-mediated 
enhancement could be measured. The fact that deletion of large parts of the cds is 
required in order to achieve  an almost complete loss of the response to 
1,25(OH)2D3/TGFb suggests that the regulation of 5-LO mRNA processing by both 
agents involves multiple parts of the cds. Similarly, the regulation of the sex-specific 
alternative splicing of the Drosophila transformer (tra) gene involves multiple binding 
sequences for the negative regulator  Sex lethal ( Sxl) located both upstream and 
downstream of the respective exon (Inoue et al., 1995). 
The attempt to identify functional binding sites for the VDR in the cds by deletion of 
putative VDREs found by sequence analysis failed (fig. 20). Together with the fact, that 
no distinct part of the cds could be shown to be essential for  1,25(OH)2D3/TGFb-
mediated induction of 5 -LO expression, this might lead to the suggestion, that 
interaction of the VDR to the cds involves a binding interface other than the DBD and 
sequence elements distinct from the classical VDREs. Alternatively, the VDR may bind 
to another DNA or RNA binding protein (possibly part of a multi-protein complex, see 
above). 
In order to antagonize the 1,25(OH)2D3-mediated effects, transiently transfected HeLa 
cells have been incubated with the 1,25(OH)2D3 analogon ZK191732. Interestingly, the 
compound displayed clear antagonistic features on 5 -LO activity in MM6 cells 
(Gaschott et al., 2001), whereas concerning endogenous 5 -LO protein expression 
antagonistic as well as agonistic effects could be distinguished (fig. 23). Thus, like 
many 1,25(OH)2D3 analoga ZK191732 is a typical selective VDR modulator (also see 
chapter 1.12.3). In the reporter gene assay system the intrinsic VDR agonistic activity of 
the compound seems to be selectively determined (fig. 22). Transfection of the positive 
control p(DR3)4tkluc as well as of pN10-cdsInJM led to the identification of ZK191732 
as agonist, suggesting that the agonistic action is not specific for 5-LO and might also 
be mediated through classical VDREs. The increased potency and dose-dependency 
observed for pN10-cdsInJM compared to p(DR3)4tkluc again indicates differential 
signalling pathways, though. Discussion  
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In summary, the results provide clear evidence that the 5-LO coding region mediates the 
upregulation of 5-LO expression by 1,25(OH)2D3 and TGFb. These effects do not seem 
to be mediated by classical VDREs in the cds. The here reported data suggest that both 
mediators regulate 5 -LO mRNA processing and possibly involve interaction of the 
liganded VDR with coactivators like SKIP/NCoA62 and/or CoAA that in turn associate 
with spliceosome components, which represents a novel mechanism in the regulation of 
gene expression by 1,25(OH)2D3 and TGFb. 
 
 
5.3  Induction of 5-LO gene expression by the Smad pathway 
 
The role of TGFb and Smad signalling in 5 -LO gene regulation with respect to a 
possible participation of sequences located in the cds was investigated. Coexpression of 
Smads, the downstream effectors in TGFb signalling, strongly enhanced reporter gene 
activity in reporter gene constructs containing the 5-LO cds. Interestingly and consistent 
with the above described VDR/RXR and 1,25(OH)2D3 effects, this upregulation did not 
depend on the 5-LO promoter and was also observed with the respective pGL3-basic 
and pGL3-promoter plasmids pGL3-ba-cdsInJM and pGL3-prom-cdsInJM. 
Furthermore, the strong coding sequence-dependent induction of reporter gene activity  
was only observed with Smads but not with TGFb as stimulus, indicating that this effect 
mainly depends on Smads but not on TGFb signalling in general. However, cell culture 
media have not been serum-depleted. Thus, TGFb contained in FCS supplements might 
have attenuated the measured TGFb-mediated effects. 
Deletion of exon 10 to exon 14 (part C) of the 5-LO cds abolished the Smad effect 
suggesting that this part contains essential REs required for Smad signalling. Deletion 
of other parts of the cds also reduced inducibility by Smads3/4 which points to the 
existence of additional REs in the other parts of the cds. 
In silico analysis of the 5-LO gene revealed putative SBEs within the promoter as well 
as in the 3’-UTR, the coding region and in particular in the region from exon 10 to 14. 
Interestingly, deletion of a Smad consensus sequence in exon 10 strongly reduced 
response to Smad3/4 coexpression. Additionally, reduction of the Smad effects was also 
observed when a short DNA stretch within intron M was deleted that contains 4 putative 
SBEs suggesting that these elements might be involved in the regulation of 5 -LO Discussion  
78 
expression by the TGFb/Smad pathway. Interestingly, coexpression of Smads did not 
significantly alter the response to TGFb (paper III: figs. 4, 7A+B, 8C) and deletion of 
various parts of the cds did not significantly change the effects of TGFb on reporter 
gene activity. Furthermore, compared to Smads, the TGFb-mediated effect is rather low 
and does not differ between the different plasmids and related deletion constructs in the 
reporter gene assays. The data suggest, that at least under the experimental conditions of 
the reporter gene assays, the cellular availability and maybe the nuclear localization of 
Smad proteins seem to be the limiting and critical parameter in the upregulation of  
luciferase gene activity. 
As found before for the regulation of cellular 5-LO mRNA expression in the human 
monocytic cell line MM6 (Härle et al., 1999) and in reporter gene assays (paper II: 
fig. 4), there is a synergistic effect between TGFb and vitamin D signalling. In 
agreement, the highest reporter gene activity was obtained when VDR/RXR and Smads 
were cotransfected and TGFb and 1,25(OH)2D3 were added (paper III: fig. 5). The 
influence of 1,25(OH)2D3 alone is attenuated and induction values are rather decreased, 
though, which is probably due to a near to maximal upregulation level. Interaction 
between the TGFb and 1,25(OH)2D3 signalling pathways has previously been 
described. The VDR has been shown to physically and functionally interact with Smad3 
and Smad7 in vitro and in vivo (Aschenbrenner et al., 2001; Yanagi et al., 1999; Yang et 
al., 2001b). Since the affinity of Smads to SBEs is rather weak, probably additional 
DNA contacts via binding partners such as the VDR are required (more information in 
chapter 1.12.4).  In another publication, multiple mechanisms responsible for 
TGFb/1,25(OH)2D3 crosstalk have been reported: ligand-binding to the VDR induces 
TGFb mRNA expression, the VDR enhances TbRII expression in certain cell types, 
Smad3 activates the VDR and the crosslink is dependent on the PI 3-kinase pathway 
(Yang et al., 2001b). The performed experiments suggest that 5-LO is another example 
for a gene where Smads and the VDR interact and activate transcription in concert. To 
measure the TGFb-mediated upregulation a 24 h preincubation time was required, 
indicating that 5-LO is not an immediate response gene of this mediator. Thus, the 
above described hierarchical model of gene regulation by TGFb (chapter 1.12.4) might 
be supported by 5-LO gene expression. TGFb-mediated activation of Smad3 may lead 
to upregulation of the VDR, thereby amplifying 5-LO induction by 1,25(OH)2D3. Discussion  
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Interestingly, the NR coactivator SKIP/NCoA62 that has been shown to interact with 
VDR and also with components of the splicing machinery  (Zhang et al., 2003), in 
addition has been found to augment TGFb-dependent transactivation by direct binding 
to Smad proteins (Leong et al., 2001). Thus, this coactivator might establish a functional 
link between the 1,25(OH)2D3 and TGFb pathway in 5-LO gene regulation. Moreover, 
the participation of mRNA processing reactions in the Smad-mediated induction of 
5-LO expression is indicated. This suggestion is further supported by the identification 
of novel Smad binding proteins that are involved in translation initiation and splicing. 
One of these is the splicing factor SF3b2/SAP145. The multiprotein complex SF3b is an 
integral component of both the major RNA splicing complex U2 snRNP and the minor 
RNA splicing complex U11/U12 di-snRNP and is essential for spliceosome assembly 
and the accurate excision of introns from pre-mRNA (Golas et al., 2003; Martinez et al., 
2001; Warner et al., 2003). Moreover, it is highly concentrated in nuclear speckles 
(Eilbracht and Schmidt-Zachmann, 2001) (also see chapter 5.3) and its subunit 
spliceosome-associated protein 130 (SAP130)  interacts with the HAT-containing 
coactivator complex STAGA (SPT3-TAFII31-GCN5L acetylase)  (Martinez et al., 
2001). 
In summary, the presented results provide evidence for the participation of the Smad 
signalling pathway in 5-LO gene regulation. Furthermore, the involvement of the cds in 
Smad signalling was demonstrated and some SBEs located in exon 10 and intron M 
have been identified that seem to be relevant for the regulation of 5-LO expression by 
Smads. Further experiments will be required to prove binding of Smads to these sites. 
In conclusion, the involvement of multi-protein complexes containing Smad proteins, 
VDR-RXR heterodimers, additional transcription factors, several coactivators, RNA 
polymerase II, and splicing factors in the regulation of 5 -LO gene expression by 
1,25(OH)2D3/TGFb is highly indicated. Thus, 5-LO gene transcription appears to be 
closely connected to mRNA processing events. Aberrant RNA splicing seems to be at 
least one mechanism to downregulate 5-LO in undifferentiated cells which is overcome 
by 1,25(OH)2D3/TGFb stimulation. 
 
 
 
 Discussion  
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5.4  Histone acetylation: impact and crosstalk with other signalling 
pathways in the regulation of (5-)LO gene expression 
 
Inhibition of HDAC activity affects the expression of only 2 % of mammalian genes 
(Van Lint et al., 1996). However, the butyrate-induced upregulation of 5 -LO and 
15-LO-1 mRNA (Kamitani et al., 2000; Wächtershäuser et al., 2000) and the valproate-
induced increase of 5-LO protein (Yildirim et al., 2003) indicate the involvement of 
histone acetylation in the regulation of LOs. Recently, it was shown that the 5-LO 
promoter was heavily methylated in 5-LO negative cell lines such as U937 (Uhl et al., 
2002). In this cell line, 1,25(OH)2D3/TGFb and demethylation by AdC show additive 
effects on 5-LO upregulation. Since methylated CpG sites are recognized by a variety of 
methyl-CpG-binding proteins that are associated either directly or indirectly with 
HDACs (Ballestar and Wolffe, 2001), chromatin condensation could be one regulatory 
mechanism of 5 -LO gene transcription (Ponton et al., 1996). For these reasons and 
because the HDACi TsA leads to hypomethylation at specific CpGs, it was of interest to 
investigate the regulation of 15-LO by histone acetylation and 1,25(OH)2D3/TGFb and 
the possible interplay of both in U937 cells, in comparison. In fact, 15-LO mRNA 
expression is enhanced by TsA but not by 1,25(OH)2D3/TGFb, suggesting that the 
15-LO promoter like the 5-LO promoter is regulated by the histone acetylation status. 
Interestingly, combination of 1,25(OH)2D3/TGFb with TsA seems to suppress TsA-
mediated 15-LO mRNA induction. 
5-LO expression is induced by TsA treatment as determined by RT-PCR in MM6 cells 
and by reporter gene assays with the 5-LO promoter reporter gene construct in HeLa 
and MM6 cells. This TsA-mediated increase in 5-LO promoter activity was independent 
of the presence of 1,25(OH)2D3/TGFb and VDR/RXR coexpression in reporter gene 
assays. In contrast, luciferase assays with the p(DR3)4tkluc construct indicated a 
synergistic mechanism of 1,25(OH)2D3 signal transduction and histone deacetylation, 
which is in agreement with previous observations made with other targets (Chen et al., 
1999; Massagué and Wotton, 2000; Rachez and Freedman, 2000; Shen et al., 2002) 
(chapter 1.12.3). 5-LO mRNA levels in MM6 cells were predominantly increased by 
1,25(OH)2D3/TGFb treatment, and the combination of both agents with TsA suppressed 
the 1,25(OH)2D3/TGFb effect. Discussion  
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Reporter gene assays with cds-containing plasmids led to similar results (fig. 27). Here, 
TsA seemed to inhibit the cds-mediated of 1,25(OH)2D3/TGFb-induced 5 -LO 
upregulation. Taken together, it is suggested, that TsA mediates transcriptional 
activation by leading to 5 -LO promoter hyperacetylation. Presence of the cds (and 
introns) opposes this e ffect. Since 1,25(OH)2D3 is able to induce histone 
hyperacetylation at the promoters of target genes through VDR and its associated 
coactivators (Chen et al., 1999), part of the 1,25(OH)2D3/TGFb-mediated induction of 
5-LO gene expression may be exerted by 5-LO promoter hyperacetylation. However, 
the strong induction of the promoterless construct pGL3-ba-cdsInJM is in contrast to 
this suggestion. Furthermore, pN10 in contrast to the cds-containing constructs does not 
significantly respond to 1,25(OH)2D3/TGFb and treatment with 
1,25(OH)2D3/TGFb/TsA does not differ from TsA alone. This observation supports the 
finding of 1,25(OH)2D3/TGFb effects on 5-LO mRNA processing which cannot occur 
using pN10. 
 
It has been shown that transcription from Sp1-driven promoters can be repressed by a 
tight association of the transcription factor Sp1 with HDAC1 in a multi-protein complex 
(Doetzlhofer et al., 1999). However, with respect to 5-LO it is obvious that inhibition of 
HDACs by TsA and the subsequent induction of 5-LO promoter transcription does not 
depend on the presence of the five tandemized Sp1 and Egr-1 sites in the 5-LO proximal 
core promoter region, which were found to be essential for basal transcription in 
previous studies (Uhl et al., 2002). These results suggest that there are binding sites for 
transcription factors outside of the five tandemized GC-boxes, which can recruit 
HDACs to the 5-LO promoter. For the promoters of some other genes like the HMG-
CoA (3-hydroxy-3-methylglutaryl-CoA) synthase, the human adenine nucleotide 
translocase isoform 2 (ANT2), p21
Waf1/Cip1, and Gai2, HDACi-mediated stimulation of 
gene expression has been mapped to promoter proximal Sp1 sites located in similar 
positions relative to the transcriptional start site (between -120 to -30 bp) (Camarero et 
al., 2003; Hodny et al., 2000; Nakano et al., 1997; Yang et al., 2001a). Based on these 
reports, the two single promoter proximal putative Sp1 sites in the 5 -LO promoter 
(fig. 7, chapter 1.10) are possible candidates for the HDACi-mediated 5-LO promoter 
activation. Consistently, the region containing both putative Sp1 sites (pN13) was 
sufficient for TsA-dependent upregulation of 5-LO promoter activity (paper IV: fig. 3). Discussion  
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Deletion and mutation studies concerning these two sites are currently performed in our 
laboratory. 
Although Sp1 is required for basal 5 -LO promoter activity  (Uhl et al., 2002), 
cotransfection of Sp1, Sp3 or Sp4 does not elevate luciferase activity of the promoter 
construct pN10 (figs. 25, 28B+E+H). This might be due to the high endogenous Sp1 
level of HeLa cells. 
Transient transfection experiments with 5-LO promoter reporter gene constructs with or 
without the 5 -LO cds plus introns J -M revealed synergistic e ffects for histone 
hyperacetylation and Sp1 or Sp4 that depend upon the presence of the cds and introns 
J-M (fig. 28). The response of the 5-LO promoter (pN10) to TsA is enhanced by Sp4 
but not Sp1 or Sp3 overexpression. Sp3 that can inhibit Sp1-mediated transactivation 
(Suske, 1999) does not induce either plasmid. It contains an inhibitory domain that has 
been described to be essential for silencing of its transcriptional activity in cell culture 
experiments. Like many other transcription factors, Sp3 is regulated by acetylation 
(Braun et al., 2001). Previously, Sp1 has also been shown to be phosphorylated (Choi et 
al., 2002) and acetylated  (Ryu et al., 2003) following HDACi treatment. The 
subsequently increased affinity of Sp1 to its binding sites might be the explanation for 
the enhanced induction by Sp1 when cells were also treated by TsA. Furthermore, the 
affinity of Sp1 to the SV 40 early promoter was prominently reduced in a nucleosomal 
context compared to naked DNA (Li et al., 1994), and the purified ATP-dependent 
chromatin remodeling SWI/SNF complex stimulated nucleosome-binding by Sp1 
(Utley et al., 1997). Hence, the synergistic effects of TsA and Sp1 or Sp4 mediated by 
the cds plus introns J-M may be due to a facilitation of Sp binding by disruption of the 
nucleosomal structure. The dependency of this profound increase on the presence of the 
cds plus introns J-M further indicates the existance of Sp binding sites in this part of the 
5-LO sequence. An alternative explanation would be a TsA-mediated upregulation of 
Sp1 and Sp4. However, Choi  et al. did not observe changes in Sp1 protein levels 
following TsA incubation in Hep3B cells (Choi et al., 2002). In addition, Sp1 has been 
shown to interact with Sp3, HDAC1 and p300. TsA treatment led to the dissociation of 
Sp3 and HDAC1 from the multi-protein complex (Choi et al., 2002). Dissociation of 
HDAC1 from the complex led to a release of repression, enabling Sp1 to associate with 
other accessory proteins to affect transcription  (Yang et al., 2001a).  Thus, it is 
suggested, that TsA regulates multi-protein complexes that might also contain other 
transcription factors such as YY1 that interact with Sp1 and/or HDACs ((Doetzlhofer et Discussion  
83 
al., 1999) and references therein). Since only a small percentage of the large number of 
Sp1 responsive genes are also activated by HDACis, the involvement of additional 
factors in the targeting of HDACs to specific promoters is highly indicated (Hodny et 
al., 2000).  In contrast to the above described data, butyrate did neither affect Sp1 
phosphorylation nor binding of Sp1 or Sp3 to the WAF1/Cip1 promoter (Nakano et al., 
1997), which might be due to different mechanisms of TsA and butyrate. In summary, 
5-LO gene expression is synergistically induced by histone hyperacetylation and 
Sp1/Sp4 in a cds- and/or introns J-M-dependent manner. Due to data from other target 
genes, enhanced affinity of Sp transcription factors to remodeled chromatin, 
posttranslational modifications of Sp family members and the regulation of multi-
protein complexes might contribute to this crosstalk. However, to elucidate the 
mechanism, additional experiments such as co-immunoprecipitation studies, EMSAs or 
ChIP assays will be required. 
In transient transfection experiments with the 5-LO promoter reporter gene construct 
pN10, TsA treatment reduced methylation-dependent repression, indicating that 
recruitment of HDACs could be involved in gene silencing by DNA methylation. The 
association of MBDs with HDACs has already been reported (Ballestar and Wolffe, 
2001; Ng et al., 1999). In addition, HDAC-independent mechanisms seem also to play a 
role, since the presence of TsA could not completely prevent the methylation-dependent 
suppression. Thus, the dominance of methylation versus TsA-sensitive histone 
deacetylation in silencing the 5 -LO promoter is indicated, which results in a TsA-
resistant repression (Boeke et al., 2000; Yu et al., 2000). This is similar to other reports, 
which showed that transcriptionally silenced genes in cancer cell lines can be partially 
reactivated in the presence of a Dnmt inhibitor, but complete reactivation was not 
achieved (Rice and Allis, 2001; Singal and Ginder, 1999). 
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6  Summary 
 
Arachidonate 5 -lipoxygenase (5-LO), the key enzyme in the biosynthesis of 
proinflammatory leukotrienes,  catalyzes the conversion of arachidonic acid to (5S)-
hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic acid (5-HpETE) and further to 
leukotriene A4 ((5S)-6-oxido-7,9,11-trans-14-cis-eicosatetraenoic acid). 
The cell type- and differentiation-specifically expressed enzyme occurs in a variety of 
immune competent cells. 5-LO is regulated on transcriptional and posttranscriptional 
levels. Basal 5-LO promoter activity seems to be regulated by DNA methylation in a 
tissue-specific manner.  Depending on the cell type, several cytokines like 
granulocyte/macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) 
have been shown to be inducers of the 5-LO pathway. 5-LO mRNA, protein expression, 
and activity are strongly increased during differentiation of myeloid cell lines such as 
Mono Mac 6 (MM6) and HL-60 cultured with transforming growth factor-b (TGFb) 
and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3). In this study, a profound cytosolic and 
nuclear accumulation of mature 5-LO mRNA but not of pre-mRNA has been measured 
in MM6 cells, which suggests enhanced mRNA processing as one mechanism of 5-LO 
upregulation. 
Sequence analysis of the 5 -LO promoter revealed the presence of several putative 
transcription factor binding sites including vitamin D response elements (VDREs). 
Binding of the vitamin D receptor-retinoid X receptor (VDR-RXR) heterodimer to 
putative VDREs within the 5 -LO core promoter region have been confirmed by 
DNAse I footprinting and electrophoretic mobility shift assay (EMSA) experiments. 
However, neither in transiently (luciferase assays with MM6, HeLa, RBL-1, HL-60, and 
U937 cells) nor in stably (RT-PCR with HL-60 cells) transfected cells 5-LO promoter 
reporter gene constructs were responsive to 1,25(OH)2D3/TGFb.  Since the stable 
integration of the sequence into the genome did not lead to inducibility, the simple lack 
of bridging factors or coactivators in transient transfections could be excluded. In 
contrast, a transiently transfected plasmid containing a 4-times concatemerized rat atrial 
natriuretic factor VDRE in front of the thymidine kinase promoter (p(DR3)4tkluc) was 
prominently activated by  1,25(OH)2D3/TGFb  when the expression vectors for the 
human receptors VDR and RXR were cotransfected. Taken together, it was strongly 
suggested that the effects of TGFb/1,25(OH)2D3 on 5-LO gene expression are mediated Summary  
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by regulatory elements located outside of the 5-LO promoter, which were absent in 
transient and stable reporter gene transfections. 
Exons, introns or the 3’untranslated region (3’UTR) might contain sequences like 
mRNA processing signals, elements that affect mRNA stability, or transcription factor 
binding sites. Thus, the possible contribution of these sequences to the regulation of 
5-LO gene expression has been investigated in transient transfection experiments 
predominantly  in HeLa cells.  Interestingly, inclusion of the coding sequence (cds) 
caused a 5-fold upregulation of reporter gene activity by TGFb and 1,25(OH)2D3 which 
was enhanced to 13-fold when the last four introns of the 5-LO gene were also included. 
This induction of reporter gene activity depended on the availability of sufficient 
amounts of both nuclear receptors VDR and RXR. T here even seems to be a 
considerable ligand-independent activity of the VDR regarding the induction of reporter 
gene activity mediated by the 5-LO cds. Strikingly, the effect did not depend upon the 
presence of the 5-LO promoter but was also obtained with plasmids containing a CMV 
or even no promoter. RT-PCR analysis of the transcripts generated by the transfected 
cells implies that parts of the cds are removed during 5-LO mRNA processing leading 
to incomplete transcripts. Addition of TGFb and 1,25(OH)2D3 induced the appearance 
of exon 13 in the 5-LO transcripts which is reflected by an about 14-fold increase of the 
corresponding PCR product. The partial inhibition of the 1,25(OH)2D3/TGFb effects by 
cycloheximide suggests that the response to both agents requires at least in part protein 
biosynthesis. Thus, it is possible that 1,25(OH)2D3/TGFb induce the generation of 
proteins involved in 5-LO mRNA splicing and/or other processing reactions. Deletion 
of various parts of the 5 -LO cds slightly reduced the inducibility by TGFb and 
1,25(OH)2D3, whereas deletion of large parts of the cds was required for an almost 
complete loss o f this response. This suggests that the regulation of 5 -LO mRNA 
processing by TGFb and 1,25(OH)2D3 involves multiple parts of the cds. 
Previously, the  1,25(OH)2D3 analogon ZK191732 has been shown to display clear 
antagonistic features on 5-LO enzyme activity in MM6 cells. However, in this thesis the 
compound induced endogenous 5 -LO protein expression but in combination with 
1,25(OH)2D3/TGFb partly antagonized the marked 5-LO protein upregulation by these 
agents in MM6 cells. In contrast, the analogon prominently induced the reporter gene 
activity of both the VDRE control plasmid and the 5-LO promoter and cds plus introns-
containing plasmid in transiently transfected HeLa cells. Nevertheless, activation of the Summary  
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control plasmid was less profound and not dose-dependent, implying a mechanism 
distinct from activation through classical VDREs in the cds-containing construct. 
In transient reporter gene assays Smads3/4,  the downstream effectors in TGFb 
signalling, mediated a prominent upregulation of reporter gene activity that strongly 
depended on the cds and to a lesser extent on the 3’-UTR and introns J to M. Since 
TGFb did not contribute to the effect to a large extent, it seemed to be mainly mediated 
by Smads. Thus, at least under the experimental conditions of the reporter gene assays, 
the cellular availability and maybe the nuclear localization of Smad proteins seems to be 
the limiting and critical parameter in the upregulation of  luciferase activity. The 
requirement for preincubation with TGFb in order to measure any induction by this 
agent indicates a secondary response mechanism. Like the effect mediated by 
VDR/RXR/1,25(OH)2D3, the upregulation of luciferase activity by Smads3/4 did not 
depend upon the 5-LO promoter. 
Deletion of various parts of the 5-LO cds reduced the inducibility by Smads3/4, the 
decrease being most profound when exons 10 to 14 were deleted. Deletion studies 
supported the existence of up to four functional Smad binding elements in intron M and 
another TGFb responsive element in exon 10 that h ad been detected by  sequence 
analysis before. 
The highest reporter gene activity was obtained when VDR/RXR and Smads3/4 were 
cotransfected and both TGFb and 1,25(OH)2D3 were added. This observation is in 
agreement with previous reports about VDR-Smad interactions and functional crosstalk 
between the TGFb and 1,25(OH)2D3 signalling pathways. Reports about interactions of 
Smad proteins with key components of the spliceosome further support a role of mRNA 
processing events in the regulation of 5-LO gene expression. 
In conclusion, 5-LO seems to be downregulated in undifferentiated cells by aberrant 
mRNA processing (splicing, mRNA maturation). Differentiation by 1,25(OH)2D3/TGFb 
activates 5 -LO gene expression by a mechanism possibly involving  multi-protein 
complexes containing Smad proteins, VDR-RXR heterodimers, other transcription 
factors, several coactivators, RNA polymerase II, and splicing factors. 
Several reports indicate the involvement of epigenetic mechanisms in the regulation of 
gene expression of lipoxygenases. In the 5 -LO negative cell line U937 the 5 -LO 
promoter is heavily methylated. Because of similarities in the gene expression of 
lipoxygenases it was of interest to investigate 15-LO expression in U937 cells in Summary  
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comparison. The regulation of chromatin organization and DNA methylation are closely 
associated processes. In fact, 15-LO mRNA expression was enhanced by 
histonedeacetylase (HDAC) inhibition with trichostatin A (TsA) but not by 
1,25(OH)2D3/TGFb, suggesting that 15-LO like 5 -LO is regulated by  histone 
acetylation status. In contrast, 5-LO mRNA was not upregulated by TsA treatment in 
U937 cells, which might be due to a domination of DNA methylation over histone 
acetylation. This same dominance of methylation has also been observed in transient 
transfection analyses with Hpa II-methylated 5-LO promoter reporter gene plasmids, 
where DNA methylation reduced the TsA-mediated activation of reporter gene activity. 
The recruitment of HDACs being part of the methylation-dependent repression is 
indicated. However, 5-LO expression is induced by TsA treatment as determined by 
RT-PCR in MM6 cells and in reporter gene assays with the 5-LO promoter reporter 
gene construct in HeLa and MM6 cells. The combination of TsA with 
1,25(OH)2D3/TGFb suppressed the prominent increase of 5 -LO mRNA induced by 
1,25(OH)2D3/TGFb in MM6 cells. Consistently, in reporter gene assays with the 
1,25(OH)2D3/TGFb-responsive cds-containing constructs TsA reduces the strong 
induction of reporter gene activity mediated by 1,25(OH)2D3/TGFb. In contrast, control 
experiments with the p(DR3)4tkluc plasmid indicated a synergistic mechanism of 
1,25(OH)2D3 signal transduction and histone acetylation. The profound TsA-mediated 
increase in 5 -LO promoter activity was independent of 1,25(OH)2D3/TGFb and 
VDR/RXR coexpression, though. A synergistic activation was not expected since the 
5-LO promoter plasmid was not responsive to 1,25(OH)2D3/TGFb and VDR/RXR, 
anyway. Taken together, it is suggested, that TsA induces transcriptional activation by 
leading to 5-LO promoter hyperacetylation. Presence of the cds (and introns) opposes 
this effect possibly by recruitment of HDACs by proteins like the VDR or Smads. These 
proteins presumably directly or indirectly interact with regulatory elements in the 
coding region in either 5-LO DNA or mRNA. 
The basal activity of the 5-LO promoter strongly depends upon the presence of multiple 
Sp1-binding sites, five of which are in tandem. Deletion experiments revealed that the 
induction of 5-LO transcription does not depend on the presence of this GC-box. The 
region containing two single promoter proximal putative Sp1 sites was sufficient for 
TsA-dependent upregulation of 5-LO promoter activity. Since these Sp1 binding sites 
are in similar positions relative to the transcriptional start site like those in other gene Summary  
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promoters to which the HDACi-mediated stimulation of gene expression has previously 
been mapped, they are likely to be the target of TsA action. 
Transient transfection experiments with 5-LO promoter reporter gene constructs with or 
without the 5 -LO cds plus introns J -M revealed synergistic effects for histone 
hyperacetylation and Sp1 or Sp4 that depended upon the presence of the coding region 
and introns J-M. Also, the response of the 5-LO promoter to TsA was enhanced by Sp4 
overexpression. These synergistic effects may be due to a facilitation of Sp transcription 
factor binding by disruption of the nucleosomal structure. The results further suggest the 
existence of Sp binding sites in the 5-LO cds and/or introns J-M. Taken together, Sp1 
and Sp4 act in concert with histone acetylation in a cds-dependent manner to activate 
5-LO gene expression. 
 Zusammenfassung  
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7  Zusammenfassung 
 
Die 5 -Lipoxygenase (5-LO) ist das Schlüsselenzym in der Biosynthese 
proinflammatorischer Leukotriene. Sie katalysiert sowohl den Einbau von molekularem 
Sauerstoff in Arachidonsäure als auch die weitere Umsetzung des Zwischenproduktes 
(5S)-Hydroperoxy-6-trans-8,11,14-cis-eicosatetraensäure zu Leukotrien A4. 
Die 5 -LO wird zelltyp- und differenzierungsspezifisch exprimiert und kommt 
hauptsächlich in immunkompetenten Zellen vor. Die 5 -LO-Expression wird auf 
transkriptioneller und posttranskriptioneller Ebene reguliert. Die gewebespezifische 
Expression der 5-LO beruht auf der Regulation der basalen Promotoraktivität durch 
DNA-Methylierung. Als Stimuli der 5 -LO-Expression wurden Zytokine wie der 
Granulozyten/Makrophagen-Kolonie-stimulierende Faktor und Interleukin-3 
identifiziert. Werden myeloide Zelllinien wie Mono Mac 6 (MM6) und HL-60 mit 
1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) und transformierendem Wachstumsfaktor b 
(TGFb) differenziert, so kommt es zu einer gleichzeitigen starken Erhöhung der 5-LO-
mRNA- und -Protein-Bildung sowie der zellulären Enzymaktivität. Im Rahmen dieser 
Arbeit konnte in MM6-Zellen mittels RT-PCR-Analyse gezeigt werden, dass durch 
1,25(OH)2D3 und TGFb nur die reife, nicht jedoch die prä-mRNA der 5-LO im Zytosol 
und im Zellkern stark angereichert wird. Die Daten legen nahe, dass mRNA-
Prozessierungsvorgänge an der Hochregulation der 5-LO in differenzierenden Zellen 
beteiligt sind. 
Durch Analyse der 5 -LO-Promotor-Sequenz wurden potentielle Bindungsstellen für 
Transkriptionsfaktoren wie den Vitamin-D-Rezeptor (VDR) identifiziert. Tatsächlich 
konnte in DNAse I-Footprinting- und EMSA-Studien die Bindung von VDR-Retinoid-
X-Rezeptor (RXR)-Heterodimeren an einen bestimmten Bereich des 5-LO-Promotors 
(-307 bis –268 bp) gezeigt werden. Unerwarteterweise wurde jedoch weder ein 5-LO-
Promotor-Luziferase-Konstrukt in transient transfizierten Mono Mac 6-, HeLa-, 
RBL-1-, HL-60- und U937-Zellen, noch ein 5-LO-Promotor-CAT-Konstrukt in stabil 
transfizierten HL-60-Zellen durch 1,25(OH)2D3 und TGFb aktiviert. Daher konnte 
ausgeschlossen werden, dass das Fehlen von Cofaktoren oder anderen Regulatoren beim 
nicht stabil ins Genom integrierten Promotor der Grund für die fehlende Induktion war. 
Die Eignung der eingesetzten Testsysteme zum Nachweis von 1,25(OH)2D3/TGFb-
vermittelten Effekten konnte jedoch in Kontrollexperimenten gezeigt werden. Ein Zusammenfassung  
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transient transfiziertes Reportergen-Plasmid, das ein viermal konkatemerisiertes 
Vitamin D-Response Element (VDRE) des atrialen natriuretischen Faktors der Ratte vor 
dem Thymidinkinase-Promotor enthält (p(DR3)4tkluc), wurde durch 1,25(OH)2D3 und 
TGFb stark aktiviert, wenn die Expressionsplasmide für die humanen Rezeptoren VDR 
und RXR cotransfiziert wurden. Die Daten legten nahe, dass die Induktion der 5-LO-
Expression durch 1,25(OH)2D3 und TGFb durch regulatorische Elemente vermittelt 
wird, die sich außerhalb des in transienten und stabilen Reportergen-Transfektionen 
untersuchten Promotor-Bereiches befinden. 
Derartige Sequenzen wie Transkriptionsfaktor-Bindungsstellen, mRNA-
Prozessierungssignale und Elemente, welche die mRNA-Stabilität beeinflussen, 
könnten sich in den Exons, den Introns oder auch der 3’-untranslatierten Region 
(3’-UTR) des 5-LO-Gens befinden. Aus diesem Grund wurden diese Sequenzbereiche 
in Reportergenkonstrukte kloniert und im Hinblick auf eine mögliche Beteiligung an der 
1,25(OH)2D3/TGFb-vermittelten Hochregulation der 5-LO mittels Reportergen-Assays 
untersucht. Interessanterweise wurde in transienten Transfektionen von HeLa-Zellen 
durch das Einfügen der kodierenden Sequenz der 5 -LO in das 5 -LO-Promotor-
Luziferase-Plasmid eine 5 -fache Induktion der Reportergen-Aktivität durch 
1,25(OH)2D3/TGFb erreicht. Durch zusätzliches Klonieren der letzten vier Introns der 
5-LO an die entsprechenden Stellen zwischen den Exons ergab sich sogar eine 13-fache 
Hochregulation. Die auf diese Weise gemessenen Stimulationen hingen allerdings von 
der Cotransfektion der nukleären Rezeptoren VDR und RXR ab. Weiterhin stimuliert 
der VDR auch unabhängig von seinem Liganden 1,25(OH)2D3 die Reportergen-
Aktivität von Plasmiden, welche die kodierende Sequenz enthalten. Diese Effekte 
waren erstaunlicherweise unabhängig vom 5 -LO-Promotor, da sie auch mit 
entsprechenden Plasmiden beobachtet wurden, die einen Cytomegalie-Virus- oder 
keinen Promotor enthielten. Die RT-PCR-Analyse der in den transfizierten Zellen 
gebildeten Transkripte wies darauf hin, dass im Laufe der mRNA-Prozessierung Teile 
der kodierenden Sequenz entfernt werden, was zu unvollständigen Transkripten führt. 
Inkubation der Zellen mit 1,25(OH)2D3 und TGFb führte zu einem verstärkten 
Auftreten des Exons 13 in der mRNA der 5-LO, was durch einen 14-fachen Anstieg des 
entsprechenden PCR-Produktes gezeigt wurde. Die Hemmung der Proteinbiosynthese 
durch Cycloheximid konnte diesen Anstieg teilweise verringern, was möglicherweise 
daran liegt, dass 1,25(OH)2D3/TGFb die Bildung von Proteinen induzieren, die am Zusammenfassung  
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Splicing und/oder anderen Prozessierungsreaktionen der mRNA der 5-LO beteiligt sind. 
Abschnittsweise Deletionen der kodierenden Region der 5 -LO verringerte die 
Induzierbarkeit durch 1,25(OH)2D3 und TGFb nur geringfügig und erst die Deletion 
größerer Teile dieser Sequenz hob die Stimulierbarkeit fast vollständig auf. Für die 
Regulation der Prozessierung der mRNA der 5 -LO durch 1,25(OH)2D3 und TGFb 
scheinen also verschiedene Teile der kodierenden Sequenz von Bedeutung zu sein. 
Um den Mechanismus der 1 ,25(OH)2D3-induzierten 5 -LO-Expression weiter zu 
charakterisieren, wurden zusätzlich Versuche mit dem Analogon ZK191732 
durchgeführt. Diese Substanz zeigte in MM6-Zellen rein 1,25(OH)2D3-antagonistische 
Effekte auf die Induktion der zellulären 5 -LO-Aktivität. Im Gegensatz dazu wirkte 
ZK191732 partial agonistisch bezüglich der Induktion der Expression des 5 -LO-
Proteins. In Reportergen-Assays zeigte das Analogon eine deutliche agonistische 
Aktivität in transient transfizierten HeLa-Zellen sowohl mit p(DR3)4tkluc als 
Positivkontrolle als auch mit dem Konstrukt, das den 5-LO-Promoter, die kodierende 
Sequenz und die Introns J-K enthält. Allerdings wies die weniger starke Stimulierung 
von p(DR3)4tkluc darauf hin, dass sich der Mechanismus der Aktivierung durch die 
kodierende Sequenz von der Transkriptionsstimulation durch klassische VDREs 
unterscheidet. 
Aufgrund der synergistischen Wirkung von 1,25(OH)2D3 und TGFb auf die 
Genexpression der 5 -LO wurde außerdem die Beteiligung des TGFb-
Signaltransduktionsweges untersucht. Die Cotransfektion der Smad-Proteine 3 und 4, 
die als TGFb-Effektoren bekannt sind, führte in Abhängigkeit von der kodierenden 
Sequenz und in geringerem Maße auch von der 3’-UTR und den Introns J-M zu einer 
starken Erhöhung der Reportergenaktivität. Dieser Effekt schien vorrangig durch Smads 
und nur geringfügig durch TGFb vermittelt zu sein. Anscheinend stellen die 
Verfügbarkeit und vielleicht auch die nukleäre Lokalisation der Smad-Proteine 
zumindest unter den experimentellen Bedinungen der Reportergen-Assays den 
limitierenden und kritischen Faktor in der Regulation der 5-LO-Expression dar. Der 
durch TGFb vermittelte geringe Effekt wurde erst nach Vorinkubation der Zellen mit 
diesem Agens vor der Transfektion beobachtet, was auf einen sekundären Effekt 
hinweist. Wie die Einflüsse von VDR/RXR und 1,25(OH)2D3, ist auch die 
stimulierende Wirkung von Smads auf die Reportergen-Aktivität unabhängig vom 
5-LO-Promotor. Zusammenfassung  
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Die Smad-Induzierbarkeit konnte durch die Deletion einzelner Teile der kodierenden 
Region verringert werden. Die stärksten Auswirkungen hatte hierbei die Deletion einer 
Sequenz von Exon 10 bis 14. Die Bedeutung einer durch Sequenzanalyse ermittelten 
Ansammlung von bis zu vier potentiellen Smad-Bindungsstellen in Intron M und einem 
weiteren TGFb-responsiven Element in Exon 10 konnte durch zusätzliche gezielte 
Deletionen bestätigt werden. 
In verschiedenen Veröffentlichungen wurden bereits Interaktionen zwischen VDR und 
Smads sowie ein Zusammenspiel der Signalkaskaden von 1,25(OH)2D3 und TGFb 
beschrieben. Daher war es nicht überraschend, dass auch in den hier durchgeführten 
transienten Transfektionen die Kombination der Cotransfektionen von VDR/RXR und 
Smads3/4 bei gleichzeitiger Inkubation mit 1,25(OH)2D3 und TGFb zu den höchsten 
absoluten Luziferaseaktivitäten führte. 
Zusammenfassend läßt sich sagen, dass die 5-LO in den untersuchten Zellen vermutlich 
durch posttranskriptionelle Prozesse (Splicing) herunterreguliert wird. Die 
Differenzierung der Zellen durch 1,25(OH)2D3 und TGFb scheint die 5-LO-Expression 
durch eine Gegenregulation zu erhöhen, an der aktivierte VDR-RXR-Heterodimere und 
Smad-Proteine beteiligt sind. 
Da bereits etliche Publikationen den Einfluss von epigenetischen Mechanismen auf die 
Genexpression von Lipoxygenasen belegen, wurde dies im zweiten Teil dieser Arbeit 
näher untersucht. Bereits früher wurde gezeigt, dass der Promotor in der 5 -LO-
negativen Zelllinie U937 stark methyliert ist. Da die LOs starke Übereinstimmungen in 
der Regulation ihrer Expression zeigen, wurde im Vergleich zur 5-LO die Expression 
der 15-LO in dieser Zelllinie untersucht. Aufgrund des bekannten Zusammenspiels von 
DNA-Methylierung und der Organisation der Chromatinstruktur, wurden die Zellen mit 
dem Histondeacetylase (HDAC)-Inhibitor Trichostatin A (TsA) inkubiert. In RT-PCR-
Experimenten wurde ein starker Anstieg der 15-LO-mRNA-Menge durch Behandlung 
der Zellen mit TsA festgestellt, wohingegen 1,25(OH)2D3/TGFb keinen Effekt zeigten. 
Die mRNA der 5-LO hingegen konnte in U937-Zellen durch TsA nicht erhöht werden, 
was an einer Dominanz der DNA-Methylierung gegenüber der Histonacetylierung 
liegen könnte. In ähnlicher Weise wurden nämlich durch  Hpa II methylierte 5 -LO-
Promotor-Reportergen-Plasmide in transienten Transfektionen in geringerem Maße 
durch TsA stimuliert als die unmethylierten Vektoren. Die Rekrutierung von HDACs 
trägt wahrscheinlich zum repressiven Effekt der Methylierung bei. Auch die 5 -LO-Zusammenfassung  
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mRNA wurde durch TsA in MM6-Zellen deutlich induziert. Allerdings reduzierte TsA 
in Kombination mit 1,25(OH)2D3/TGFb die durch 1,25(OH)2D3/TGFb erhaltene 
Steigerung der 5 -LO-mRNA-Menge. In gleicher Weise wurde die starke 
1,25(OH)2D3/TGFb-vermittelte Stimulation der Plasmide, die die kodierende Sequenz 
der 5 -LO enthalten, durch TsA deutlich gehemmt. Im Gegensatz dazu wurde  die 
Reportergenaktivität des VDRE-Kontrollplasmides durch 1,25(OH)2D3 und 
Histonacetylierung synergistisch induziert. Die TsA-induzierte Hyperacetylierung des 
5-LO-Promotors führt einerseits zu einer transkriptionellen Aktivierung, während die 
cds-vermittelte 5 -LO-Induktion durch 1,25(OH)2D3/TGFb von TsA gehemmt wird. 
Dies legt nahe, dass die auf mRNA-Prozessierungsvorgängen beruhende 5 -LO-
Induktion durch Histonhyperacetylierung eher verringert wird. 
Die basale 5 -LO-Promotoraktivität wird durch multiple Sp1-Bindungsstellen im 
Promotor vermittelt. Es wurde gezeigt, dass eine Region des Promotors, die zwei 
proximale putative Sp1-Bindungsstellen umfasst, die TsA-induzierte Stimulation der 
5-LO-Promotoraktivität vermittelt. 
Bei einem Vergleich der 5-LO-Promotor-Konstrukte mit und ohne kodierender Sequenz 
plus Introns J-M in Reportergen-Assays stellte sich heraus, dass die kodierende Region 
plus Introns J -M zu einem deutlichen Synergieeffekt von Sp1 bzw. Sp4 und der 
Histonhyperacetylierung führt. Außerdem wurde auch die TsA-vermittelte Aktivierung 
des 5-LO-Promotors durch die Cotransfektion von Sp4 verstärkt. Die Auflockerung der 
Chromatinstruktur durch Histonacetylierung ist vermutlich an der Synergie beteiligt. 
Außerdem könnten die durch die kodierende Sequenz vermittelten Effekte auch auf 
zusätzliche Sp-Bindungsstellen in diesem Bereich des 5-LO-Gens hinweisen. References  
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  Vitamin D-responsive elements within the human 5-lipoxygenase gene promoter 
bind vitamin D receptor, but do not confer vitamin D-dependent transcriptional 
activation 
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ABSTRACT:  The role of the vitamin D receptor (VDR) in the regulation of the 5 -lipoxygenase (5-LO) 
expression during cell differentiation by 1,25-dihydroxyvitamin D 3 (1,25(OH)2D3) and transforming growth 
factor beta (TGFb) was investigated. Several putative VD-responsive elements (VDREs) were identified in the 
human 5 -LO gene promoter sequence ( -313 to  -258 bp).  DNase I footprinting assays and electrophoretic 
mobility shift assays revealed that the purified VDR binds to putative VDREs within the 5-LO promoter as a 
heterodimer together with retinoic X receptor (RXR). Nuclear proteins extracted from TGFb/1,25(OH)2D3-
differentiated Mono Mac 6 cells caused similar band shifts, and consistent with the VDR expression levels, 
protein binding from extracts of undifferentiated cells (no TGFb/1,25(OH)2D3) was less pronounced. 
In cells transiently (Mono Mac 6, HeLa, RBL-1, HL-60 and U937) or stably (HL-60) transfected with reporter 
gene plasmids containing various 5 -LO promoter regions, stimulation with TGFb/1,25(OH)2D3 caused no 
significant change in reporter gene expression, although the transcriptional activity of a reporter gene containing 
a 4-times concatemerized rat atrial natriuretic factor vitamin D response element was strongly upregulated by 
TGFb/1,25(OH)2D3. Detailed analysis of the 5-LO promoter in Mono Mac 6 cells revealed a positive regulatory 
region (-778 to -229 bp). Deletion of this region led to a reduction of 5-LO promoter activity when the VDR and 
the RXR were coexpressed.  In summary, the VDR/RXR complex binds to putative VDREs in the 5 -LO 
promoter, but the regulatory sequences involved in the prominent induction of 5-LO mRNA expression by TGFb 
and 1,25(OH)2D3 seem to be located in other parts of the 5-LO gene. 
  
    Arachidonate 5 -lipoxygenase (5-LO) catalyzes the 
first two steps in the conversion of arachidonic acid to 
leukotriene A 4 (LTA4) and plays a critical role in the 
control of cellular leukotriene production  (1,2). 5 -LO 
expression is believed to be upregulated during normal 
myeloid cell differentiation and in the myeloid cell lines 
HL-60 and Mono Mac 6, TGFb and 1,25(OH)2D3 were 
identified as potent inducers of 5-LO gene expression 
(3-5). In Mono Mac 6 cells, treatment with TGFb and 
1,25(OH)2D3 led to an up to 5-fold increase in primary 
transcripts, a 64-fold increase in 5-LO mRNA, a 128-
fold increase in protein amount and a more than 500-
fold increase in 5-LO activity compared to the untreated 
controls (6). 
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Interestingly, addition of cycloheximide inhibited the 
TGFb but not the calcitriol effects, suggesting that there 
is a direct stimulation of 5 -LO mRNA expression by 
1,25(OH)2D3 in presence of TGFb-induced proteins (7). 
Also, 1,25(OH)2D3 upregulated 5 -LO metabolism in 
blood monocytes differentiating to mature monocytes, 
and ionophore induced formation of LTB4 and 5-HETE 
was reduced in alveolar macrophages from 
1,25(OH)2D3-deficient rats (8,9). 
It has been shown that the transcription factors Egr-1 
and/or Sp1 can stimulate transcription of 5-LO reporter 
gene constructs in transfected cells  (10).  Naturally 
occurring mutations were found in the 5-LO promoter 
consisting of the deletion of one or two, or the addition 
of one Sp1-binding site  (11). These mutations only 
slightly alter 5 -LO promoter activity in reporter gene 
assays but have a significant impact on the response of 
asthma patients to 5-LO inhibitors (12). Recently, the 
core part of the mouse 5 -LO gene promoter, which 
contained only one Sp1/Sp3 binding site and displays 
only weak homology to the human promoter, mediated 
high basal transcription of reporter genes in the RAW 
264.7 monocyte-macrophage cell line, but not in 3T3 
cells (13). 
Further analysis of the 5 -LO promoter indicated the 
presence of putative response elements for TGFb, the 
retinoid Z receptor (RZR)  (14), and the vitamin D 
receptor (VDR)  (15), which is the mediator of the 
manuscript genomic actions of 1,25(OH)2D3. Among the putative 
VDREs within the 5-LO promoter, the sequence located 
at positions  -290 bp to  -275 bp (AATTCA GGAG 
AGAACG) shows some homology to the DR4-type 
mouse phosphate intestinal transporter VDRE 
(AGTTCA TGAG AGTTCA) and the sequence –309 bp 
to –294 bp (AGGGCA AAG GGTGGA) was previously 
proposed for possible VDR binding (15). 
In this study we addressed whether the VDR physically 
interacts with the putative VDREs within the 5 -LO 
promoter and we determined the effects of 
TGFb/1,25(OH)2D3 on receptor binding and VDR 
expression. To define the mechanisms involved in the 
regulation of 5 -LO expression by TGFb and 
1,25(OH)2D3 and to examine putative DNA responsive 
elements controlling expression of 5 -LO, the 5 -LO 
promoter was analyzed in 5-LO positive as well as in 
5-LO negative cell lines. 
 
 
MATERIALS AND METHODS 
   Reagents.  Molecular biology reagents were from MBI 
Fermentas, Sigma, GIBCO, Promega or other sources as 
indicated in the text. Insulin was a gift from Aventis. Human 
TGFb1 was purified from outdated platelets according to (16). 
Nucleospin Extract columns for direct purification of pDNA 
were from Macherey-Nagel (Düren, Germany). 
Poly(dIdC)•poly(dIdC), poly(dAdT)•poly(dAdT) and [ g-
32P]dATP (3000 Ci/mmol) were from Amersham Pharmacia. 
Oligonucleotides were synthesized at Scandinavian Gene 
Synthesis AB (Köping, Sweden). Human recombinant VDR 
and RXRb protein were purchased from Biomol (Plymouth 
Meeting, PA). The plasmid p(DR3)4tkluc containing the four 
times concatemerized  rat atrial natriuretic factor  (rANF) 
VDRE (AT GGGTCA TAT GGTTCA) in front of a thymidine 
kinase promoter driven luciferase reporter gene, the 
pSG5VDR and pSG5RXR expression plasmids for the human 
vitamin D receptor (VDR) and retinoid X receptor alpha 
(RXRa) have been described previously. 
   Cells and cell culture. HL-60 cells, U937 and RBL-1 cells 
were grown at 37°C in a humified atmosphere with 6 % CO2 
in RPMI 1640 medium supplemented with 10 % (vol/vol) 
fetal calf serum (FCS), streptomycin (100 µg/ml) and 
penicillin (100 U/ml). For cell culture of Mono Mac 6 cells, 
which were kindly provided by Dr. H.W.L. Ziegler-Heitbrock 
(Munich), the culture medium was supplemented with 
1·nonessential amino acids, sodium pyruvate (1 mM), 
oxalacetate (1 mM) and insulin (10 µg/ml) (17). HeLa cells 
were obtained from Dr. W.E. Müller (Pharmacological 
Institute, Biocenter, Frankfurt) and grown in Dulbecco’s 
modified Eagle's medium (DMEM) supplemented with 10 % 
(vol/vol) FCS, 100 µg/ml streptomycin and 100 units/ml 
penicillin. 
    RT-PCR analysis.  HL-60 cells were seeded at  4×10
5 
cells/ml and incubated for 24h with or without 1,25(OH)2D3 
(50 nM) and TGFb (1 ng/ml). Cells were harvested  by 
centrifugation at 1200×g for 10 min at room temperature (RT), 
total RNA was isolated from cells by the guanidinium 
thiocyanate method (18) and RT-PCR analysis was performed 
as decribed previously (6). The following PCR-primers were 
used at a concentration of 5 ng/µl: 
b-actin (24 cycles) 5‘GAGGAGCACCCCGTGCTGCTGA3‘ 
and 
5‘CTAGAAGCATTTGCTGTGGACGATGGAGGGGCC3‘; 
5-LO (30 cycles) 
5‘ACCATTGAGCAGATCGTGGACACGC3‘ and 
5‘GCAGTCCTGCTCTGTGTAGAATGGG3‘, CAT (35 
cycles) 5‘CCTATAACCAGACCGTTCAGC3’ and 
5‘CGCCAGCGGCATCAGCACC3’.  
Signal intensities  of ethidium bromide stained DNA bands 
were quantitated by densitometry (BioRad Gel Doc 1000 
system) and analyzed with the Molecular Analyst program 
(BioRad). Results are expressed as relative changes in RNA 
amounts normalized with b-actin as internal standard. 
   Plasmid construction.  The 5 -LO promoter reporter gene 
deletion constructs were prepared using restriction enzymes 
and PCR methods. Starting with the plasmids K1 (provided by 
Dr Shigeru Hoshiko) and pGL3Basic (Promega), the 5-LO-
promoter containing plasmid K1 was digested first by BstE II, 
the restriction site was blunted with T4 DNA polymerase, then 
digested with  Kpn I and ligated into the  promoterless 
luciferase reporter vector pGL3Basic, which was opened with 
Kpn I and Sma I. The intermediate construct obtained was then 
partially digested with  Cfr42  I,  digested with  Xho I and 
blunted with T4 DNA polymerase before final religation 
(pN0). The plasmids pN1-pN11 were constructed by digestion 
of pN0, which contains the promoter region from –6079 bp to 
+53 bp in relation to the transcription start (-6144 bp from the 
5-LO ATG) using the restriction enzyme Kpn I and then Afl II 
(pN1),  Van91l (pN2),  Nde  I (pN3),  Pvu  II (pN5),  Eco147l 
(pN6),  EcoR I (pN7),  EcoRV (pN8),  Pme  I (pN9),  Pau I 
(pN10) and BstX I (pN11).  Overhangs were blunted by T4 
DNA polymerase treatment and religated with T4 DNA ligase. 
Plasmids pN12, pN13 and pN14 were obtained by PCR 
deletion, using pN10 as the template, the reverse primer 
TATCGATAGAGAAATGTTCTGGCA, the forward primers  
CGCGTGAAGAGTGGGAGAGAAGTACTGCGG (pN12), 
CAGCCGGGAGCCTGGAGCCAGACC (pN13) or 
AGGGACCAGTGGTGGGAGGAGGCT (pN14), and  Pfu  I 
DNA polymerase. Following temperature cycling, the product 
was treated with Dpn I, plasmid ends were phosphorylated by 
T4 polynucleotide kinase and l igated by T4 DNA ligase. 
Plasmid sequences were confirmed by DNA sequencing. 
   Transfection of myeloid cell lines by electroporation. Cells 
(Mono Mac 6, HL-60, RBL-1 and U937) were seeded to 
2×10
5 cells/ml and cultured at 37°C in a humified atmosphere 
with 6  % CO2. After 48 hrs, cells were harvested by 
centrifugation (1200×g, 5 min, RT), washed twice with 
RPMI-1640, and resuspended at a density of 46×10 
6cells/ml 
(Mono Mac 6 and U937), 24 × 10
6  cells/ml (RBL-1) and 
20×10
6 cells/ml (HL-60), respectively in RPMI-1640 without 
glutamine. 300 µl (Mono Mac 6, U937) or 500 µl (HL-60, 
RBL-1) of the cell suspension were placed into a 0.4-cm 
electroporation cuvette. Forty micrograms of supercoiled 
plasmid DNA and 1 µg of internal standard (in 30 µl of water) 
were added to the cell suspension. For cotransfections, 5 µg 
of the expression vectors pSG5hVDR and pSG5hRXR were 
included. After 5 min incubation at RT (Mono Mac 6, RBL-1, 
HL-60) or 10 min on ice (U937), electroporation was 
performed using a Biorad Gene pulser II at 975 µF and 200 V 
(Mono Mac 6), 300 V (RBL-1) or 250 V (HL-60, U937). The  
cuvettes were immediately placed on ice for 20 min (Mono 
Mac 6, RBL-1, HL-60, U937) or for 5 min (U937). After 
another 5 min at RT (U937) or 20 min on ice the cells were 
transferred to 10 ml of cell culture medium. 
   Transfection of HeLa cells. Cells were plated into a 24-well 
tissue culture plate at a density of 6×10
4 cells per well, so that 
60-80 % of the cells were confluent at the time of transfection 
(after about 24 hrs). Plasmid DNA (0.4 µg) and 0.01 µg 
pCMVSEAP as internal standard (diluted in 5 µl serum free 
DMEM) were precomplexed with 5 µl of PLUS reagent 
(Gibco) by incubation for 15 min at RT. Precomplexed plasmid DNA was mixed with 25 µl of 1:50 diluted 
Lipofectin reagent and incubated for 30 min at RT. Then, the 
medium was replaced by 200 µl of fresh serum free DMEM 
and incubated 37 
oC in 5  % CO2  with the DNA-PLUS-
Lipofectin reagent complexes. After 5 hrs, 1 ml of DMEM 
containing 15 % (vol/vol) FCS was added. 24 h after 
transfection, cells were washed once in phosphate-buffered 
saline pH 7.4 (PBS) and luciferase activity was determined as 
described below. 
   Stable transfections of HL-60 cells. HL-60 cells were stably 
transfected with the 5 -LO promoter-CAT construct 
p5LO6079CAT containing the 5 -LO promoter sequences 
-6079 bp to +81 bp (HL60-6079-5LO), the SV40-promoter 
containing plasmid pCATControl (HL60-SV40) and with the 
promoterless plasmid pCATBasic (HL60-Basic). Cells were 
cotransfected with pMC1NeopolyA+ and stably transfected 
cells were selected for neomycin resistance at 600 µg/ml. 
   Luciferase assays. 6 h (Mono Mac 6, U937, HL-60, RBL-1) 
and 24 h (HeLa) after transfection, cells were washed once in 
PBS containing 0.5 mM MgCl2, 0.5 mM CaCl2 and lysed in 
100 µl lysis buffer (Luciferase Reporter Gene Assay constant 
light signal kit, Boehringer Mannheim, Germany). Luciferase 
activity was determined by monitoring light emission with a 
Microlumat Plus LB96V EG&G Berthold luminometer (19). 
The light emission signal was integrated for 5 seconds. 
Transfection efficiency was monitored and normalized by 
cotransfection with pCMVSEAP using the Phospha-Light￿ 
kit (Tropix) to determine the secreted placental alkaline 
phosphatase (SEAP) activity (19-23). 
   Preparation of nuclear extracts.  Mono Mac 6 cells were 
grown in absence or presence of TGFb (2 ng/ml) plus 
1,25(OH)2D3 (50 nM) as described (5). After four days, cells 
(0.5-1·10
9) were harvested and nuclear extracts were prepared 
according to the protocol of Shapiro et al.  (24). Nuclear 
extracts (protein content: 2-8 µg/µl) were immediately frozen 
in aliquots and stored at –70°C for several months. 
   Electrophoretic mobility shift assays. The following 
oligonucleotides were used in the gel retardation assays: 
mouse osteopontin VDRE MO-23 mer: 
5`-ACAAGGTTCACGAGGTTCACGTC-3´; 5LO-23 mer:  
5´-AGGCAGGGCAAAGGGTGGAAGCA-3´ ( -313 bp to 
-291 bp); 5LO-56 mer: 
5´-AGGCAGGGCAAAGGGTGGAAGCAATTCAGGAGAG
AACGAGTGAACGAATGGATGAG-3´ ( -313 bp to 
-258 bp). To prepare double-stranded oligonucleotides, equal 
amounts of the complementary single-stranded DNA were 
combined in a solution containing 10 mM MgCl2 and heated 
to 80°C for 5 min, and slowly cooled down to room 
temperature. The annealed oligonucleotides were endlabelled 
with [
32P]-g-ATP using T4 DNA polynucleotide kinase (NEB, 
Beverly, MA). Radiolabelled double-stranded 
oligonucleotides w ere purified by Sephadex G -25 spin 
columns (Roche Molecular Biochemicals), and stored at 
-20°C. 
The binding reaction was performed at RT for 25 min in 
binding buffer (Tris HCl 10 mM pH 7.5, glycerol 4 %, MgCl2 
5 mM, EDTA 0.5 mM, DTT 0.5 mM, NaCl 50 mM, 
0.05 mg/ml poly (dI-dC)•poly(dI-dC)), containing 50,000 cpm 
labeled probe and nuclear extracts (corresponding to 10 µg 
protein) or VDR and RXR (1 µg, each) in a total reaction 
volume of 12 µl. For competition studies, a 150-fold molar 
excess of unlabelled oligonucleotide was added to the reaction 
mixture prior to the addition of radiolabelled probe. EMSA 
reactions were resolved on 5 % or 10 % pre-run nondenaturing 
polyacrylamide TBE gels (BioRad, premade) which were 
electrophoresed at 100 V for 45-90 min. Gels were dried under 
vacuum and then exposed to Fuji Super RX film. 
   Western blot. Nuclear extracts (10 µg protein in 10 µl) were 
mixed with the same volume of 2  · SDS-b and boiled for 
5 min at 95°C. Then, 4 µl of glycerol/0.1% bromphenolblue 
(1:1, vol/vol) were added and proteins were separated by SDS-
PAGE using a Mini Protean system (Bio-Rad) on a 10 % gel. 
After electroblot to nitrocellulose membrane (Amersham 
Pharmacia), membranes were blocked with 5% non fat dry 
milk in 50 mM Tris/HCl, pH 7.4 and 100 mM NaCl (TBS) for 
1 h at room temperature. Membranes were washed and then 
incubated with specific antibodies against the VDR (Santa 
Cruz Biotech, C-20, 1:1,000 dilution (Santa Cruz, CA)) for 
overnight at 4°C. The membranes were washed with TBS and 
incubated  with 1:1,000 dilution of alkaline phosphatase-
conjugated rabbit IgGs (Sigma) for 2 h at RT. After washing 
with TBS and TBS plus 0.1 % NP40, proteins were visualized 
with nitro blue tetrazolium and 5 -bromo-4-chloro-3-
indolylphosphate (Sigma) in detection buffer (100 mM 
Tris/HCl, pH 9.5, 100 mM NaCl, 5 mM MgCl2). 
   DNase I footprinting.  For DNase I footprinting, an 
oligonucleotide was obtained by restriction enzyme digestion 
of the plasmid 5LO931CAT  (25). First, the plasmid was 
digested with  Sac II. The smaller fragment was then purified 
by agarose  gel electrophoresis and extracted with the 
QiaQuick gel extraction kit (Qiagen, Hilden, Germany).  After 
digestion with Alu I, the DNA was treated with calf intestinal 
alkaline phoshatase (MBI Fermentas, Lithuania) and 
radiolabelled at the 5´ends using T4  polynucleotide kinase 
(NEB, Beverly, MA). The labelled DNA was digested with 
Sca I, and the subsequent  32P-Alu I/Sca I fragment of the 
5LO gene promoter was purified as after the first cleavage. 
50,000 cpm (0.1-0.2 pmol) of  
32P-5´ labelled DNA 
(nucleotides  -363 to  -119) was incubated with various 
amounts (0.4-3 µg) of RXR and/or VDR (both from Biomol, 
Plymouth Meeting, PA) prior to digestion with DNase I.  For 
DNase I footprinting reactions the SureTrack Footprinting Kit 
from Amersham Pharmacia was used,  following the 
manufacturers intructions. The samples, resuspended in 
water/loading dye (4/6, v/v; loading dye is deionized 
formamide containing 10 mM EDTA, 0.3 % bromophenol 
blue and 0.3 % xylene cyanol), were heated at 85°C for 2 min 
and immediately loaded onto 8 % polyacrylamide sequencing 
gels. An A+G ladder covering the appropriate DNA sequence 
was prepared according to the sequencing method of Maxam 
& Gilbert and run alongside the samples. 
 
RESULTS 
   VDR/RXR protect parts of the 5-LO promoter in the 
DNase I footprinting assay. 
 
 
FIGURE 1.  Localization of putative VDREs within the 
human 5-LO promoter. 
 
Sequence analysis of the 5 -LO promoter reveals the 
presence of several putative VDRE from  –313 bp to 
-258 bp (fig. 1), numbered with the major trancription 
start site as zero. DNase I footprinting was performed 
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-279using a probe (245 bp long) containing the sequence 
between the  Alu I site ( -363 bp) and the Sca I site 
(-119 bp) of the 5-LO gene promoter. The fragment was 
labelled at the Alu I end. When RXR and VDR proteins 
were mixed and incubated with the probe, an apparent 
hypersensitive site appeared at –268 bp. The 96 bp of 
the probe upstream (5´) of this position was protected 
from DNase I, whereas the downstream part of the 
probe (149 bp) was accessible for DNase I. 
One of the best protected parts of the sequence, giving a 
clear footprint, was the region between nucleotides  
-307 and -299 that matches the VDRE (-309 to –294 bp) 
proposed by Carlberg (15),  (fig. 2). Protection against 
DNase I also comprised the DR4-type response element 
with homology to the mouse phosphate intestinal 
transporter VDRE and suddenly stopped at the 
hypersensitive site at  –268 bp. The protection against 
DNase I was most prominent when RXR and VDR were 
combined. VDR alone gave slightly weaker footprints 
and RXR alone did not bind to the probe (data not 
shown). Purified SP1 protein (Promega, Madison, WI) 
alone gave no footprint in this part of the 5LO promoter, 
and in combination with VDR/RXR there was no 
additional protection against DNase I. 
   VDR and RXR bind to putative VDRE present in the 
5-LO promoter; EMSA studies.  In order to explore 
VDR/RXR binding to putative VDREs, EMSAs were 
performed using synthetic oligonucleotides 
corresponding to the sequence  –313 to  –291 bp 
(5LO-23) and –313 to –258 bp (5LO-56) of the 5-LO 
promoter, respectively. The well-documented VDRE 
from the mouse osteopontin promoter (MO-23) was 
used as a positive control. As depicted from fig. 3, VDR 
or RXR hardly bound to any of these oligonucleotides. 
However, the combination of both RXR and VDR 
caused retardation of 5LO-23 and 5LO-56 
oligonucleotides, with comparable magnitudes to 
MO-23. Due to its larger size, the  5LO-56/VDR/RXR 
complex migrated slightly slower compared to the 23bp 
oligo/VDR/RXR complexes of 5LO-23 and MO-23. 
Purified SP1 protein alone caused no band shift and 
together with VDR/RXR there was no additional signal 
observed (not shown). 
Next, we determined the ability of the oligonucleotides 
to bind endogenous proteins derived  from nuclear 
extracts of Mono Mac 6 cells, cultured in presence or 
absence of 1 ng/ml TGFb plus 50 nM 1,25(OH)2D3. A 
considerable higher amount of oligonucleotides was 
retarded by nuclear proteins derived from differentiated 
(TGFb plus 1,25(OH)2D3) cells, as compared to 
untreated cells (fig. 4A). This correlated with the total 
amounts of VDR protein present in such extracts as 
determined by Western blot (fig. 4B). When EMSAs 
were performed using purified VDR and RXR proteins 
as well as nuclear extracts (obtained from 
TGFb/1,25(OH)2D3-differentiated Mono Mac 6 cells) 
side by side, the migration pattern was apparently the 
same for 5LO-23 and MO-23 (fig. 3C). However, for 
5LO-56 an additional more intense shift was observed 
after incubation with nuclear extracts  from 
TGFb/1,25(OH)2D3-differentiated cells (but not with 
extracts from untreated cells), implying the occurence of 
additional protein(s) induced by TGFb/1,25(OH)2D3 
that are capable to bind the VDR/RXR/5LO-56 
complex. 
FIGURE 2.  Protection of regions in the 5 -LO gene 
promoter by VDR and RXR.  DNase1 footprinting was 
performed with the  Alu  I ( -363 bp) to  Sca I ( –119 bp) 
fragment of the promotor region of the 5 -LO gene, 
radiolabelled at the Alu I end.  
Lane 1: no addition (positive control). Lane 2: the probe was 
incubated with VDR protein (3 µg) and RXR protein (3 µg) 
prior to digestion with DNase I. Lane 3: VDR (1.5 µg) and 
RXR (1.5 µg). Lane 4: VDR (1.5 µg) and RXR (1.5 µg) and 
purified Sp1 (1 footprinting unit). Lane 5: only purified Sp1 
protein (1 footprinting unit). Lane 6: no addition (positive 
control). Lane 7: Maxam-Gilbert A+G ladder. Electrophoresis 
was done with a 8  % polyacrylamide sequencing gel. Star 
indicates the hypersensitive site ( -268 bp), and the heavily 
protected region  -307 to  –299 bp is indicated. Parentheses 
indicate parts of the sequence conforming to DR3 and DR4 
motifs. 
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FIGURE 3.  The VDR and the RXR together bind to 
putative VDREs located within the 5 -LO promoter. 
Purified VDR and RXR ( 1 µg each) were incubated with 
32P-
labelled  (T4  DNA polynucleotide kinase) double-stranded 
oligonucleotides resembling the sequences of the 5 -LO 
promoter  -315 to  -293 bp (5LO-23) and  -315 to  -259 bp 
(5LO-56), and the mouse osteopontin promoter (MO) as 
indicated. Protein-DNA complexes were resolved on 5 % pre-
run nondenaturing polyacrylamide TBE gels and visualized by 
autoradiography. Arrows indicate the positions of the 
protein/DNA complexes. Similar results were obtained in at 
least three additional experiments. 
 
   Effects of 1,25(OH)2D3/TGFb  on transcriptional 
activity of the 5-LO and the rANF promoter. In order to 
investigate effects of TGFb/1,25(OH)2D3 on the 5-LO 
promoter activity, the myeloid cell lines RBL-1, Mono 
Mac 6, HL-60 and U937, as well as HeLa cells were 
transiently transfected with the p lasmid pN10, 
composed of a  5-LO promoter sequence ( -778 to 
+53 bp, containing at least four putative VDREs ( see 
fig. 1)) in front of a luciferase gene (pGL3Basic). The 
luciferase reporter gene plasmid p(DR3)4tkluc, 
containing a 4-times concatemerized rANF vitamin D 
response element in front of the thymidine kinase 
promoter, was used as a positive control. To ensure the 
availability of sufficient amounts of nuclear receptor 
proteins, cells were cotransfected with expression 
vectors for VDR and RXR. After transfection, cells 
were incubated for 6 h (RBL-1, Mono Mac 6, HL-60 
and U937) or 24 h (HeLa) in presence or absence of 
50 nM 1,25(OH)2D3 and 1 ng/ml TGFb  ￿￿ respectively.  
As shown in fig. 5A, the relative transcriptional activity 
of pN10 to pGL3Basic depends on the cell type. 
Compared to the promoterless vector pGL3Basic, only 
moderately higher (about 7- to 86-fold) 5-LO promoter 
activities were found in RBL-1, HeLa, HL-60 and U937 
cells. However, in Mono Mac 6 cells, transcription from 
the 5 -LO promoter was about 1200-fold higher than 
from pGL3Basic. Of particular interest, incubation of 
cells in presence of 1,25(OH)2D3 and TGFb, that 
increased 5 -LO mRNA expression in Mono Mac 6, 
HL-60 and U937 cells (not shown, compare (5,26)) and 
nuclear protein binding to 5LO-23 and 5-LO-56 (fig. 4), 
caused no enhancement of luciferase activity in either 
cell type (fig. 5A).  
 
FIGURE 4.  Effects of TGFb b and 1,25(OH)2D3 on the 
expression of VDR and nucleotide-binding capacity of the 
nuclear proteins from Mono Mac 6 cells. Mono Mac 6 cells 
were grown with or without 1,25(OH)2D3 (50 nM) and TGFb 
(1 ng/ml) for four days and nuclear extracts were prepared as 
described. ( A) To determine effects of TGFb and 
1,25(OH)2D3 on nucleotide binding capacity, nuclear extracts 
(10 µg) from untreated or 1,25(OH)2D3/TGFb-treated cells 
were incubated with 
32P-labelled 5LO-23, MO, and 5LO-56 as 
indicated.  (B) To determine the expression of the VDR 
protein, nuclear extracts (10 µg) from untreated or 
1,25(OH)2D3/TGFb-treated cells were separated by SDS-
PAGE and analyzed by Western blot. The results from three 
different experiments are shown (I, II, III; left panel), the 
corresponding relative intensities of blot bands (right panel) 
were determined by densitometry (arbitrary units) and are 
given as mean + S.E. ( C) To compare the electrophoretic 
mobility of protein-DNA complexes, purified VDR and RXR 
proteins or nuclear proteins derived from Mono Mac 6 cells 
treated with TGFb and 1,25(OH)2D3 were incubated with 
32P-
labelled 5LO-23, MO, and 5LO-56 as indicated. Protein-DNA 
complexes were resolved on 5  % pre-run nondenaturing 
polyacrylamide TBE gels and visualized by autoradiography. 
Arrows indicate the positions of the protein/DNA complexes. 
Similar results were obtained  in at least three additional 
experiments. 
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plasmid p(DR3)4tkluc was cell type dependent in a 
similar fashion (fig. 5B). However, in sharp contrast to 
pN10, treatment of myeloid cells (but not HeLa cells) 
with 1,25(OH)2D3 and TGFb led to a considerable 
upregulation of the trancription of the p(DR3)4tkluc 
reporter gene construct (165-, 54-, 34- and 5.1-fold in 
HL-60, RBL-1, Mono Mac 6 and HeLa cells, 
respectively) which strongly depended on the 
coexpression  of VDR/RXR. Without coexpression of 
VDR and RXR,  TGFb/1,25(OH)2D3  increased 
transcription from  p(DR3)4tkluc by 9-, 2.3- and 1.6-
fold in RBL-1, Mono Mac 6 and HeLa cells, 
respectively.  
Taken together, unlike the VDREs in p(DR3)4tkluc, the 
VDREs of the 5-LO promoter appear to be unable to 
mediate an upregulation of transcriptional activity of 
pN10 in myeloid cells by 1,25(OH)2D3 and TGFb. 
FIGURE 5.  Effects of TGFb b and  1,25(OH)2D3 on 
transcriptional activity of pN10 (A) and p(DR3)4tkluc (B) 
in various cell  lines.  The constructs pN10 (A) and 
p(DR3)4tkluc (B) were transiently transfected into the 
indicated cell lines together with the expression vectors 
pSG5hRXR and pSG5hVDR. After transfection 1,25(OH)2D3 
and TGFb (50 nM and 1 ng/ml, respectively) were added and 
reporter gene activity was determined after 6  h (RBL-1, 
HL-60, Mono Mac 6 and U937) or 24 h (HeLa). Results are 
presented as mean  + SE of triplicate transfections. Values 
were normalized for transfection efficiency by cotransfection 
of pCMVSEAP. 
 
   Identification of positive and negative regulatory 
regions of the 5 -LO promoter.  In order to identify 
positive and negative regulatory regions of the 5 -LO 
promoter, Mono Mac 6 and HeLa cells were transiently 
transfected (6 h for Mono Mac 6, 24 h for HeLa) with 
plasmids encoding deletion  constructs of the 5 -LO 
promoter ( -6079 to +53 bp)  in front of the luciferase 
gene. To ensure the availability of sufficient amounts of 
nuclear receptor proteins, cells were cotransfected  with 
expression vectors for VDR and RXR.  
 
FIGURE 6. 5-LO promoter analysis in Mono Mac 6 (A) 
and HeLa cells (B). The 5-LO promoter luciferase reporter 
gene construct pN0, processive deletion variants (pN1-pN14) 
or the promoterless vector pGL3Basic and the expression 
vectors pSG5hRXR and pSG5hVDR were transiently 
transfected into Mono Mac 6 and HeLa cells. After 
transfection,  1,25(OH)2D3  and TGFb (50 nM and 1  ng/ml, 
respectively) were added and reporter gene activity was 
determined after 6 h (Mono Mac 6) or 24 h (HeLa). Results 
are presented a s mean  + SE of triplicate transfections, and 
were normalized for transfection efficiency by cotransfection 
of pCMVSEAP. 
 
As shown in f ig. 6A,  the full length 5 -LO promoter 
reporter gene construct (pN0,  -6079 to +53 bp) 
significantly induced luciferase activity (by  57-fold) 
versus the promoterless vector in Mono Mac 6 cells. 
Systematic deletion of the 5-LO promoter indicates the 
presence of two negative ( -5814 bp to  –5395 bp and 
-913 bp to –778 bp) and two positive regulatory regions 
(–778 bp to –229 bp and –141 bp to –78 bp). The most 
prominent promoter activities were observed with the 
pN10 construct (-778 to +53 bp), which gave 1290-fold 
and 1210-fold higher activities compared to the 
promoterless vector. Again, except for the pN11 
construct ( -229 to +53 bp), there was no significant 
upregulation of the reporter gene activity in presence of 
TGFb/1,25(OH)2D3 compared to untreated cells, 
indicating that TGFb/1,25(OH)2D3 caused no 
transcriptional transactivation. 
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A
BAlso in HeLa cells, pN10 caused the most prominent 
upregulation of transcriptional activity among the 
reporter gene constructs (fig. 6B). In contrast to Mono 
Mac 6 cells, no positive regulatory region was found 
from –778 to –229 bp in HeLa cells. Similarly as found 
for Mono Mac 6 cells, the 5-LO promoter reporter gene 
constructs were not significantly responsive to 
TGFb/1,25(OH)2D3 stimulation in HeLa cells. 
 
FIGURE 7.  Effects of VDR/RXR coexpression on the 
transcriptional activity of  pN9-pN14 in transiently 
transfected Mono Mac 6 cells. The 5-LO promoter reporter 
gene constructs pN9, processive deletion variants (pN10-
pN14) or the promoterless vector pGL3Basic were transiently 
transfected into Mono Mac 6 cells with or without the 
expression vectors pSG5hRXR and pSG5hVDR. After 
transfection  1,25(OH)2D3  and TGFb (50 nM and 1  ng/ml, 
respectively) were added as indicated and reporter gene 
activity was determined after 6  h. The luciferase activity 
obtained from pGL3Basic with coexpression of receptors was 
set to 1. Results are presented as mean  + SE of triplicate 
transfections, and were normalized for transfection efficiency 
by cotransfection of pCMVSEAP. 
 
   Effects of VDR/RXR coexpression on 5-LO promoter 
activity. 
In order to check the effects of VDR/RXR coexpression 
on 5 -LO promoter activity, Mono Mac 6  cells were 
transiently transfected with the 5-LO promoter reporter 
gene constructs pN9 – pN14 or pGL3Basic in presence 
or absence of plasmids encoding the VDR 
(pSG5hVDR) and the RXR (pSG5hRXR). Compared to 
pN10, the pN9 construct gave 4 to 5 -fold lower 
transcriptional activity (fig. 7 ). Also, the presence of 
TGFb and 1,25(OH)2D3 did not significantly increase 
expression of the pN9 and pN10 reporter gene 
constructs, and coexpression of the VDR/RXR caused 
no change in the promoter activity. 
However, coexpression of VDR/RXR in Mono Mac 6 
cells resulted in a 2 to 3-fold reduction of reporter gene 
activity for pN11, pN12, pN13 and pN14 which all lack 
the sequences from -778 bp to –229 bp (containing the 
putative VDREs). T he expression of these truncated 
reporter constructs was not altered by treatment of cells 
with TGFb and 1,25(OH)2D3. 
Thus, coexpression of the receptors VDR and RXR does 
not significantly affect 5-LO promoter activity when the 
VDREs are present (plasmids pN9, pN10) but reduces 
5-LO promoter activity in reporter gene constructs 
(pN11-pN14) that lack the DNA sequence from –778 bp 
to  –229 bp, which contains the putative VDREs. 
Obviously, these sequences are  required for maximal 
promoter activity when expression of VDR/RXR is 
high. 
 
FIGURE 8. Effects of TGFb b/1,25(OH)2D3 on transcription 
of stably transfected CAT reporter gene constructs (A) 
and on endogenous 5 -LO mRNA expression (B).  HL-60 
cells were stably transfected with a 5-LO promoter construct 
comprising sequences from –6079 bp to +81 bp of the 5-LO 
promoter (HL60-6079-5LO), the SV40 promoter (HL60-
SV40) or a promoterless plasmid (HL60-Basic) in front of the 
CAT reporter gene. After  24 h incubation with or without 
1,25(OH)2D3  (50 nM) and TGFb (1 ng/ml), cells were 
harvested and CAT mRNA transcripts were determined (A). 
Results are presented as mean  + SE of three independent 
experiments. (B) RT-PCR analysis of endogenous 5 -LO 
mRNA expression in the stably transfected HL-60 cells. 
Mature 5-LO mRNA was analysed by RT-PCR and quantified 
as described under “Materials and Methods”. Values are given 
as mean + SE of at least three independent experiments. 
 
   Transcription of the stably transfected 5-LO promoter 
CAT reporter gene in HL-60 cells is independent of 
TGFb/1,25(OH)2D3.  In order to investigate w hether 
integration of the 5 -LO promoter into the genome is 
required for the upregulatory effects of  TGFb and 
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x1,25(OH)2D3, HL-60 cells were stably transfected with 
5-LO promoter-CAT constructs and cultured with or 
without 1 ng/ml TGFb and 50 nM 1,25(OH)2D3. After 
24 h, CAT and endogenous 5 -LO mRNA expression 
was determined by RT-PCR. TGFb and 1,25(OH)2D3 
did not significantly affect CAT expression in HL60-
6079-5LO cells which contain a stably integrated CAT 
gene under the control of the 5-LO promoter (-6079 to 
+81 bp). TGFb and 1,25(OH)2D3 slightly stimulated 
(1.9- and 1.7-fold) CAT mRNA expression in HL60-
SV40 (where the CAT reporter gene is under the control 
of an SV40 promoter)  and in  HL60-Basic  cells, 
respectively (fig. 8A). In contrast, when the expression 
of endogenous 5-LO mRNA was determined, TGFb and 
1,25(OH)2D3 caused a 13.8-fold, 11.1-fold and 7.1-fold 
increased gene expression in HL60-SV40, HL60-Basic, 
and HL60-6079-5LO, respectively (fig. 8B). Thus, 
induction of 5 -LO mRNA expression by TGFb and 
1,25(OH)2D3 seems to be mediated by regulatory 
elements located outside of the 5-LO promoter.  
 
 
DISCUSSION 
   Previous reports have established a prominent role for 
1,25(OH)2D3 and TGFb in the upregulation of 5 -LO 
expression in myeloid cells during maturation  (5). It 
was found that the about 42- to 64-fold induction of 
5-LO mRNA in Mono Mac 6 cells cultured with TGFb 
and 1,25(OH)2D3 was due to both increased 5-LO gene 
transcription (about 5-fold) and to stimulated transcript 
elongation and maturation  (7). Both TGFb and 
1,25(OH)2D3 were required for these effects. 
Genomic actions of 1,25(OH)2D3 are generally mediated 
via ligation of the VDR that in turn transactivates 
VDREs (for review, see (26)). Since the 5-LO promoter 
contains several putative VDREs (within  –313 bp to 
-258 bp), it appeared reasonable that the upregulative 
effects of 1,25(OH)2D3 on 5-LO mRNA expression are 
due to ligand-dependent transactivation of the VDRE by 
VDR. In fact, we demonstrate such binding of VDR 
together with RXR to 5 -LO promoter fragments 
spanning the putative VDREs in vitro which was similar 
to the well-documented VDRE of the mouse 
osteopontin promoter (figs. 2, 3). Also, differentiation 
of Mono Mac 6 cells by 1,25(OH)2D3 and TGFb caused 
markedly enhanced protein binding to VDREs from 
nuclear extracts, as compared to untreated cells (fig. 4). 
However, luciferase reporter gene assays failed to 
demonstrate significant transcriptional activation of the 
5-LO promoter upon stimulation with 1,25(OH)2D3 
(plus TGFb) in various  myeloid cell lines (fig. 5A), 
although expression of a reporter construct containing a 
4-times concatemerized rANF vitamin D response 
element in front of the thymidine kinase promoter 
(p(DR3)4tkluc) was strongly increased after treatment 
of these cell lines with 1,25(OH)2D3 and TGFb 
(fig. 5B). Moreover, in stably transfected HL-60 cells 
endogenous 5-LO mRNA was strongly upregulated by 
1,25(OH)2D3 and TGFb, whereas the CAT reporter 
gene, representing the entire 5-LO promoter fragment 
(-6079 to +81 bp), was not responsive (fig. 8). Together, 
we conclude that the strong induction of 5-LO mRNA 
expression by 1,25(OH)2D3 and TGFb in myeloid cells 
seems to be mediated by regulatory elements located 
outside of the 5-LO promoter, and apparently does not 
involve the V DR/RXR interaction with the VDREs 
located within the 5-LO promoter. 
The human 5-LO gene promoter was first characterized 
by Funk  et al.  (27) and Hoshiko  et al.  (25). Several 
features of the promoter region like the lack of TATAA 
or CCAAT boxes and repeated G+C-rich elements are 
characteristic for so called housekeeping genes. A major 
transcriptional start site was found 65 bp upstream of 
the translation start codon (ATG) and sequence analysis 
indicated the presence of putative cis-acting control 
elements such as multiple Sp1 sites, tandem repeat sites, 
several putative AP-2 b inding sites and putative 
response elements, such as for the transcription factor 
NFkB. Five tandem Egr-1/Sp1 consensus binding sites 
comprising the sequences from  –147 bp to  –23 bp in 
relation to the transcriptional start site were required for 
functional interaction and activation of the promoter in 
Egr-1/Sp-1 cotransfection studies  (10). Recent results 
underlined the importance of the 5-LO core promoter 
region from  –193 bp to –31 bp and revealed a strong 
involvement of DNA methylation in the regulation of 
cell-type specific 5-LO gene expression (28). Moreover, 
TsA treatment of Mono Mac 6 and HeLa cells, which 
were transiently transfected with the 5 -LO promoter 
reporter gene construct pN10, indicated a strong 
involvement of HDAC in the r egulation of 5 -LO 
promoter activity (29). However, the data indicated, that 
DNA methylation or histone acetylation were not 
related to the prominent effects of TGFb/1,25(OH)2D3 
on the increase in 5-LO mRNA observed in Mono Mac 
6 and HL-60 cells (6). 
By means of reporter gene assays using HeLa and Mono 
Mac 6 cells, we could confirm previous findings that the 
promoter region containing the five tandemized Sp1-
sites is essential for basal promoter activity. For both 
cell lines we could show that there is a positive 
regulatory region located between –5814 and –5395 bp. 
Hoshiko et al. identified a positive regulatory region 
(-6079 to –3635 bp) which comprises our sequence. On 
the other hand, in HeLa cells we did not observe the 
presence of a negative regulatory region at  –662 to 
-227 bp that was reported before. The reason for this 
discrepancy is unknown but could be due to different 
transfection protocols, different deletion constructs or 
experimental conditions. Interestingly, we could 
identify a new inhibitory region (from  –5395 to 
-4894 bp) which contains two putative binding sites for 
the transcription factor p53 that match the consensus 
sequence (GAACATGTCC) to more than 80 %. 
Using Mono Mac 6 cells we found a positive regulatory 
region (-778 to –229 bp) that is not functional in the 
5-LO negative HeLa cell line. Interestingly, putative 
VDREs are located in that region, but as stated above, in 
reporter gene experiments  TGFb/1,25(OH)2D3 did not 
alter 5 -LO  promoter activity in any cell type 
investigated. These findings are in agreement with 
results from nuclear run-off assays (6,7) and previous transfections (28), where increased transcription of the 
5-LO gene could not be demonstrated.  
Of interest, the coexpression of the VDR and RXR was 
found to be essential for high level induction of reporter 
gene activity of p(DR3)4tkluc, since low expression of 
VDR and RXR (no expression vectors added), caused 
only marginal effects of TGFb/1,25(OH)2D3, except for 
RBL-1 cells, which could be due to a high expression 
level of VDR and/or VDR related coactivators.   
Reporter gene activities of the 5 -LO promoter 
constructs pN9-pN14 were also compared in 
experiments conducted with or without the 
cotransfection of the receptor expression vectors for 
VDR/RXR. Interestingly, coexpression of the receptors 
VDR and RXR does not significantly affect 5 -LO 
promoter activity when the VDREs are present 
(plasmids pN9, pN10) but reduces 5 -LO promoter 
activity in reporter gene constructs (pN11-pN14) that 
lack the DNA sequence from  -778 to –229 bp, which 
contains the putative VDREs. One possible explanation 
could be that VDR/RXR recruit coactivators that are 
required for high 5 -LO promoter activity. However, 
with 5-LO promoter constructs that lack the VDREs, the 
VDR does not bind anymore and instead sequesters 
coactivators from the 5-LO promoter. This conclusion is 
supported by DNA footprinting and EMSA analyses 
where a strong interaction of VDR/RXR with the 
VDREs at –309 to –294 bp and at –290 to –275 bp with 
homology to the VDRE of the mouse phosphate 
intestinal transporter could be demonstrated.  
Generally, the amount of VDR and the differentiation of 
leukemic cells do not strictly correlate (30-32) and other 
factors, for example cell  line-specific nuclear 
transcription factors, e.g. coactivators could play a role. 
Some of these factors, acting in large complexes, have 
histone modifying activities  (33-39). However, the 
simple lack of bridging factors or coactivators in 
transient transfections could be excluded by 
experiments with the stably transfected cell line HL-60, 
where the endogenous 5 -LO mRNA expression was 
strongly induced in presence of TGFb/1,25(OH)2D3, but 
the CAT reporter gene mRNA and b-actin mRNA levels 
were not altered (fig. 8).  
Collectively our data show that although VDR/RXR are 
capable to bind to  putative VDREs in the 5 -LO 
promoter, the regulatory sequences involved in the 
prominent induction of 5 -LO mRNA expression by 
TGFb and 1,25(OH)2D3 in the human myeloid cell lines 
HL-60 and Mono Mac 6 seem to be located outside this 
part of the 5-LO promoter. 
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    5-Lipoxygenase expression is strongly induced by 
transforming growth factor-b b (TGFb b) and 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in the human myeloid 
cell line Mono Mac 6. In this study the mechanism of  the TGFb b 
and 1,25(OH)2D3 mediated upregulation of 5-lipoxygenase gene 
expression was investigated. RT-PCR analysis of 5-lipoxygenase 
RNA expression in Mono Mac 6 cells revealed a profound 
cytosolic and nuclear accumulation of mature 5 -lipoxygenase 
mRNA but not of pre-mRNA. In reporter gene assays where 
HeLa cells were transiently transfected with plasmids 
containing the 5-lipoxygenase core promoter plus different parts 
of the 5-lipoxygenase gene we found that the promoter failed to 
mediate transcriptional activation by TGFb b and 1,25(OH)2D3. 
However, inclusion of the coding sequence caused a 5 -fold 
upregulation of reporter gene activity by TGFb b and 
1,25(OH)2D3 which was enhanced to 13-fold when the last four 
introns of the 5-lipoxygenase gene were also included. RT-PCR 
analysis of the transcripts generated by the transfected cells 
implies that parts of the coding sequence are removed during 
5-lipoxygenase mRNA processing leading to incomplete 
transcripts. Addition of TGFb b and 1,25(OH)2D3 induced the 
appearance of exon 13 in the 5-lipoxygenase transcripts which is 
reflected by an about 14-fold increase of the corresponding PCR 
product. Deletion of various parts of the 5-lipoxygenase coding 
sequence slightly reduced inducibility by TGFb b and 
1,25(OH)2D3 whereas deletion of large parts of the coding 
sequence was required for an almost complete loss of the 
response. This suggests that the regulation of 5 -lipoxygenase 
mRNA processing by TGFb b and 1,25(OH)2D3 involves multiple 
parts of the coding sequence. 
Key words: coding sequence, mRNA processing, HeLa cell, reporter gene 
assay 
_____________________________________________________ 
   The enzyme 5-lipoxygenase (5-LO) catalyzes the conversion of 
arachidonic acid to (5S)-hydroperoxy-6-trans-6,11,14-cis-
eicosatetraenoic acid (5-HPETE) and further to leukotriene A 4 
((5S)-6-oxido-7,9,11,trans-14-cis-eicosatetraenoic acid)  (Lewis et 
al., 1990; Samuelsson et al., 1987). 5-LO is expressed in a variety 
of immune competent cells including B-lymphocytes, granulocytes, 
monocytes, mast cells and dendritic cells  (Steinhilber, 1999). 
Leukotrienes have been shown to be involved in inflammatory 
reactions and recent data suggest that the 5-lipoxygenase pathway 
plays a role in the development of cardiovascular diseases 
(Helgadottir et al., 2004; Mehrabian and Allayee, 2003). 
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element; RXR, retinoid X receptor; SBE, Smad binding element; SEAP, 
secreted alkaline phosphatase; TGFb, transforming growth factor b; TRE, 
TGFb responsive element; UTR, untranslated region; VDR, vitamin D 
receptor; VDRE, vitamin D responsive element. 
 
 
 
 
   Expression of 5 -LO, the key enzyme in the biosynthesis of 
proinflammatory leukotrienes, is regulated on transcriptional and 
posttranscriptional levels. Basal 5-LO promoter activity seems to be 
regulated by DNA methylation. It has been shown that DNA 
methylation of the GC-rich core region strongly suppresses 5-LO 
promoter activity. Furthermore, the 5-LO promoter was found to be 
methylated in 5 -LO negative cell lines whereas it is c ompletely 
demethylated in 5-LO positive cells (Uhl et al., 2002). 
Depending on the cell type, several cytokines have been shown to 
be inducers of the 5-LO pathway. In granulocytes, 5-LO expression 
is stimulated by GM-CSF  (McColl et al., 1991) whereas IL-3 
regulates the development of the 5-LO pathway in mouse mast cells 
(Murakami et al., 1995).  5-LO activity, protein expression and 
mRNA are strongly increased during differentiation of myeloid cell 
lines such as Mono Mac 6 and HL-60. Transforming growth factor-
b (TGFb) and 1,25-dihydroxyvitamin D 3 (1,25(OH)2D3) were 
identified as potent inducers of 5-LO gene expression (Brungs et 
al., 1994; Brungs et al., 1995). In Mono Mac 6 cells, treatment with 
TGFb and 1,25(OH)2D3 led to an up to 5-fold increase in primary 
transcripts, a 64-fold increase in mature 5-LO mRNA, a 128-fold 
increase in protein expression and a more than 500-fold increase in 
5-LO activity (Härle et al., 1999). The upregulation of 5-LO mRNA 
expression only partially depended on protein synthesis which 
indicated that 5-LO is a primary and secondary vitamin D response 
gene. 
Interestingly, this strong increase in 5-LO mRNA expression does 
not seem to be mediated by the promoter since TGFb and 
1,25(OH)2D3 had no effect on 5-LO transcription in nuclear run-off 
assays using nuclear extracts from Mono Mac 6 cells  (Härle et al., 
1999) and on 5 -LO promoter activity in reporter gene assays in 
different cell types  (Uhl et al., 2002).  These data suggested that 
induction of of 5-LO mRNA expression by TGFb and 1,25(OH)2D3 
is mediated by response elements that are located outside of the 
5-LO promoter region. Thus, the contribution of the coding region, 
the 3’-untranslated region (3’-UTR)  and introns J, K, L and M to 
the induction of 5 -LO gene expression  was investigated and we 
found that the coding sequence mediates the induction of 5 -LO 
mRNA expression by TGFb and 1,25(OH)2D3 and that both agents 
affect 5-LO mRNA processing. 
  
MATERIALS AND METHODS 
    Reagents. Molecular biology reagents were from MBI Fermentas, Sigma, 
Invitrogen, Promega or other sources as indicated in the text. Insulin was a 
gift from Aventis. Human TGFb1 was purified from outdated platelets 
according to  (Werz et al., 1996). Nucleospin Extract columns for direct 
purification of pDNA were from Macherey-Nagel (Düren, Germany). The 
plasmid p (DR3)4tkluc and the pSG5-VDR and pSG5-RXR expression 
plasmids for the human vitamin D receptor (VDR) and retinoid X receptor 
alpha (RXRa), respectively, were obtained from Dr. Carsten Carlberg 
(Kuopio, Finland). 
    Cells and cell culture. Mono Mac 6 cells, which were kindly provided by 
Dr. H.W.L. Ziegler-Heitbrock (Munich), were grown at 37 °C in a humified 
atmosphere with 6 % CO2 in RPMI 1640 medium supplemented with 10 % 
(vol/vol) fetal calf serum (FCS), streptomycin (100 µg/ml), penicillin 
(100 U/ml), 1 · nonessential amino acids, sodium pyruvate (1 mM), 
oxalacetate (1 mM) and insulin (10 µg/ml) (Ziegler-Heitbrock et al., 1988). 
HeLa cells were obtained from Dr. W.E. Müller (Pharmacological Institute, 
Biocenter, Frankfurt) and grown in Dulbecco’s modified Eagle's medium   2
(DMEM) supplemented with 10 % (vol/vol) FCS, 100 µg/ml streptomycin 
and 100 units/ml penicillin. 
    Isolation of cytosolic and nuclear RNA and RT-PCR analysis. Mono 
Mac 6 cells were seeded at 4×10
5 cells/ml and incubated for 24 h with or 
without 1,25(OH)2D3 (50 nM) and TGFb (1 ng/ml). Cells were harvested by 
centrifugation at 1200×g for 10 min at room temperature (RT). Cytosolic 
RNA was isolated as described in (Sambrook, 1989). The pelleted nuclei 
were subjected to an isolation of total RNA by the guanidinium thiocyanate 
method (Chomczynski and Sacchi, 1987). RT-PCR analysis of nuclear and 
cytosolic RNA fractions was performed as described previously (Härle et 
al., 1999). 
Transiently transfected HeLa cells were preincubated with or without TGFb 
(1 ng/ml) for 24 h. After transfection cells were grown  with or without 
1,25(OH)2D3 (50 nM), TGFb (1 ng/ml) and cycloheximide (10 µM) for 8 h. 
Cells were harvested by scraping and centrifugation at 1200×g for 10 min at 
RT. Total RNA was isolated  by the guanidinium thiocyanate method 
(Chomczynski and Sacchi, 1987). Prior to reverse transcription, RNA was 
incubated with DNAse I (1 unit/µg RNA) to remove plasmid DNA. RT-
PCR analysis was performed as described previously (Härle et al., 1999). 
PCR-primers (Tab. 1) were used at a concentration of 50 pmol/µl. 
Signal intensities of ethidium bromide stained DNA bands were quantified 
by densitometry (BioRad Gel Doc 1000 system) and analyzed with the 
Molecular Analyst program (BioRad). Results are expressed as x -fold 
induction of mRNA amounts, with respect to untreated cells and normalized 
with b-actin as internal standard. 
    Plasmid constructs.  5-LO promoter reporter gene contructs were 
prepared using restriction enzymes and PCR methods. 
The 3’-UTR of the 5-LO gene was obtained by PCR amplification using 
random hexamer-primed cDNA from Mono Mac 6 cells as a template and 
the primers 
5’-GTATTCTAGATGAGCACACTGCCAGTCTCA-3’ and 
5’-CGGCTCTAGACTGATTTATTTTTATGGCAAC-3’ and  Pfu I DNA 
polymerase. Following digestion of the PCR fragment and the plasmid 
pN10 (Klan et al., 2003) with Xba I, insert and pDNA were ligated using 
T4 DNA ligase (pN10-3UTR). 
5-LO coding sequence (cds) was amplified using the plasmid pT3-5LO 
(Zhang et al., 1992) as  a template and the primers 
5’-CCCTCCTACACGGTCACCGTG-3’ and 
5’-ATGGCCACACTGTTCGGAATCC-3’ and  Pfu I DNA polymerase. 
pN10-3UTR was digested with Nco I, blunted using T4 DNA polymerase 
and ligated with the PCR fragment using T4 DNA ligase (pN10-cds3UTR). 
The part of the 5 -LO coding sequence containing the last four introns 
(introns J, K, L and M) was obtained by PCR amplification using genomic 
DNA from Mono Mac 6 cells as a template and the primers 
5’-TATGCCTCCCTGTGCTTTCCCGA-3’ and 
5’-AGGTTCTTGCGGAATCGGGCCA-3’ and Pfu I DNA polymerase. The 
fragment was digested with Sfi I and partially with Nco I (besides the Nco I 
site used for cloning there is an additional one in intron M). pN10-cds3UTR 
was digested with Sfi I and Nco I. Insert and pDNA were ligated using T4 
DNA ligase (pN10-cdsInJM3UTR). 
Contructs pN10-cds and pN10-cdsInJM were obtained by deleting the 
3’-UTR via digestion of pN10-cds3UTR and pN10-cdsInJM3UTR, 
respectively, with Xba I and religation. 
Plasmid pN10-cdsInJM-inv was obtained by cloning of the Xho I-framed 
fragment cdsInJM from pN10-cdsInJM into the Sal I site of pN10. 
Contructs pGl3-ba-cdsInJM and pGL3-prom-cdsInJM were prepared using 
plasmids pGL3-Basic and pGL3-Promoter (both from Promega), 
respectively, and restriction fragments obtained from pN10-cdsInJM using 
Xba I and Bgl II or Xba I and Hind III (partial). 
Sequential deletion of the coding sequence divided in four parts lead to the 
pN10-cds deletion constructs pdcdsA, pdcdsB, pdcdsC, pdcdsD, pdcdsAB, 
pdcdsBC, pdcdsCD, pdcdsABC and pdcdsBCD. Deletions were performed 
using PCR mutation and restriction enzymes. 
Plasmid sequences were confirmed by DNA sequencing. 
    Transient transfections. 24 h prior to transfection, HeLa cells were plated 
into a 24-well tissue culture plate at a density of 5×10
4 cells per well. TGFâ 
was added for a 24 h-preincubation. Transient transfections were performed 
with the standard calcium phosphate method, adding 800 ng of reporter 
plasmid, 100 ng of different expression plasmids and 20 ng pCMV-SEAP as 
internal standard p er well. After 16 h the calcium phosphate-DNA 
precipitate was removed, new cell culture medium added and incubated for 
another 8 h. 
    Luciferase assays.  Cells were transfected as indicated, harvested and 
lysed in 100 µl lysis buffer (Steady-GloTM Luciferase Assay System, 
Promega). Luciferase activity was determined by monitoring light emission 
with a Microlumat Plus LB96V EG&G Berthold luminometer (Martin et al., 
1996). The light emission signal was integrated for 5 seconds. Transfection 
efficiency was monitored and normalised by cotransfection of pCMV-SEAP 
using the Phospha-Light TM kit (Tropix) to determine the secreted placental 
alkaline phosphatase (SEAP) activity (Yang et al., 1997). 
  
RESULTS 
    1,25(OH)2D3 and TGFb induce accumulation of mature 5-LO 
mRNA. The 5-LO positive human myeloid cell line Mono Mac 6 
was incubated with 1,25(OH)2D3 and TGFb for 24 hours. 
Subsequently, nuclear and cytosolic RNA was isolated and 
subjected to RT-PCR analysis, using either oligo(dT)12-18 or random 
hexamer primers for cDNA synthesis for the determination of 
mature and pre-mRNA, respectively. The time course experiment 
revealed a prominent increase of mature  5-LO mRNA in the 
nucleus as well as in the cytosol following incubation with 
1,25(OH)2D3 and TGFb, whereas pre-mRNA levels were not 
significantly elevated (fig. 1). 
 
FIG. 1. Effects of 1,25(OH)2D3 and TGFb b on nucleic and cytosolic 5-LO 
mRNA in Mono Mac 6 cells.  Mono Mac 6 cells were  grown with or 
without 1,25(OH)2D3 (50 nM) and TGFb (1 ng/ml) for 24 h. Then, cytosolic 
and nucleic RNA was isolated as described and RT-PCR analysis  was 
performed. Signal intensities of ethidium bromide stained DNA bands were 
quantified by densitometry. Results are expressed as fold induction in 
mRNA amounts in relation to untreated cells and normalized with b-actin as 
internal standard. Results are displayed as mean  – SE of at least three 
independent experiments. 
 
    Cotransfection of VDR and RXR induces reporter gene activity 
when the 5-LO coding sequence is present. In order to study the 
effects of VDR/RXR coexpression and to identify regulatory 
sequences located outside of the 5 -LO promoter, reporter gene 
assays with plasmid constructs containing the 3’-untranslated 
region, the coding sequence (cds) and the last four introns (introns 
J, K, L and M) were performed in the presence and absence of 
pSG5-VDR and pSG5-RXR. For that purpose, the 3’-untranslated 
region, the coding sequence and the last four introns were cloned 
into the construct pN10 and in the pGL3 vectors (Promega). The 
constructs were cloned in such a way that the 5 -LO coding 
sequence was in frame to the luciferase sequence. Two sets of 
luciferase reporter gene plasmids were constructed, the first 
containing the 5-LO core promoter (–778 to +53 bp) in the plasmid 
pGL3-Basic plus different parts of the 5-LO gene and the second 
containing the 5-LO cds plus the last four introns in front of the 
luciferase gene using the pGL3-Basic, pGL3-Promoter or pGL3-
Control vector, respectively (fig. 2). 
HeLa cells were transiently transfected with these reporter gene 
plasmids in the presence or absence of VDR and RXR expression 
constructs. As shown in fig. 3, reporter gene activity of constructs 
containing the 5 -LO promoter alone o r in combination with the 
3’-UTR was not upregulated by cotransfection of RXR/VDR which 
was comparable to controls pGL3-Basic, -Promoter and -Control. 
However, inclusion of the 5-LO coding sequence led to an about 
3-fold induction of luciferase activity by nuclear receptor 
overexpression and addition of  introns J-M even led to an about 
6-fold induction. This upregulation seemed to be independent from 
the 5 -LO promoter since it was also observed with plasmids 
containing no promoter, an SV40-promoter or an SV40-promoter 
time [h]
0 5 10 15 20 25 30
x
-
f
o
l
d
 
i
n
d
u
c
t
i
o
n
0
5
1
0
1
5
2
0
2
5 nucl. mRNA 
cyt. mRNA 
nucl. pre-mRNA 
cyt. pre-mRNA   3
plus  -enhancer (pGL3-ba-cdsInJM, pGL3-prom-cdsInJM and 
pGL3-ctrl-cdsInJM, respectively). 
 
FIG. 2. Overview of luciferase reporter gene plasmids. 
 
RT-PCR was used to confirm these data on mRNA level. HeLa cells 
were transiently transfected with pN10-cdsInJM in the presence or 
absence of expression plasmids for the nuclear receptors VDR and 
RXR and RT-PCR analysis was performed, using either 
oligo(dT)18-20 or random hexamer primers for cDNA synthesis and 
different sets of primers for PCR reactions. VDR/RXR mediated 
induction of 5-LO pre-mRNA and mature mRNA was 2.2- (–0.4) 
and 4.6- (–1.8) fold, respectively. Taken together, the data show 
that the 5-LO coding sequence mediates induction by VDR/RXR. 
Interestingly, no effect of VDR/RXR overexpression was observed 
with the p(DR3)4tkluc plasmid that contains a 4 -times 
concatemerized VDRE.  
 
FIG. 3. Effects of VDR/RXR on the transcriptional activity of luciferase 
reporter gene constructs in transiently transfected HeLa cells. The 
indicated plasmids were transiently transfected into HeLa cells with or 
without the expression vectors pSG5-hVDR and pSG5-hRXR. 
p(DR3)4tkluc, containing a four times concatemerized DR3-type vitamin D 
response element in front of the thymidine kinase promoter was used as a 
positive control. Reporter gene activity was measured 24 hours after 
transfection. Each experiment was performed in triplicates. Results are 
presented as mean  – SE of at least three independent experiments after 
normalization for transfection efficiency by cotransfection of pCMV-SEAP. 
Inductions are expressed in respect to pSG5-cotransfected cells. 
    Induction of reporter gene activity by 1,25(OH)2D3 and TGFb 
is also mediated by the 5-LO coding sequence. In Mono Mac 6 
cells, 5-LO mRNA expression is strongly enhanced by 1,25(OH)2D3 
and TGFb, but previous reporter gene assays with the 5-LO core 
promoter construct pN10 failed to show a transcriptional 
upregulation following incubation with 1,25(OH)2D3 and TGFb 
(Uhl et al., 2002). In order to investigate whether the effect of these 
agents also depends on sequences located outside of the promoter 
like the coding region and 3’-UTR, reporter gene assays with the 
corresponding plasmid constructs (fig. 2) were performed. HeLa 
cells were incubated with 1  ng/ml TGFb for 24 hours before 
transfection. Transfection was done as described above and after 
exchange of medium, cells were incubated with 1  ng/ml TGFb 
and/or 50 nM of 1,25(OH)2D3 for another 8 hours before reporter 
gene activity was determined. TGFb alone led to an only slight 
increase in reporter gene activity but the combination of both agents 
revealed a significant synergistic effect with reporter gene 
constructs that contain the coding sequence (fig. 4). In agreement to 
the well-known fact that VDR binds to DNA predominantly as 
heterodimer with RXR, overexpression of both nuclear receptors 
was required for upregulation of 5-LO expression by  TGFb and 
1,25(OH)2D3 (data not shown). The upregulation by 1,25(OH)2D3 
and TGFb depended on the used constructs. With pN10 and 
pN10-3UTR, induction by TGFb and 1,25(OH)2D3 did not differ 
from the negative control pGL3-Basic but presence of the 5-LO 
coding sequence (pN10-cds) led to a 5.1-fold induction and 
inclusion of the coding sequence plus introns J-M (pN10-cdsInJM) 
to an 12.4-fold upregulation. The reporter gene activity of the 
promoterless plasmid pGL3-ba-cdsInJM was also  induced (about 
16-fold) and the positive control plasmid p(DR3)4tkluc containing 
a 4 -times concatemerized VDRE gave a 9 -fold induction. 
Interestingly, introduction of the coding sequence plus the introns J-
M downstream of the translational stop codon of the luciferase gene 
(pN10-cdsInJM-inv) led to a significant reduction of inducibility 
(3.6-fold). 
Taken together, the data show that the 5 -LO coding sequence 
mediates induction of reporter gene activity by 1,25(OH)2D3 and 
TGFb. 
 
FIG. 4. Effects of 1,25(OH)2D3 and TGFb b on the transcriptional activity 
of luciferase reporter gene constructs in transiently transfected HeLa 
cells. The indicated plasmids and the expession vectors pSG5-hVDR and 
pSG5-hRXR were transiently transfected into HeLa cells. p(DR3)4tkluc was 
used as positive control. Before transfection, cells were preincubated with 
TGFb (1ng/ml) for 24 h and 16 h after transfection 1,25(OH)2D3 (50 nM) 
and TGFb (1 ng/ml) were added for another 8 h before reporter gene activity 
was determined. Each experiment was performed in triplicates. Results are 
presented as mean  – SE of at least three independent experiments after 
normalization for transfection efficiency by cotransfection of pCMV-SEAP. 
Inductions are expressed with respect to untreated cells. 
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    1,25(OH)2D3 and TGFb regulate 5 -LO mRNA processing.  In 
order to check whether the effects of 1,25(OH)2D3/TGFb occur at 
the mRNA level, HeLa cells were transiently transfected with 
pN10-cdsInJM and pSG5-VDR and pSG5-RXR and the formed 
mRNA transcripts were analyzed by  RT-PCR.  Cells were 
preincubated with TGFb for 24 h and after transfection, 
1,25(OH)2D3/TGFb were added together with or without 
cycloheximide (CHX) for 8  h. After extraction  of total RNA 
(Chomczynski and Sacchi, 1987), RT-PCR analysis was performed, 
using either oligo(dT)18-20 or random hexamer priming for cDNA 
synthesis and different sets of primers for PCR reactions (tab. 1, fig. 
5). With primer pairs that are located in the beginning or the end of 
the coding sequence, 28 PCR cycles were sufficient to obtain 
defined PCR products of correct size whereas 35 cycles were 
required when the respective primer pairs were located between 
exons 8 and 13 indicating that central parts of the coding sequence 
are removed during mRNA processing. Interestingly, when we used 
a primer pair (cds_start/Asurev) that spans the complete coding 
region, we got multiple PCR products indicating that mRNA 
processing seems to occur at several sites. The 1,25(OH)2D3/TGFb 
mediated induction of transcripts varied significantly (given as fold 
induction, fig. 5) depending on the RNA position that was analyzed 
by PCR. The most prominent increase in 5 -LO mRNA which 
roughly corresponds to the increase in luciferase activity was 
observed when primers that span intron M like 5 -LO1/Asurev 
(14.6-fold) and InJM_5/Asurev (9.8-fold) or primers that are 
located within intron M (7.8-fold) were used. Interestingly, with 
these primer pairs, the increase was significantly inhibited when 
cycloheximide was added together with 1,25(OH)2D3 and TGFb, 
indicating that protein synthesis was required (figs. 6B and D). 
Strikingly, using primers cds_start/1883_rev or Ncofor1/Asurev 
that amplify exons 1 to 8 or parts of exon 14 and the luciferase 
gene, respectively, (fig. 5) an only weak increase in the respective 
PCR signals (6.0-fold or 2.5-fold, respectively) was obtained that 
was not inhibited by cycloheximide (figs. 6A and C). Interestingly, 
these parts of the mRNA were prominently expressed since 28 
cycles were sufficient to obtain clear PCR signals of correct size. 
 
 
 
 
 
 
 
 
 
 
 
Taken together, characterization of the transcribed RNA species by 
RT-PCR suggests that central parts of the 5-LO coding sequence 
are removed during RNA processing and that 1,25(OH)2D3 and 
TGFb induce the inclusion of exon 13 into the mature mRNA. 
 
    Upregulation of 5-LO mRNA processing by 1,25(OH)2D3/TGFb 
does not depend on a distinct part of the coding sequence. In order 
to identify sequences in the coding region that participate in the 
1,25(OH)2D3/TGFb-mediated regulation of 5 -LO expression, 
deletion constructs of the vector pN10-cds were cloned and 
analyzed in reporter gene assays. The coding region was divided 
into four parts which were subsequently deleted (fig. 7). Domain A 
ranges from exon 1 to 4, domain B from exon 4 to 10, domain C 
from exon 10 to 14 and domain D represents the last part of 
exon 14 (fig. 5).  
The respective deletion of parts A to D reduced induction of 
reporter gene activity by 1,25(OH)2D3/TGFb (figs. 8A and B). A 
significant decrease in 5 -LO upregulation by 1,25(OH)2D3/TGFb 
could be seen when parts B+C, A+B+C or B+C+D were deleted 
(from 5.1-fold to 2.6-, 2.0- and 2.2-fold, respectively). In constructs 
in which large parts of the coding sequence are deleted (pdcdsABC 
and pdcdsBCD), the 1,25(OH)2D3-mediated induction of reporter 
gene activity was completely lost and only the minor TGFb-
mediated enhancement could be measured. 
Taken together, the deletion analysis demonstrates that  for an 
almost complete loss of the response to  1,25(OH)2D3/TGFb, 
removal of large parts of the coding sequence is required. This 
suggests that the regulation of the 5-LO RNA processing by TGFb 
and 1,25(OH)2D3 involves multiple parts of the coding sequence. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 5.  Effects of 1,25(OH)2D3/TGFb b on mRNA transcripts generated from the transiently transfected luciferase reporter gene construct 
pN10-cdsInJM. The reporter gene construct pN10-cdsInJM and the expession vectors pSG5-hVDR and pSG5-hRXR were transiently transfected into HeLa 
cells, which were preincubated with TGFb (1 ng/ml) for 24 h. 16 h after transfection, 1,25(OH)2D3 (50 nM) and TGFb (1 ng/ml) were added for another 8 h. 
Then, RT-PCR analysis was performed as described in “Materials and Methods”. Different pairs of primers were used to scan the coding region. Localization 
of amplified fragments and the  relative induction of the respective PCR products by 1,25(OH)2D3 (50 nM)/TGFb (1ng/ml) are given. Values are expressed as 
mean – SE of at least three independent experiments. The localizations of domains A-D of the coding sequence deletion constructs are indicated below and the 
numbers of PCR cycles are given above. 
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TAB. 1. PCR primer sequences.  Primers used for reverse transcription (RT-) analysis. Tm, annealing temperature. 
 
 
DISCUSSION 
    Previous reports have established a prominent role for 
1,25(OH)2D3 and TGFb in the upregulation of 5 -LO gene 
expression in myeloid cells during maturation (Brungs et al., 1995). 
It was found that the about 40- to 60-fold induction of 5-LO mRNA 
in Mono Mac 6 cells cultured with TGFb and 1,25(OH)2D3 was 
mainly to due posttranscriptional events  (Härle et al., 1998). Both 
TGFb and 1,25(OH)2D3 were required for these effects. Nuclear 
1,25(OH)2D3 signalling is generally mediated via binding of the 
1,25(OH)2D3/VDR/RXR complex to VDREs in gene promoters (for 
review, see (Carlberg, 2003; Carlberg and Polly, 1998)).  
Primer 
pair 
Locations  Primer sequence 
 
 
Tm 
[°C] 
Cycles 
b-actin 1/2 
(Clontech) 
  5‘-GAGGAGCACCCCGTGCTGCTGA-3‘ 
5‘-CTAGAAGCATTTGCTGTGGACGATGGAGGGGCC-3‘ 
 
60  24 
 
5-LO 1/2  exon 
13/14 
5‘-ACCATTGAGCAGATCGTGGACACGC-3‘ 
5‘-GCAGTCCTGCTCTGTGTAGAATGGG-3’ 
 
60  28 
intron A 
1/2 
intron A  5’-AGATGAGTCATGCTCACAGAACT-3’ 
5’-AGATCAGCATTAGGAACTAGCTT-3’ 
 
60  35 
cds_start 
ex3rev 
exon 1/3  5’-ATGCCCTCCTACACGGTCAC-3’ 
5’-CAGTTCTTTACGTCGGTGTTGCTTGAG-3’ 
 
56  28 
cds_start 
ex6rev 
exon 1/6  5’-ATGCCCTCCTACACGGTCAC-3’ 
5’-CAGCTTCCTGCCAGTGATTCATG-3’ 
 
56  28 
cds_start 
1883_rev 
exon 1/8  5’-ATGCCCTCCTACACGGTCAC-3’ 
5’- GAGGAAAATAGGGTTCTCATCTCCC-3’ 
 
56  28 
1883_for 
2260_rev 
exon 
8/10 
5’-GGGAGATGAGAACCCTATTTTCCTC-3’ 
5’-GGGCCTTGATGGCCTC-3’ 
 
56  35 
SfiI_for 
Exon11B 
exon 
10/11 
5’-GACCTGACCTATGCCTCCCTGTGCTTTC-3’ 
5’-CATGCCGTACACGTAGACATCGTT-3’ 
 
60  35 
Exon11A 
Exon11B 
exon 11  5’-GAGGTGGTAGACATCTACTAC-3’ 
5’-CATGCCGTACACGTAGACATCGTT-3’ 
 
60  35 
Exon11A 
Exon12B 
exon 
11/12 
5’-GAGGTGGTAGACATCTACTAC-3’ 
5’-TGGCCGAAGTTGACCGCGGCGT-3’ 
 
60  35 
Exon11A 
Exon13B 
exon 
11/13 
5’-GAGGTGGTAGACATCTACTAC-3’ 
5’-CTCGTTTTCCTGGAACTGGCTCA-3’ 
 
60  35 
5-LO1 
Asurev 
exon 
13/luc 
5’-ACCATTGAGCAGATCGTGGACACGC-3‘ 
5’-GCCAACCGAACGGACATTTC-3’ 
 
56  28 
InJM_5 
Asurev 
exon 
13/luc 
5’-CTGAGCCAGTTCCAGGAAAACGAG-3‘ 
5’-GCCAACCGAACGGACATTTC-3’ 
 
56  28 
Ncofor1 
Asurev 
exon 
14/luc 
5’-GAAGCCTGTGAAGGAAGCCATG-3’ 
5’- GCCAACCGAACGGACATTTC-3’ 
 
56  28 
intron M 
1/2 
intron M  5’-AGGGTGTGCAGGGCAGGAGA-3’ 
5’-GGTTACGAGATGATGCAGATGAAGCTG-3’ 
 
60  28 
   6
 
 
 
 
 
 
However, in reporter gene assays no significant transcriptional 
activation of the 5-LO promoter (pN10) by 1,25(OH)2D3 and TGFb 
was observed. From these results we concluded that the strong 
induction of 5-LO mRNA expression by 1,25(OH)2D3 and TGFb 
might be mediated by regulatory elements located outside of the 
5-LO promoter. In fact, we could demonstrate with reporter gene 
assays, that induction of reporter gene activity by 1,25(OH)2D3 and 
TGFb depends on the 5 -LO coding sequence (fig.  4). This 
upregulation was independent of the promoter (5-LO, CMV, no 
promoter) indicating that at least under the in-vitro conditions of 
reporter gene assays, the 5 -LO promoter is not required for the 
1,25(OH)2D3 and TGFb effect. 
On the other hand,  the induction of reporter gene activity mediated 
 
 
 
 
 
 
by the coding sequence depended on the coexpression of 
VDR/RXR which indicates that the vitamin D receptor is involved 
in signalling. Coexpression of VDR/RXR was  also required for 
vitamin D signalling in our control experiments, i.e. the stimulation 
of reporter gene activity of the p(DR3)4tkluc plasmid that contains 
a four times concatemerized DR3 vitamin D response element in 
front of the thymidine kinase promoter. However, there was a 
significant difference in the reporter gene assays between classical 
vitamin D signalling and the induction of reporter gene activity 
mediated by the coding sequence. Whereas coexpression of 
VDR/RXR did not affect reporter gene activity of the p(DR3)4tkluc 
plasmid in the absence of 1,25(OH)2D3 and TGFb (fig. 3), it led to 
an up to 6-fold stimulation of luciferase activity of vector constructs 
containing the 5-LO coding sequence. This suggests that there is a 
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FIG. 6. Effects of cycloheximide on the induction of mRNA transcripts by 1,25(OH)2D3 and TGFb b. Hela cells were transiently transfected with the 
luciferase reporter gene construct pN10-cdsInJM and preincubated as described in the legend to fig. 5. After transfection, cyloheximide (10 µM) was added 
together with 1,25(OH)2D3 (50 nM) and/or TGFb (1 ng/ml). Then, RT-PCR analysis was performed as described in “Materials and Methods” with the 
indicated primer pairs. Values are expressed as  mean – SE of at least three independent experiments.   7
considerable ligand-independent activity of the vitamin D receptor 
regarding the induction of reporter gene activity mediated by the 
5-LO coding sequence. Inclusion of the last four introns (J, K, L 
and M) even enhanced the inducibility of the reporter g ene 
constructs. 
 
FIG. 7. Overview of coding sequence deletion plasmids. 
 
 As it was found before in Mono Mac 6 cells, 1,25(OH)2D3 and 
TGFb induce 5-LO mRNA expression mainly by posttranscriptional 
mechanisms (Härle et al., 1998). RT-PCR data obtained with Mono 
Mac 6 cells (fig. 1) gave a prominent induction of mature 5-LO 
mRNA but not pre-mRNA by 1,25(OH)2D3/TGFb, which suggests 
enhanced mRNA processing as mechanism of 5-LO upregulation. 
This conclusion is also supported by the fact that in reporter gene 
assays, there is an enhanced inducibility of plasmids containing 
intronic sequences by 1,25(OH)2D3/TGFb suggesting that splicing 
processes are involved. Another possible mechanism could be 
transcriptional arrest mediated by the coding sequence that is 
overcome by 1,25(OH)2D3 and TGFb. However, such a mechanism 
is rather unlikely because RT-PCR data show that there is only low 
expression of the middle part of the 5-LO coding sequence but not 
of the 3’-end. Furthermore, inducibility by 1,25(OH)2D3/TGFb was 
rather low with the pN10-cdsInJM-inv plasmid which contains the 
5-LO coding sequence after the luciferase reporter gene. However, a 
transcriptional stop site should also be operative under these 
conditions. 
It can only be speculated, if the first (very long) introns of the 5-LO 
gene also participate in its regulation. It was not possible to include 
these introns in the reporter gene experiments because of their huge 
size. Thus, it is very well possible that these introns also participate 
in the regulation of the expression of the 5-LO gene and that there 
are differences in the mechanisms that contribute to the observed 
1,25(OH)2D3/TGFb effects on 5 -LO expression in Mono Mac 6 
cells and in our reporter gene assays.  
The partial inhibition of the 1,25(OH)2D3/TGFb effects by 
cycloheximide suggest that the response to both agents requires at 
least in part protein biosynthesis. Thus, it is possible that  
1,25(OH)2D3/TGFb induce the biosynthesis of proteins involved in 
5-LO mRNA splicing and/or processing. This would explain the 
observed induction of luciferase activity without concomitant 
increases on the mRNA level in the reporter gene assays. In our 
constructs, the 5-LO and luciferase coding sequences are merged in 
frame so that translation of the transcribed RNA yields a 5-LO-
luciferase fusion protein. Thus, aberrant RNA processing that leads 
to a frame shift in the 5 -LO coding region prevents correct 
translation of the luciferase. Consequently, induction of correct 
5-LO RNA processing by 1,25(OH)2D3/TGFb generates correctly 
translated luciferase protein and subsequent activity. 
 
FIG. 8. Effects of 1,25(OH)2D3 and TGFb b on the transcriptional activity 
of coding sequence deletion constructs in transiently transfected HeLa 
cells.  The indicated pN10-cds deletion constructs were transiently 
transfected into HeLa cells together with the expession vectors pSG5-hVDR 
and pSG5-hRXR. Before transfection, cells were preincubated with TGFb 
(1 ng/ml) for 24 h. 16 h after transfection, 1,25(OH)2D3 (50 nM) and TGFb 
(1 ng/ml) were added for another 8  h and reporter gene activity was 
determined. Each experiment was performed in triplicates. Results are 
presented as mean  – SE of at least three independent experiments after 
normalization for transfection efficiency by cotransfection of pCMV-SEAP. 
Inductions are expressed with respect to untreated cells. 
 
Interestingly, nuclear receptors such as VDR have recently been 
shown to be involved in coupling of transcription to splicing 
(Zhang et al., 2003) (for review, see  (Fong and Zhou, 2001; 
Maniatis and Reed, 2002)). Generally, the presence of introns in the 
transcription unit was shown to activate gene expression in yeast 
and mice (Fong and Zhou, 2001). Moreover, 1,25(OH)2D3, retinoic 
acid and TGFb have been described as stimuli of alternative 
splicing events (Magnuson et al., 1991) (for review, see (Akker et 
al., 2001)). Thus, our results with the 5-LO coding sequence clearly 
support the concept that mRNA processing/splicing is involved in 
the regulation of gene expression by 1,25(OH)2D3/TGFb.   
RT-PCR analysis of the transcripts generated during the reporter 
gene assays was difficult to perform when the region between exon 
8 and 13 was amplified. More cycles were necessary (Tab. 1) and in 
some PCR reactions multiple products were detected. It was not 
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possible to amplify the whole coding sequence, at least three 
definite bands that were smaller than expected where obtained. 
Sequencing a 450 bp PCR product solely allowed to verify the last 
100 bp of exon 14. The sequencing data further upstream could not 
be interpreted due to superimposing of different sequences.  
Taken together, it seems that in untreated Hela cells, 5-LO mRNA 
processing occurs that removes parts of the coding sequence. Our 
data suggest that 1,25(OH)2D3/TGFb￿induce the generation of 
more complete transcripts. Coding sequence deletion studies (figs. 7 
and 8) revealed that the respective deletion of parts A to D reduced 
induction of reporter gene activity by 1,25(OH)2D3/TGFb (fig. 8). 
In constructs in which larger parts of the coding sequence are 
deleted (pdcdsABC and pdcdsBCD), the 1,25(OH)2D3-mediated 
induction of reporter gene activity was almost completely lost and 
only the minor TGFb-mediated enhancement could be measured. 
The fact that deletion of large parts of the coding sequence is 
required in order to achieve an almost complete loss of the response 
to  1,25(OH)2D3/TGFb suggests that the regulation of the 5 -LO 
mRNA processing by both agents involves multiple parts of the 
coding sequence. 
Taken together, our results provide clear evidence that the 5-LO 
coding region mediates the upregulation of 5 -LO expression by 
1,25(OH)2D3 and TGFb. These effects do not seem to be mediated 
by classical VDREs in the coding sequence. Our data suggest that 
both mediators regulate 5-LO mRNA processing which represents a 
novel mechanism of regulation of gene expression by 1,25(OH)2D3 
and TGFb. 
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    5-Lipoxygenase (5-LO) expression is strongly induced by 
transforming growth factor-b b (TGFb b) and 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in Mono Mac 6 cells. 
Since Smad proteins have been described as downstream 
effectors of TGFb b, we have investigated the role of the 
TGFb b/Smad signalling system in the regulation of 5-LO gene 
expression. In transient reporter gene assays with plasmids 
containing the 5-LO promoter plus different parts of the gene 
Smads3/4 mediated a prominent upregulation of reporter 
activity that strongly depended on the coding sequence and to a 
lesser extent on the 3’-UTR and introns J to M. 
Deletion of various parts of the 5-LO coding sequence reduced 
inducibility by Smads3/4, the decrease being most profound 
when exons 10 to 14 were deleted. Deletion studies indicated the 
existence of up to four functional Smad response elements in 
intron M and a TGFb b responsive element in exon 10, that had 
been detected by sequence analysis. 
 
Key Words: 5-lipoxygenase; coding sequence; transforming growth 
factor b; Smad3/4; gene expression; reporter gene assay. 
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   Arachidonate 5 -lipoxygenase (5-LO)
1, the key enzyme in the 
biosynthesis of proinflammatory leukotrienes,  is expressed in a 
variety of immune competent cells including B -lymphocytes, 
granulocytes, monocytes, mast cells and dendritic cells  [1]. 
Leukotrienes have been shown to be involved in inflammatory 
reactions and recent data suggest that the 5-lipoxygenase pathway 
plays a role in the development of cardiovascular diseases [2, 3]. 
Expression of 5 -LO  is regulated on transcriptional and 
posttranscriptional levels. Basal 5-LO promoter activity seems to be 
regulated by DNA methylation and it has been shown that DNA 
methylation of the GC-rich core region strongly suppresses 5-LO 
promoter activity. Furthermore, the 5-LO promoter was found to be 
methylated in 5 -LO negative cell lines whereas it is completely 
demethylated in 5-LO positive cells [4]. 
 
 
____________________________________________________ 
   This study was supported by grants from EU (QLG1-CT-2001-01521) and 
the Wilhelm Sander Foundation.  
   To whom correspondence should be addressed: Dr. Dieter Steinhilber, 
Institute of Pharmaceutical Chemistry, University of Frankfurt, Marie-
Curie-Str. 9, 60439 Frankfurt, Germany, phone: +49-69-798 29324, fax: 
+49-69-798 29323, e-mail: steinhilber@em.uni-frankfurt.de. 
   
1The abbreviations used are: 1,25(OH)2D3, 1,25-dihydroxyvitamin D 3; 
cds, coding sequence; 5-LO, 5-lipoxygenase; luc, luciferase; RE, responsive 
element; RXR, retinoid X receptor; SBE, Smad binding element; SEAP, 
secreted alkaline phosphatase; TGFb, transforming growth factor b; TRE, 
TGFb responsive element; UTR, untranslated region; VDR, vitamin D 
receptor; VDRE, vitamin D responsive element. 
                                            
 
 
 
 
 
   Depending on the cell type, several cytokines have been shown to 
be inducers of the 5-LO pathway. In granulocytes, 5-LO expression 
is stimulated by GM-CSF  [5] whereas IL-3 regulates the 
development of the 5-LO pathway in mouse mast cells [6]. 5-LO 
activity, protein expression and mRNA are dramatically increased 
during differentiation of myeloid cell lines such as Mono Mac 6 and 
HL-60. Transforming growth factor-beta (TGFb) and 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) were identified as potent 
inducers of 5 -LO gene expression [7, 8]. In Mono Mac 6 cells, 
treatment with TGFb and 1,25(OH)2D3 led to an up to 5 -fold 
increase in primary transcripts, a 64-fold increase in mature 5-LO 
mRNA, a 128-fold increase in protein expression and a more than 
500-fold increase in 5-LO activity [9]. The upregulation of 5-LO 
mRNA expression partially depended on protein synthesis. This 
strong increase in 5 -LO mRNA expression does not seem to be 
mediated by the promoter since TGFb and  1,25(OH)2D3 had no 
effect on 5-LO transcription in nuclear run-off assays using nuclear 
extracts from Mono Mac 6 cells [9] and on 5-LO promoter activity 
in reporter gene assays in different cell types [4]. 
Since Smad proteins have been described as downstream effectors 
of TGFb, we further investigated the role of TGFb/Smad signalling 
in 5 -LO gene regulation by reporter gene analyses. Sequence 
analyses and deletion studies led to the identification of several 
functional TGFb and Smad3/4 response elements within the 5-LO 
gene. 
  
MATERIALS AND METHODS 
    Reagents. Molecular biology reagents were from MBI Fermentas, Sigma, 
Invitrogen, Promega or other sources as indicated in the text. Insulin was a 
gift from Aventis. Human TGFb1 was purified from outdated platelets 
according to  [10]. Nucleospin Extract columns for direct purification of 
pDNA were from Macherey-Nagel (Düren, Germany). The plasmid 
p(DR3)4tkluc and the pSG5-hVDR and pSG5-hRXR expression plasmids 
for the human vitamin D receptor (VDR) and retinoid X receptor alpha 
(RXRa), were obtained from Dr. Carsten Carlberg (Kuopio, Finland). The 
vector p3TP-Lux was provided by Dr. Joan Massagué (New York, USA). 
The pCGN-Smad3 and pCGN-Smad4 expression plasmids were obtained 
from Dr. X.F. Wang (Durham, USA). 
    Cells and cell culture. HeLa cells were obtained from Dr. W.E. Müller 
(Pharmacological Institute, Biocenter, Frankfurt) and grown in Dulbecco’s 
modified Eagle's medium (DMEM) supplemented with 10 % (vol/vol) FCS, 
100 µg/ml streptomycin and 100 units/ml penicillin. Mono Mac 6 cells, 
which were kindly provided by Dr. H.W.L. Ziegler-Heitbrock (Munich), 
were grown at 37 °C in a humified atmosphere with 6 % CO2 in RPMI 1640 
medium supplemented with 10 % (vol/vol) fetal calf serum (FCS), 
streptomycin (100 µg/ml), penicillin (100 U/ml), 1 · nonessential amino 
acids, sodium pyruvate (1 mM), oxalacetate (1 mM) and insulin (10 µg/ml) 
[11]. 
    Plasmid constructs.  5-LO promoter reporter gene contructs were 
prepared using restriction enzymes and PCR methods. 
The 3’-UTR of the 5-LO gene was obtained by PCR amplification using 
random hexamer-primed cDNA from Mono Mac 6 cells as a template and 
the primers 
5’-GTATTCTAGATGAGCACACTGCCAGTCTCA-3’ and 
5’-CGGCTCTAGACTGATTTATTTTTATGGCAAC-3’ and  Pfu I DNA 
polymerase. Following digestion of the PCR fragment and  the plasmid   2
pN10 (-778 to +53 bp) [12] with Xba I, insert and pDNA were ligated using 
T4 DNA ligase (pN10-3UTR). 
5-LO coding sequence (cds) was amplified using the plasmid pT3-5LO [13] 
as a template and the primers 5’-CCCTCCTACACGGTCACCGTG-3’ and 
5’-ATGGCCACACTGTTCGGAATCC-3’ and  Pfu I DNA polymerase. 
pN10-3UTR was digested with Nco I, blunted using T4 DNA polymerase 
and ligated with the PCR fragment using T4 DNA ligase (pN10-cds3UTR). 
The part of the 5 -LO coding sequence containing the last four introns 
(introns J, K, L and M) was obtained by PCR amplification using genomic 
DNA from Mono Mac 6 cells as a template and the primers 
5’-TATGCCTCCCTGTGCTTTCCCGA-3’ and 
5’-AGGTTCTTGCGGAATCGGGCCA-3’ and Pfu I DNA polymerase. The 
fragment was digested with Sfi I and partially with Nco I (besides the Nco I 
site used for cloning there is an additional one in intron M). pN10-cds3UTR 
was digested with Sfi I and Nco I. Insert and pDNA were ligated using T4 
DNA ligase (pN10-cdsInJM3UTR). 
Contructs pN10-cds and pN10-cdsInJM were obtained by deleting the 
3’-UTR via digestion of pN10-cds3UTR and pN10-cdsInJM3UTR, 
respectively, with Xba I and religation. 
Plasmid pN10-cdsInJM-inv was obtained by cloning of the Xho I-framed 
fragment cdsInJM from pN10-cdsInJM into the Sal I site of pN10. 
Contructs pGl3-ba-cdsInJM and pGL3-prom-cdsInJM were prepared using 
plasmids pGL3-Basic and pGL3-Promoter (both from Promega), 
respectively, and restriction fragments obtained from pN10-cdsInJM using 
Xba I and Bgl II or Xba I and Hind III (partial). 
Sequential deletion of the coding sequence divided in four parts lead to the 
pN10-cds deletion constructs pdcdsA, pdcdsB, pdcdsC, pdcdsD, pdcdsAB, 
pdcdsBC, pdcdsCD, pdcdsABC and pdcdsBCD. Deletions were performed 
using PCR mutation and restriction enzymes. Deletions of putative response 
elements leading to plasmids pdTGFRE1, pdTGFRE2, pdTGFRE1+2 and 
pdSBE2 were performed by substitution of mutated PCR fragments with the 
native sequences. 
Plasmid sequences were confirmed by DNA sequencing. 
    Transient transfections. 24 h prior to transfection, HeLa cells were plated 
into a 24-well tissue culture plate at a density of 5×10
4 cells per well. TGFâ 
was added for a 24 h-preincubation. Transient transfections were performed 
with the standard calcium phosphate method, adding 800 ng of reporter 
plasmid, 100 ng of different expression plasmids and 20 ng pCMV-SEAP as 
internal standard per well. After 16 h the calcium phosphate-DNA 
precipitate was removed, new cell culture medium added and incubated for 
another 8 h. 
    Luciferase assays.  Cells were transfected as indicated, harvested and 
lysed in 100 µl lysis buffer (Steady-GloTM Luciferase Assay System, 
Promega). Luciferase activity was determined by monitoring light emission 
with a Microlumat Plus LB96V EG&G Berthold luminometer  [14]. The 
light emission signal was integrated for 5 seconds. Transfection efficiency 
was monitored and normalised by cotransfection of pCMV-SEAP using the 
Phospha-Light TM kit (Tropix) to determine the secreted placental alkaline 
phosphatase (SEAP) activity [15]. 
  
 
FIG. 1. Overview of luciferase reporter gene plasmids. 
    
RESULTS 
    Effects of TGFb on 5-LO reporter gene activity. HeLa cells were 
transiently transfected with luciferase reporter gene constructs (for 
overview see fig. 1) in the absence of VDR/RXR and 
Smad3/Smad4 expression constructs. The constructs were cloned in 
such a way that the 5 -LO coding sequence was in frame  to the 
luciferase sequence. Cells were preincubated with or without TGFâ 
(1 ng/ml) for 24 h. After transfection, cells were grown  with or 
without  1,25(OH)2D3  (50 nM), TGFb (1 ng/ml) for another 8  h. 
TGFb led to an about 1.5-fold induction of reporter gene activity 
with the control pGL3-Basic (fig. 2). A similar induction was 
observed with pN10-3UTR and pN10-cdsINJM-inv. Interestingly, 
slightly increased effects (about 2 -fold induction) were observed 
with plasmids that contain the 5 -LO coding sequence (pN10cds, 
pN10-cdsInJM, pGL3-ba-cdsInJM and pGL3-prom-cdsInJM). With 
all plasmids tested,  1,25(OH)2D3 alone did not significantly 
enhance transcriptional activity under these experimental 
conditions, i.e. in the absence of cotransfected VDR/RXR. A slight 
induction of transcriptional activity was obtained with the 
p(DR3)4tkluc plasmid when 1,25(OH)2D3 and  TGFb were 
combined. 
 
FIG. 2. Effects of TGFb b /1,25(OH)2D3 on the transcriptional activity of 
luciferase reporter gene constructs in transiently transfected HeLa 
cells. The indicated plasmids were transiently transfected into HeLa cells. 
p(DR3)4tkluc containing a four times concatemerized DR3-type vitamin D 
response element in front of the thymidine kinase promoter was used as a 
positive control. Before transfection, cells were preincubated with TGFb 
(1 ng/ml) for 24 h. 16 h after transfection, 1,25(OH)2D3 (50 nM) and TGFb 
(1 ng/ml) were added for another 8  h before reporter gene activity was 
determined. Each experiment was performed in triplicates. Results are 
presented as mean  – SE of at least three independent experiments after 
normalization for transfection efficiency by cotransfection of pCMV-SEAP. 
Inductions are expressed with respect to untreated cells. 
 
    Smad3/Smad4 strongly induce reporter gene activity when the 
5-LO coding sequence is present.  HeLa cells were transiently 
transfected with luciferase reporter gene constructs (fig. 1) and 
cotransfected with either pCGN-Smad3 and pCGN-Smad4 or an 
empty cytomegalovirus (CMV) promoter construct as control. 
Coexpression of Smads increased reporter gene activity obtained 
with pN10 (containing the 5-LO core promoter, –778 to +53 bp) by 
3.7-fold. Interestingly, the TGFb-responsive plasmid p3TP-Lux, 
carrying three TGFb tetradecanoyl phorbol acetate response 
elements from the PAI-1 gene, was only induced by 1.6-fold  which 
was comparable to the negative control pGL3-Basic (2.2-fold). The 
effects of the Smad proteins on 5-LO gene expression was strongly 
enhanced by the presence of the coding sequence (fig. 3). Induction 
of pN10-cds and of pN10-cdsInJM (containing also introns J-M) 
was 17.5-fold and 24.0-fold, respectively. Interestingly, the 
upregulation of the 3’-UTR-containing plasmid pN10-3UTR was 
significantly higher than with pN10 (8.8-fold versus 3.7-fold) but 
inclusion of the 3’-UTR did not further enhance the induction of the 
constructs containing the coding sequence (pN10-cds3UTR and 
pN10-cdsInJM3UTR). When the 5 -LO coding and intronic 
sequences were inserted behind the luciferase stop codon (pN10-
pN10
pN10-3UTR
pN10-cds
pN10-cdsInJM
pN10-cdsInJM-inv
pGL3-ba-cdsInJM
pGL3-Basic
pGL3-prom-cdsInJM
p(DR3)4tkluc
x
-
f
o
l
d
 
i
n
d
u
c
t
i
o
n
0
1
2
3
4
w
/
o
 
1
n
g
/
m
l
 
T
G
F
ß
 
5
0
n
M
 
1
,
2
5
(
O
H
)2D3 
50nM 1,25(OH)2D3 + 1ng/ml TGFß 
5-LO promoter
cds
cds with introns J-M
luciferase
3‘-UTR
SV 40 promoter
pN10-cdsInJM3UTR 9964 bp
pN10 5618 bp
pN10-3UTR 6045 bp
pN10-cds3UTR 8067 bp
pN10-cdsInJM 9537 bp
pN10-cds 7640 bp
pN10-cdsInJM-inv 9486 bp
pGL3-ba-cdsInJM 8737 bp
pGL3-prom-cdsInJM 8929 bp
5-LO promoter
cds
cds with introns J-M
luciferase
3‘-UTR
SV 40 promoter
pN10-cdsInJM3UTR 9964 bp
pN10 5618 bp
pN10-3UTR 6045 bp
pN10-cds3UTR 8067 bp
pN10-cdsInJM 9537 bp
pN10-cds 7640 bp
pN10-cdsInJM-inv 9486 bp
pGL3-ba-cdsInJM 8737 bp
pGL3-prom-cdsInJM 8929 bp  3
cdsInJM-inv) there was a strong reduction of the upregulation by 
cotransfection of Smad3/4 to pN10 levels (3.1-fold). Induction of 
reporter gene activity by Smad3/Smad4 also occurred with 
pGL3-ba-cdsInJM and pGL3-prom-InJM containing no and a SV 
40 promoter, respectively, which suggests that the Smad3/4 effects 
do not depend on the 5-LO promoter. 
FIG. 3. Effects of Smads3/4 on the transcriptional activity of luciferase 
reporter gene constructs in transiently transfected HeLa cells.  The 
indicated reporter gene plasmids were transiently transfected into HeLa cells 
with or without the expression vectors pCGN-Smad3 and pCGN-Smad4. 
Reporter gene activity was measured 24 h after transfection. Each 
experiment was performed in triplicates. Results are presented as mean – SE 
of at least three independent experiments after normalization for transfection 
efficiency by cotransfection of pCMV-SEAP. Inductions are expressed with 
respect to pCMV-cotransfected cells. 
 
    TGFb effects are only marginally enhanced by Smad3/Smad4. In 
the absence of coexpressed Smads, TGFb enhanced reporter gene 
activity by 1.5- to 2.7-fold for 5-LO promoter constructs and up to 
4.1-fold for the positive control p3TP-Lux (fig. 4). Interestingly, in 
cells that were cotransfected with Smad3 and Smad4 there was no 
significantly altered response to TGFb indicating that the TGFb 
effects are independent of Smad overexpression. 
FIG. 4.  Effects of TGFb b on the transcriptional activity of luciferase 
reporter gene constructs in transiently transfected HeLa cells.  The 
indicated reporter gene plasmids and the TGFb-responsive construct 
p3TP-Lux were transiently transfected into HeLa cells with or without the 
expression vectors pCGN-Smad3 and pCGN-Smad4. Before transfection, 
cells were preincubated with TGFb (1 ng/ml) for 24 h. 16 h after 
transfection, TGFb (1 ng/ml) was added for another 8 h before luciferase 
activity was measured. Each experiment was performed in triplicates. 
Results are presented as mean  – SE of at least three independent 
experiments and were normalized for transfection efficiency by 
cotransfection of pCMV-SEAP. Inductions are expressed with respect to 
uninduced reporter activity. 
    Synergism between RXR/VDR and Smad3/Smad4. Cotransfection 
of expression plasmids for VDR/RXR and/or Smad proteins 3/4 
profoundly enhanced absolute reporter gene activity (fig. 5). In cells 
cotransfected with VDR/RXR, addition of TGFb or 1,25(OH)2D3 
upregulated reporter gene activity  and both ligands displayed a 
synergistic effect. In cells cotransfected with Smads only TGFb 
enhanced reporter gene activity whereas 1,25(OH)2D3 was without 
effect. In cells cotransfected with Smads and VDR/RXR, reporter 
gene activity was higher than in the cells transfected with either 
Smads or VDR/RXR alone. As expected, addition of either 
1,25(OH)2D3 or TGFb increased reporter gene activity and 
combination of both agents had a synergistic effect (fig. 5). 
Interestingly, coexpression of Smads and VDR/RXR increased 
reporter gene activity by 12.6-fold, whereas the ligand-mediated 
inductions by 1,25(OH)2D3 or TGFb and the combination of both 
agents were 2.4-, 2.6- and 5.9-fold, respectively, suggesting a 
remarkable constitutive activity of Smads and VDR/RXR, 
respectively. 
FIG. 5. Simultaneous cotransfection of VDR/RXR and Smads3/4 in 
transiently transfected HeLa cells.  The 5 -LO promoter reporter gene 
construct pN10-cdsInJM was transiently transfected into HeLa cells with or 
without the expression vectors pSG5-hVDR/pSG5-hRXR and 
pCGN-Smad3/-Smad4. Before transfection, cells were preincubated with 
TGFb (1 ng/ml) for 24 h. 16 h after transfection, 1,25(OH)2D3 (50 nM) and 
TGFb (1 ng/ml) were added for another 8  h. Reporter gene activity was 
measured 24 h after transfection. Each experiment was performed in 
triplicates. Results are presented as mean – SE of at least three independent 
experiments and were normalized for transfection efficiency by 
cotransfection of pCMV-SEAP. 
 
    Identification of sequence elements with significance for Smad 
signalling in 5-LO gene regulation. In order to identify sequences 
in the coding region and introns that participate in Smad3/4 and 
TGFâ-mediated enhancement of 5 -LO expression, deletion 
constructs from the vector pN10-cds were cloned and analyzed in 
reporter gene assays. The coding sequence was divided into four 
parts which were deleted. Part A ranges from exon 1 to 4, part B 
from exon 4 to 10, part C from exon 10 to 14 and part D 
corresponds to the end of exon 14. As shown in fig. 6A deletion of 
parts A, B or D reduced Smad3/4-mediated induction of 5 -LO 
expression from 14.7-fold (pN10-cds) to 8.8-, 8.6- and 9.0-fold, 
respectively. A prominent decrease to 3.9-fold was observed, when 
part C was deleted. Comparably, the 5-LO promoter plasmid pN10 
gives a 3.7-fold upregulation of 5-LO gene expression by Smad3/4 
coexpression. Deletion of two or three parts of the coding sequence 
rather decreased the inhibitory effect (fig. 6B). In contrast to the 
Smad3/4 mediated effects, transcriptional activation by TGFâ was 
not affected by the deletion of parts of the coding region 
(figs. 7A+B). 
Sequence analysis revealed the existence of several putative Smad 
binding elements (SBEs) in the 5-LO coding sequence and introns. 
Deletion of a 286 bp sequence in intron M from the vector 
pN10-cdsInJM comprising 4 putative SBEs (fig. 8A) led to a 
construct which is less responsive to coexpression of Smad proteins 
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(pdSBE2 10.4-fold, pN10-cdsInJM 18.4-fold) (fig. 8B), suggesting 
that these SBEs could be involved in the regulation of 5-LO mRNA 
expression by Smads. Again, the TGFâ-mediated upregulation of 
5-LO expression was not altered by the deletion (fig. 8C). 
Furthermore, the two most promising putative TGFâ responsive 
elements (TREs), located in exon 10 and intron J, were deleted from  
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plasmid pN10-cdsInJM (fig. 8A). Deletion of TRE 1 significantly 
reduced the Smad-mediated enhancement of 5-LO expression from 
16.2- to 6.7-fold (fig. 8B), whereas deletion of TRE 2 or of both led 
to no marked changes. The TGFâ-mediated transcriptional 
activation of 5-LO was not affected by either deletion (fig. 8C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIG. 6. Effects of Smads3/4 on the transcriptional activity of coding sequence deletion plasmids in transiently transfected HeLa cells. pN10-cds 
deletion constructs (A. Single deletions, B. double/triple deletions) were transiently transfected into HeLa cells with or without the expression vectors 
pCGN-Smad3 and pCGN-Smad4. Reporter gene activity was measured 24 h after transfection. Each experiment was performed in triplicates. Results are 
presented as mean – SE of at least three independent experiments and were normalized for transfection efficiency by cotransfection of pCMV-SEAP. 
Inductions are expressed with respect to pCMV-cotransfected cells. 
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FIG. 7. Effect of TGFb b on the transcriptional activity of coding sequence deletion plasmids in transiently transfected HeLa cells. pN10-cds deletion 
constructs (A. Single deletions, B. double/triple deletions) were transiently transfected into HeLa cells together with the expression vectors pCGN-Smad3 and 
pCGN-Smad4. Before transfection cells were preincubated with TGFb (1 ng/ml) for 24 h. 16 h after transfection, TGFb (1 ng/ml) was added for another 8 h 
before luciferase activity was measured. Each experiment was performed in triplicates. Results are presented as mean – SE of at least three independent 
experiments and were normalized for transfection efficiency by cotransfection of pCMV-SEAP. Inductions are expressed with respect to uninduced reporter 
activity.   5
 
 
 
 
 
 
FIG. 8. Influence of deletion of four putative SBEs and two putative TREs on TGFb b- and Smad3/4- mediated 5-LO upregulation. A) Schematic 
presentation of the mutated plasmid constructs. Deletion of a 286 bp fragment in intron M, containing four putative SBEs yielded pdSBE2. Two putative 
TREs, located in exon 10 and intron J were deleted from the plasmid pN10-cdsInJM in pTGFRE1  and pTGFRE2, respectively. B) Effects of Smad 
coexpression. HeLa cells were transiently transfected with the indicated plasmids together with or without the expression vectors pCGN-Smad3 and 
pCGN-Smad4. C) Effects of TGFb. Cells were preincubated with or without TGFb (1 ng/ml) for 24 h. 16 h after transfection, TGFb (1 ng/ml) was added for 
another 8 h, before luciferase activity was measured. Each experiment was performed in triplicates. Results are presented as mean – SE of at least three 
independent experiments. Luciferase activity was normalized for transfection efficiency by cotransfection of pCMV-SEAP and determination of SEAP 
activity. 
 
 
DISCUSSION 
    Previous reports have established a prominent role for 
1,25(OH)2D3 and TGFb in the upregulation of 5 -LO gene 
expression in myeloid cells during maturation [7, 8]. It was found 
that the about 40- to 60-fold induction of 5-LO mRNA in Mono 
Mac 6 cells cultured with TGFb and 1,25(OH)2D3 was due to both 
increased 5-LO gene transcription (about 5-fold) and to stimulated 
transcript elongation and maturation  [16]. Both TGFb and 
1,25(OH)2D3 were required for these effects. 
    In this study we further investigated the role of TGFb and Smad 
signalling on 5 -LO gene regulation. Having in mind that Smads 
have been identified as downstream effectors in  TGFb signalling 
(for review, see  [17]), cotransfection studies with the receptor-
regulated Smad3 and the cooperating Smad4 were performed. We 
found that coexpression of Smads strongly enhanced reporter gene 
activity in reporter gene constructs containing the 5 -LO coding 
sequence. Interestingly, this effect did not depend on the 5 -LO 
promoter and was also observed with the respective pGL3-basic and 
pGL3-promoter plasmids pGL3-ba-cdsInJM and pGL3-prom-
cdsInJM. 
    Furthermore, the strong coding sequence-dependent induction of 
reporter gene activity  was only observed with Smads but not with 
TGFb as stimulus, indicating that this effect mainly depends on 
Smads but not on TGFb signalling in general. 
Deletion of exon 10 to exon 14 (part C) of the 5 -LO coding 
sequence abolished the Smad effect suggesting that this part 
contains essential response elements required for Smad signalling. 
Deletion of other parts of the coding sequence also reduced 
inducibility by Smad3/4 which points to the existence of additional 
response elements in the other parts of the coding sequence. 
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    In silico analysis of the 5-LO gene revealed putative SBEs within 
the promoter as well as in the 3’-UTR, the coding region and in 
particular in the region from exon 10 to 14. Interestingly, deletion 
of a Smad consensus sequence in exon 10 strongly reduced 
response to Smad3/4 coexpression. Additionally, reduction of the 
Smad effects was also observed when a short DNA stretch within 
intron M was deleted that contains 4 putative Smad binding 
elements suggesting that these elements could be involved in the 
regulation of 5 -LO expression by the TGFb/Smad pathway. 
Interestingly, coexpression of Smads did not significantly alter the 
response to TGFb (figs. 4, 7A+B, 8C) and deletion of various parts 
of the coding sequence did not significantly change the effects of 
TGFb￿on reporter gene activity. Furthermore, compared to Smads, 
the TGFb-mediated effect is rather low and does not differ between 
the different plasmids and related deletion constructs in the reporter 
gene assys.  The data suggest, that at least under the experimental 
conditions of the reporter gene assays, the cellular availability and 
maybe the nuclear localization of Smad proteins seems to be the 
limiting and critical parameter in the upregulation of  reporter gene 
activity. 
    As found before for the regulation of cellular 5 -LO mRNA 
expression in the human monocytic cell line Mono Mac 6, there is a 
synergistic effect between TGFb/Smad and vitamin D signalling 
(fig. 5). Thus, the highest reporter gene activity was obtained when 
VDR/RXR and Smads  were cotransfected and when TGFb and 
1,25(OH)2D3 were added. Interaction between the TGFb and 
1,25(OH)2D3 signalling pathways has been described. The VDR has 
been shown to physically and functionally interact with Smad3 and 
Smad7 in vitro and in vivo [18-20]. The affinity of Smads to SBEs 
is rather weak. Hence, probably additional DNA contacts via 
binding partners such as the VDR are required  [17].  In another 
publication, multiple mechanisms responsible for 
TGFb/1,25(OH)2D3 crosstalk have been reported: ligand-binding to 
the VDR induces TGFb mRNA expression, the VDR enhances 
TGFb receptor II expression in certain cell types, Smad3 activates 
the VDR and the crosstalk is dependent on the PI3-kinase pathway 
[18]. Our experiments suggest that 5-LO is another example for a 
gene where Smads and the VDR interact and activate transcription 
in concert. 
    In summary, our results provide evidence for the participation of 
the Smad signalling pathway in 5-LO gene regulation. Furthermore, 
we could demonstrate the involvement of the coding sequence in 
Smad signalling and identified several Smad binding elements 
located in exon 10 and intron M that seem to be relevant for the 
regulation of 5-LO expression by Smads. Further experiments will 
be required to prove binding of Smads to these sites. 
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 Introduction
5-Lipoxygenase (5-LO) catalyzes the conversion of
arachidonic acid to leukotriene A4 [(5S)-6-oxido-7,9,11,
trans-14-cis-eicosatetraenoic acid] which can be further
converted to the biologically active leukotrienes that are
mediators of inflammatory and allergic reactions
(Samuelsson et al., 1987; Ford-Hutchinson et al., 1994).
5-LO expression occurs in a tissue- and cell-specific
manner; a variety of immunecompetent cells including B
lymphocytes, granulocytes, monocytes, mast cells and
dendritic cells prominently express the 5-LO gene (Stein-
hilber, 1999).
Previous studies of the 5-LO promoter suggested that
the transcription factors Egr-1 and/or Sp1 are required for
basal transcription, and that they functionally interact with
the 5-LO promoter and activate it via repeated response
elements located between positions –147 and –23bp rel-
ative to the transcriptional start site (Hoshiko et al., 1990;
Silverman et al., 1998). Interestingly, naturally occurring
mutations were found in the 5-LO promoter consisting of
the deletion of one or two, or the addition of one Sp1-
binding site (In et al., 1997). These mutations only slightly
alter 5-LO promoter activity in reporter gene assays but
have a significant impact on the response of asthma pa-
tients to 5-LO inhibitors (Drazenetal., 1999). Recently, we
could show that the 5-LO promoter is regulated by DNA
methylation, and methylation of CpG sites within the 5-LO
promoter strongly reduces its activity (Uhl et al., 2002).
Since recent publications suggest a link between DNA
methylation and histone acetylation, it was of interest to
investigate whether changes in histone acetylation affect
5-LO promoter activity. The histone acetylation status is
regulated by the equilibrium of histone acetyltransferase
(HAT) and histone deacetylase activity (HDAC). Acetyla-
tion of the N-terminal region of the core histones by HATs
alters nucleosome and higher order chromatin structure,
facilitating transcriptional elongation and the binding of
transcription factors to nucleosomes associated with reg-
ulatory DNA sequences (Davie, 1997). Recently, it was
shown for 15-LO that its expression is increased by HDAC
inhibitors (Kamitani et al., 2001). In this study, the effects
of HDAC inhibitors like trichostatin A (TsA) were investi-
gated on cellular 5-LO mRNA expression in Mono Mac 6
cells and on 5-LO promoter activity after transient trans-
fection of several 5-LO promoter luciferase reporter gene
constructs into HeLa and Mono Mac 6 cells and subse-
quent determination of luciferase activity. 5-LO promoter-
reporter gene constructs with or without the five tandem-
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5-Lipoxygenase (5-LO) mRNA expression in Mono
Mac 6 cells is induced by the histone deacetylase in-
hibitor trichostatin A (TsA). In order to study the ef-
fects of TsA and several structurally related com-
pounds such as MD85, D237 and M232 on 5-LO
promoter activity, we have analyzed the response of a
5-lipoxygenase (5-LO) promoter luciferase reporter
gene construct to histone deacetylase inhibitors in
transiently transfected Mono Mac 6 and HeLa cells.
We show that the activity of 5-LO promoter con-
structs comprising the sequences –778 to +53 and of
several successive deletions of the 5-LO promoter is
strongly increased upon TsA treatment. The data sug-
gest a significant involvement of histone deacety-
lases in the regulation of 5-LO gene transcription. The
basal activity of the 5-LO promoter strongly depends
on the presence of multiple Sp1-binding sites (GC-
boxes), five of which are positioned in tandem. Dele-
tion of the five tandemized GC-boxes in the 5-LO re-
porter gene construct revealed that the induction of
5-LO promoter activity by TsA seems to be independ-
ent of these GC-boxes. Methylation of 5-LO reporter
gene constructs by M.HpaII reduced 5-LO promoter
activity but did not prevent induction of promoter ac-
tivity by TsA, although the activated reporter gene ac-
tivities were lower compared to the unmethylated
plasmid, indicating the dominance of methylation
over TsA-sensitive histone deacetylation in silencing
of the 5-LO gene. The structure-activity data obtained
for histone deacetylase inhibitors suggest that this
assay system might serve as a cellular screening tool
for the development of HDAC inhibitors.
Key words: DNA methylation/Histone deacetylase/
5-Lipoxygenase/Mono Mac 6 cells/Trichostatin A.
Trichostatin A and Structurally Related Histone
Deacetylase Inhibitors Induce 5-Lipoxygenase
Promoter Activityized Sp1 binding sites were used for this study since re-
cent studies indicated the involvement of multiple Sp1
binding sites in the transcriptional activation of other
genes like Gα 12 and WAF/Cip1 by HDAC inhibitors like
sodium butyrate, trichostatin A or HC toxin (Nakanoetal.,
1997; Yang et al., 2001).
Previously, transforming growth factor β (TGFβ ) and
1,25-dihydroxyvitamin D3 [1,25(OH)2D3] have been identi-
fied as strong inducers of 5-LO gene expression in the
myeloid cell lines HL-60 and Mono Mac 6 (Brungs et al.,
1994, 1995; Härle et al., 1998, 1999). Participation of his-
tone acetylation in gene regulation by steroid hormones
has become increasingly evident (Beato et al., 1996) and
TsA has been shown to synergistically enhance cell dif-
ferentiation by 1,25(OH)2D3 and retinoic acid (Kosugi
et al., 1999). Therefore, it was of interest to study effects
of the vitamin D receptor (VDR) and its interacting partner,
the retinoid X receptor (RXR), on 5-LO promoter activity in
the presence or absence of the ligand 1,25(OH)2D3 and
TGFβ in combination with TsA. 
Finally, we present a series of inhibitors of HDAC.
These compounds were synthesized recently (Jung et al.,
1999) and are structurally related to the potent inhibitors
trapoxin B and trichostatin A. We investigated structure-
activity relationships (SARs) of several analogs for inhibi-
tion of HDAC in order to check whether the induction of
5-LO promoter activity by HDAC inhibitors may serve as
a cellular screening system for potential inhibitors of his-
tone deacetylase.
Results
TSA Induces 5-LO mRNA Expression in 
Mono Mac 6 Cells
In order to study the effects of TsA on 5-LO mRNA ex-
pression, Mono Mac 6 cells were cultured with TsA
(330 nM) and/or TGFβ (1 ng/ml) and 1,25(OH)2D3 (50 nM)
for 24 h. The cells were harvested, total RNA was ex-
tracted and reverse transcribed into cDNA. 5-LO and β -
actin expression was analyzed by PCR employing 28 and
24 cycles, respectively (Brungs et al., 1995). TsA alone
lead to an about 11-fold increase in 5-LO mRNA expres-
sion, whereas induction by 1,25(OH)2D3/TGFβ was 43-
fold (compare Brungs et al., 1995) (Figure 1). Interesting-
ly, combination of TsA with 1,25(OH)2D3/TGFβ did not
increase the effect of 1,25(OH)2D3/TGFβ but rather inhib-
ited (62%) the effect of both agents and lead to a 16-fold
increase in 5-LO mRNA compared to the control. Thus,
TsA alone strongly increases 5-LO mRNA expression in
Mono Mac 6 cells but does not enhance the induction of
5-LO mRNA expression by 1,25(OH)2D3/TGFβ . 
TsA Strongly Induces 5-LO Promoter Activity in
Transiently Transfected Mono Mac 6 and HeLa cells
To determine the effects of histone acetylation on trans-
activation of the 5-LO gene promoter, TsA, a potent in-
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Fig. 1 Induction of 5-LO mRNA Expression in Mono Mac 6
Cells. 
Cells were cultured for 24 h in the presence or absence of TsA
(330 nM), TGFβ (1 ng/ml) and 1,25(OH)2D3 (50 nM). Cells were
then harvested and total RNA was extracted (Chomczynski and
Sacchi, 1987), transcribed into cDNA and analyzed by PCR as
described (Brungs et al., 1995). Twenty-four and 28 PCR cycles
were used for β -actin and 5-LO amplification, respectively.
Fig. 2 Induction of 5-LO Promoter Reporter Gene Transcrip-
tion by TsA. 
Mono Mac 6 cells (A) and HeLa cells (B) were transfected with
the 5-LO promoter luciferase reporter gene construct pN10 and
the expression vectors pSG5hRXR and pSG5hVDR by electro-
poration and lipofection, respectively. 1,25(OH)2D3 (50 nM), TGFβ
(1 ng/ml) and TsA (330 nM) were added immediately after trans-
fection as indicated. After 6 h (Mono Mac 6) and 24 h (HeLa),
cells were harvested and luciferase activity was determined. Re-
sults are presented as mean values ± SEM of triplicate transfec-
tions. Results were normalized for transfection efficiency by co-
transfection of pCMVSEAP.hibitor of histone deacetylases, was added to Mono Mac
6 and HeLa cells immediately after transfection with the
5-LO promoter/luciferase reporter construct pN10 (com-
prising the sequence –778 bp to +53 bp relative to the
transcriptional start site) or with the pGL3Basic reporter
plasmid, which lacks the promoter region as a negative
control. When the expression vectors for the receptors
VDR and RXR were cotransfected, TsA (330 nM) strongly
potentiated 5-LO promoter-driven transcription 11-fold
in HeLa cells, and 8-fold in Mono Mac 6 cells (Figure 2). In
the absence of the receptor expression vectors, TsA
(330 nM) induced the 5-LO promoter activity by 25- and
5-fold in HeLa and Mono Mac 6 cells, respectively (data
not shown). Transcription from the promoterless
pGL3Basic vector was unaffected by TsA in HeLa and
Mono Mac 6 cell lines.
5-LO Promoter Activity Is Independent of
1,25(OH)2D3/TGF  in Reporter Gene Assays
No increase in 5-LO promoter activity could be seen for
any construct in reporter gene assays in response to
1,25(OH)2D3 and TGFβ in Mono Mac 6 and HeLa cells,
both with or without TsA and in the presence (Figure 2) or
absence (data not shown) of the expression vectors for
VDR/RXR.
Interestingly, when the p(DR3)4tkluc plasmid contain-
ing a 4-times concatemerized VDRE in front of the thymi-
dine kinase promoter was transfected together with VDR
and RXR, transcription from this plasmid increased up to
34-fold (Mono Mac 6) and 8-fold (HeLa) after addition of
TGFβ and 1,25(OH)2D3. In the absence of the receptor ex-
pression vectors for VDR/RXR, induction of reporter gene
activity by 1,25(OH)2D3 and TGFβ was only 2.3-fold in
Mono Mac 6 cells and 1.6-fold in HeLa cells (data not
shown) which indicates the requirement of coexpression
of both receptors in order to observe strong vitamin D ef-
fects under the experimental conditions of our reporter
gene assays.
Interestingly, TsA (330 nM) potentiated the effects of
1,25(OH)2D3/TGFβ on transcription from p(DR3)4tkluc
(Figure 3). Compared to the untreated control, addition
of TsA to HeLa cells led to a 5.5-fold induction of pro-
moter activity and the combination of TsA with
1,25(OH)2D3/TGFβ resulted in a 73-fold increase which
was 12-fold higher than the promoter activity obtained
with TsA alone.
TsA-Mediated Induction of 5-LO Promoter Activity
Does Not Depend on the Five Tandemized GC-Boxes
In order to determine whether the induction of 5-LO pro-
moter activity by TsA is dependent on the presence of
the GC-rich region required for basal transcription (Uhl
et al., 2002), the constructs pN10 (comprising the region
–778 bp to +53 bp containing five Sp1 sites in tandem,
termed GC-boxes) and the deletion constructs pN11-16
(Figure 4B) were transfected into HeLa cells and lu-
ciferase activity was determined. Induction of reporter
gene activity by TsA was observed with plasmids pN10
to pN13, thus indicating an effect that seems to be in-
dependent of the GC-boxes since pN13 lacks the five
tandemized GC-boxes. In HeLa cells, transcription from
pGC0 that also lacks the GC box sequences from
–111 bp to –78 bp was also induced 3.5-fold compared
to the untreated control (data not shown). Further dele-
tion of the 5-LO promoter (pN14, pN15, pN16) led to the
loss of TsA inducibility. This could be due to the lack of
a functional promoter which is in agreement with the
very low transcriptional activity of these plasmids. In
contrast, the absolute transcriptional activity of the con-
struct pN13, containing sequences –78 bp to +53 bp
and lacking the five Sp1 binding sites, was still 15-fold
and 60-fold higher than the activity of the promoterless
vector (pGL3Basic) in HeLa and Mono Mac 6 cells, re-
spectively.
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Fig. 3 Effects of TsA and 1,25(OH)2D3/TGFβ on the Transcrip-
tional Activity of p(DR3)4tkluc. 
(A) HeLa cells were transfected with p(DR3)4tkluc and the ex-
pression vectors pSG5hRXR and pSG5hVDR by lipofection. Af-
ter transfection, TsA (330 nM), 1,25(OH)2D3 and TGFβ (50 nM and
1 ng/ml, respectively) were added as indicated and reporter
gene activity was determined after 24 h. Results are presented
as mean ± SEM of triplicate transfections, and were normalized
for transfection efficiency by cotransfection of pCMVSEAP.
(B) Schematic representation of the luciferase reporter gene
construct p(DR3)4tkluc with the direct repeat type (DR3) vitamin
D response element (VDRE) of the rANF promoter in front of a
thymidine kinase promoter.DNA Methylation Dominates over Histone
Acetylation in the Regulation of 5-LO Promoter
Activity
Next, we performed transient transfection experiments
using in vitro methylated plasmid DNA (pDNA). pDNA of
the construct pN10 was methylated in vitro at CCGG
residues by HpaII methyltransferase (MTase), purified
and transfected into HeLa cells by lipofection. HpaII
MTase methylates the sites –453 bp, –75 bp, –56 bp,
–45 bp, –39 bp and +35 bp in relation to the 5-LO tran-
scriptional start site, but does not methylate the GC-box-
es in the 5-LO promoter. Methylation decreased the tran-
scriptional activity of the 5-LO promoter reporter gene
construct pN10 3.8-fold (Figure 5A), whereas a CMV pro-
moter-driven luciferase reporter gene construct or the
promoterless vector pGL3Basic were not affected (Fig-
ure 5B). Inhibition of 5-LO promoter activity by methyla-
tion was lower (1.7-fold) in the presence of TsA (330 nM).
Thus, with the unmethylated plasmid, TsA gave a 12-fold
induction of promoter activity, whereas a 27-fold increase
by TsA was observed when the plasmid is methylated
(Figure 5A). Furthermore, no effect of 1,25(OH)2D3/TGFβ
was observed under the indicated assay conditions.
These data suggest that TsA treatment partially reversed
methylation-dependent suppression of 5-LO promoter
activity.
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Fig. 4 Effect of Deletion of the Five Tandemized GC-Boxes on
the Induction of 5-LO Promoter Activity by TsA. 
(A) HeLa cells were transfected by the calcium phosphate pre-
cipitation method with the indicated promoter luciferase reporter
gene constructs together with receptor expression vectors
pSG5hRXR and pSG5hVDR. Immediately after transfection, TsA
was added and the cells were incubated for 24 h prior to analy-
sis of luciferase activity. Luciferase activity was normalized to
transfection efficiency and is presented as the relative increase
in promoter activity induced by TsA. The activity obtained in the
absence of TsA was set to 1. Results are presented as mean ±
SEM of triplicate transfections. 
(B) Schematic representation of the 5-LO promoter luciferase re-
porter gene constructs.
Fig. 5 Effect of CpG Methylation on 5-LO Promoter Activity. 
(A) HeLa cells were transiently transfected with the 5-LO pro-
moter luciferase reporter gene construct pN10, which was in vit-
ro methylated by M.HpaII or mock methylated. After transfec-
tion, cells were grown for 24 h with or without TGFβ (1 ng/ml) and
1,25(OH)2D3 (50 nM).
(B) Effects of CpG methylation on pGL3Basic and pCMVluc re-
porter gene activity. Results are given as luciferase activity nor-
malized to SEAP activity (mean ± SEM of at least three experi-
ments).Evaluation of TsA Analogs 
Finally, our transient transfection system was used for the
evaluation of TsA analogs and structurally related com-
pounds without HDAC inhibitory activity (Hoffmann et al.,
2000). A pharmacophore for inhibitors of HDAC has been
postulated, which is related to structural elements of the
potent inhibitor TsA (Figure 6). Hydroxamic acids, such as
TsA and the analogs MD85, D237 and M232, are potent
HDAC inhibitors (Jung, 1997, 2001; Jung et al., 1999;
Remiszewskietal., 2002). Since we found that TsA strong-
ly induces 5-LO promoter reporter gene transcription, we
wanted to use this assay to investigate the effects of these
analogs. HeLa cells were transiently transfected with the
5-LO promoter luciferase reporter gene construct pN10 by
lipofection and the cells were grown for 24 h with the indi-
cated concentrations of the test compounds (Figure 7).
TsA, D237, MD85 and M232 showed prominent induc-
tion of transcriptional activity of pN10 in HeLa cells (Fig-
ure 7), whereas the compounds MD83A, M293 and M309
were inactive at 2.2 µM, 2 µM and 2.2 µM, respectively.
TsA-mediated induction of pN10 luciferase reporter gene
expression in HeLa cells was independent of the pDNA
amount in the range of 0.1–10 µg (data not shown). In
order to obtain EC50 values, HeLa cells transiently trans-
fected with pN10 were incubated with the indicated con-
centrations of HDAC inhibitors (Figure 7). We found EC50
values of 37nMfor TsA and of 2.9, 5.0 and 0.3µMfor com-
pounds M232, MD85 and D237, respectively. The ob-
tained EC50 values (Figure 7) are in agreement with previ-
ous results in other assay systems (Table 1; Jung et al.,
1999; Hoffmann et al., 2000; Remiszewski et al., 2002). 
Thus, inhibition of HDAC activity and induction of 5-LO
promoter activity depends on the presence of the hy-
droxamic acid group and the length of the spacer be-
tween the hydroxamic acid group and the second amide
bond with maximal activity at five and six methylene
groups (compound MD85 and compounds M232 and
D237, respectively; see Figure 6). The activity decreases
drastically when the spacer becomes shorter than four
methylene groups (M309), which is in agreement with
previous results (Jung et al., 1999). MD83a, the corre-
sponding carboxylic acid derivative to MD85, was com-
pletely inactive. 
Discussion
Analysis of the sequences immediately upstream from
the transcription initiation site of 5-LO showed no TATAA
or CCAAT boxes but repeated G+C-rich elements, such
as repeated Sp1 and Egr-1 transcription factor binding
sites located between positions –147 bp and –23 bp rel-
ative to the transcriptional start site. Previous data sug-
gested that this part of the promoter, which binds the
transcription factors Egr-1 and/or Sp1, is required for
basal 5-LO transcription (Hoshiko et al., 1990; Zhang
et al., 1994; In et al., 1997; Silverman et al., 1998; Silver-
man and Drazen, 2000). In this study, we wanted to in-
vestigate possible interactions between histone acetyla-
tion, DNA methylation and 1,25(OH)2D3/TGFβ signalling
in the regulation of 5-LO gene transcription.
In agreement to previous observations in nuclear run
on assays (Härle et al., 1999), no 1,25(OH)2D3/TGFβ -
dependent induction of 5-LO promoter activity was
observed in reporter gene assays in HeLa and Mono
Mac 6 cells, with or without cotransfection of expression
vectors for the human receptors VDR and RXR. In con-
trast, in control experiments we detected a strong in-
duction of the rANF type vitamin D response element
(VDRE)-containing reporter gene construct p(DR3)4tkluc
by 1,25(OH)2D3/TGFβ that depended on the coexpres-
sion of VDR and RXR (Figure 3), indicating that our assay
systems are suitable to detect transcriptional activation
by these agents. These results suggest that induction of
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Fig. 6 Structures of HDAC Inhibitors.
Fig. 7 Induction of 5-LO Promoter Activity by TsA Analogs. 
Concentration-dependent induction of pN10 luciferase reporter
gene transcription was determined in transiently transfected
HeLa cells after treatment of the cells with the indicated test
compounds for 24 h. Results are given as mean ± SEM of at
least three experiments.5-LO gene expression by 1,25(OH)2D3/TGFβ does not oc-
cur at the transcriptional level. This conclusion is in
agreement with previous data from nuclear run-on as-
says and RT-PCR analyses (Härle et al., 1998, 1999). 
Addition of TsA to Mono Mac 6 cells induced 5-LO ex-
pression, and similar results were obtained in reporter
gene assays with the 5-LO promoter. In the absence of
1,25(OH)2D3/TGFβ , TsA increased transcription of the 5-
LO reporter gene in HeLa and Mono Mac 6 cells with or
without the coexpression of the receptors VDR and RXR
(Figure2). Thus, the TsA-dependent increase in 5-LO pro-
moter activity was independent of the presence of
1,25(OH)2D3/TGFβ and VDR/RXR coexpression.
In the case of the p(DR3)4tkluc construct, the
1,25(OH)2D3/TGFβ -dependent induction of reporter gene
transcription was potentiated by TsA, indicating a syner-
gistic mechanism of vitamin D signal transduction and hi-
stone deacetylation (Figure 3), which is in agreement with
previous observations made with other targets (Yanagi
et al., 1999; Massagué and Wotton, 2000; Rachez and
Freedman, 2000). However, TsA induction of 5-LO pro-
moter activity seems to be independent of VDR signaling.
Recent data obtained with human myeloid cell lines
show that the basal 5-LO promoter activity is silenced by
DNA methylation within the CpG-rich core promoter re-
gion (Uhl et al., 2002). Furthermore, in the 5-LO negative
myeloid cell lines U937 and HL-60 TB, 5-LO promoter
demethylation is required in order to achieve high cellular
induction of 5-LO expression by 1,25(OH)2D3/TGFβ .
Since methylated CpG sites are recognized by a variety
of methyl-CpG-binding proteins that are associated ei-
ther directly or indirectly with histone deacetylases
(Ballestar and Wolffe, 2001), chromatin condensation
could be one regulatory mechanism of 5-LO gene tran-
scription (Pontonetal., 1996; Ngetal., 1999; Rice and Al-
lis, 2001; Singal et al., 2001). It has been shown that tran-
scription from Sp1-driven promoters can be repressed
by a tight association of the transcription factor Sp1 with
histone deacetylase 1 in a multiprotein complex (Doetzl-
hofer et al., 1999). However, with respect to 5-LO it is ob-
vious that inhibition of HDACs by TsA and the subse-
quent induction of 5-LO promoter transcription does not
depend on the presence of the five tandemized Sp1 and
Egr-1 sites of the 5-LO proximal core promoter region,
which were found to be essential for basal transcription in
previous studies (Uhl et al., 2002). These results suggest
that there are binding sites for transcription factors out-
side of the five tandemized GC-boxes which can recruit
histone deacetylases to the 5-LO promoter.
Interestingly, in vitro methylation of the 5-LO promoter
reporter gene construct by M.HpaII led to a prominent
decrease in transcriptional activity, although the multiple
CpG sites within the five tandemized GC-boxes are not
methylated. In our transfection experiments, TsA treat-
ment reduced methylation-dependent repression, indi-
cating that recruitment of histone deacetylases could be
involved. In addition, histone deacetylase-independent
mechanisms of repression seem also to play a role, since
the presence of TsA could not completely prevent the
methylation-dependent repression. Thus, our data indi-
cate the dominance of methylation versus TsA-sensitive
histone deacetylation in silencing the 5-LO promoter, re-
sulting in a trichostatin A-resistant repression (Boeke
et al., 2000; Yu et al., 2000). This is similar to other reports
which showed that transcriptionally silenced genes in
cancer cell lines can be partially reactivated in the pres-
ence of a DNA methyltransferase inhibitor, but complete
reactivation was not achieved (Singal and Ginder, 1999;
Rice and Allis, 2001).
Taken together, our results support an active role of
HDAC in transcriptional regulation of the 5-LO gene.
Moreover, for the 1,25(OH)2D3-inducible p(DR3)tkluc con-
struct it was found that TsA and 1,25(OH)2D3 are able to
synergistically increase reporter gene activity in transient
reporter gene assays.
The results obtained with the TsA analogs in our tran-
sient transfection experiments with the 5-LO promoter
reporter gene in HeLa cells are similar to previously re-
ported potencies of these histone deacetylase inhibitors
obtained with other assay systems. We could confirm a
clear dependence of the inhibitory activity on the spacer
length with maximal inhibition at 5–6 methylene groups,
which points to a competition with an acetyl-lysine. The
strong difference between hydroxamates and the car-
boxylates can be explained by differences in affinity for
the zinc ion at the active site of histone deacetylases
(Finnin et al., 1999). The inhibitors of HDAC presented
here were previously shown to induce histone hyper-
acetylation in leukemic cells, which correlated with their
ability to induce terminal cell differentiaton (Jung et al.,
1999). Since the obtained EC50 values in this model are in
agreement with the extent of HDAC inhibition found in
other in vitro systems, our assay may be a useful tool for
the prediction of the potency of HDAC inhibitors.
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Table 1 EC50 and IC50 Values of TsA and TsA Analogs in Different Assays.
Compound Rat liver HDAC and  Rat liver HDAC and  P21 promoter  5-LO promoter 
fluorescent substrate  labeled histones  induction assay transcription assay
(Hoffmann et al., 2000) (Hoffmann et al., 2000) (Remiszewski et al., 2002)
TsA 0.0133±0.001 µM 0.022±0.002 µM 0.4±0.3 µM 0.038±0.0008 µM
M232 1.0000±0.700 µM 13.400±1.000 µM – 2.900±0.4000 µM
D237 – – 2.1 µM 0.300±0.0400 µM
MD85 0.4800±0.020 µM 1.380±0.040 µM >10µM 5.000±0.2000 µMMaterials and Methods
Materials
Molecular biology reagents were purchased from MBI Fermen-
tas (St. Leon-Rot, Germany), Sigma (Deisenhofen, Germany),
GIBCO (Karlsruhe, Germany), Promega (Mannheim, Germany)
and NEB (Frankfurt, Germany) or other sources as indicated in
the text. Insulin was a gift from Aventis (Frankfurt, Germany). Hu-
man TGFβ 1 was purified from outdated platelets according to
Werz et al. (1996). Nucleospin extract columns for direct purifi-
cation of pDNA were obtained from Macherey-Nagel (Düren,
Germany). The VDRE plasmid p(DR3)4tkluc and the pSG5VDR
and pSG5RXR expression plasmids for the human vitamin D re-
ceptor (VDR) and the human retinoid X receptor α (RXRα ) were
obtained from Dr. Carsten Carlberg (Kuopio, Finland).
Construction of Reporter Plasmids
The 5-LO promoter containing plasmid K1 was digested first by
BstEII. The restriction site was blunted with T4 DNA polymerase
and then digested with KpnI and ligated into the promoterless lu-
ciferase reporter vector pGL3Basic, which was opened with
KpnI and SmaI. The intermediate construct obtained was then
partially digested with Cfr42I, digested with XhoI and blunted
with T4 DNA polymerase before final religation (pN0). pN10 and
pN11 were constructed by digestion of pN0, which contains the
promoter region from +53 bp in relation to the transcription start
(–12 bp from the 5LO translation start) up to position –6079 bp
(–6144 bp from the 5-LO ATG) using the restriction enzymes
KpnI and PauI or Bst XI, respectively. Overhangs were blunted
by T4 DNA polymerase treatment and religated using the T4
DNA ligase. Plasmids pN12-pN16 and pGC0 were obtained by
PCR deletion, using pN10 as the template, the reverse primer
TAT CGA TAG AGA AAT GTT CTG GCA (pN12, pN13, pN14,
pN15 and pN16), the forward primers CGC GTG AAG AGT GGG
AGA GAA GTA CTG CGG (pN12), CAG CCG GGA GCC TGG
AGC CAG ACC (pN13), AGG GAC CAG TGG TGG GAG GAG
GCT (pN14), GCT AGA TGC GGA CAC CTG GAC CGC (pN15)
and GGC TCC CGG CGC TCG CTG CTC (pN16) or the primers
Rapid GC1: CAG CCG GGA GCC TGG AGC CAG ACC and
Rapid GC 2: CCG CAG TAC TTC TCT CCC ACT CTT CAC GCG
(pGC0) and Pfu I DNA polymerase. Following temperature cy-
cling, the products were treated with DpnI, plasmid ends were
phosphorylated with T4 polynucleotide kinase and ligated with
T4 DNA ligase. Plasmid constructs were verified by DNA se-
quencing. 
Cell Culture
Mono Mac 6 cells which were kindly provided by Dr. H.W.L.
Ziegler-Heitbrock (Munich, Germany) were grown at 37°C in a
humified atmosphere with 6% CO2 in RPMI 1640 medium sup-
plemented with 10% (v/v) fetal calf serum (FCS), streptomycin
(100 µg/ml) and penicillin (100 U/ml), 1× nonessential amino
acids, sodium pyruvate (1 mM), oxalacetate (1 mM) and insulin
(10 µg/ml) (Ziegler-Heitbrock et al., 1988). HeLa cells were ob-
tained from Dr. Müller (Pharmacological Institute, Frankfurt, Ger-
many) and grown in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% (v/v) FCS, 100 µg/ml streptomycin and 100
units/ml penicillin.
In vitro DNA Methylation 
Ten µg plasmid DNA were incubated for 24 h at 37°C with HpaII
methyltransferase at 1 unit/µg pDNA in 50 mM Tris-HCl, 10 mM
EDTA, 5 mM 2-mercaptoethanol (pH 7.5), supplemented with
80 µM S-adenosylmethionine in a final volume of 50 µl. For trans-
fections, methylated pDNAs were purified on Nucleospin extract
columns. Complete methylation at CCGG sites was confirmed
by endonuclease HpaII digestion of the plasmids. 
Transfection of Mono Mac 6 Cells
Mono Mac 6 cells (2× 105 cells/ml) were grown for 48 h, harvest-
ed by centrifugation at 1000 g for 5 min at room temperature and
washed twice at room temperature with RPMI-1640 without FCS
and L-glutamine. Then, cells were resuspended at 4.6× 107
cells/ml in RPMI-1640 without supplements, and 0.3 ml of the
cell suspension were placed into a 0.4 cm electroporation cu-
vette (Bio-Rad, Munich, Germany). Forty micrograms of super-
coiled luciferase reporter gene plasmid DNA and 1 µg internal
standard pCMVSEAP in 30 µl water were added to the cell sus-
pension. In cotransfection experiments, 5 µg of the expression
vector pSG5VDR and 5 µg pSG5RXR were added. After 5 min at
room temperature, electroporation was performed at 975 µF and
200 V using a Bio-Rad GenePulser (Klan and Steinhilber, 2003).
The cuvettes were immediately cooled on ice for 20 min. The
cells were transferred into 10 ml of RPMI-1640 containing 10%
FCS, insulin, glutamine and nonessential amino acids.
1,25(OH)2D3 (50 nM) and TGFβ (1 ng/ml) were added immediate-
ly after cell transfer as indicated. Six hours after transfection,
cells were harvested for determination of luciferase activity.
Transfection of HeLa Cells
When HeLa cells were transfected by the calcium phosphate
precipitation method, cells were plated into a 24-well tissue cul-
ture plate at a density of 4× 104 cells per well 24 h before trans-
fection, so that 60–80% of the cells were confluent at the time
of transfection. For the transfection, 0.8 µg plasmid DNA of the
luciferase reporter gene construct, 0.1 µg pSG5RXR, 0.1 µg
pSG5VDR and 0.01 µg internal standard pCMVSEAP were used
per well. The calcium phosphate-DNA coprecipitation was per-
formed by overnight incubation. The medium was changed 16 h
after transfection and the cells were incubated for 24 h with TsA
at 330 nM. Subsequently, cells were harvested, the medium was
exchanged by 100 µl fresh medium and luciferase activity was
determined.
When HeLa cells were transfected by lipofection, cells were
plated into a 24-well tissue culture plate at a density of 6× 104
cells per well for 24 h, so that 60–80% of the cells were conflu-
ent at the time of transfection. Plasmid DNA of the luciferase re-
porter gene construct (0.4 µg) and internal standard pCMVSEAP
(0.01 µg) were diluted into serum free Dulbecco’s modified Eagle
medium and precomplexed with 5 µl of PLUS reagent (GIBCO)
by incubation at room temperature for 15 min. Precomplexed
plasmid DNA was mixed with 25 µl of 1:50 diluted Lipofectin
reagent and incubated for 30 min at room temperature. Then,
the medium was replaced by 200 µl of fresh serum free medium
and the DNA-PLUS-Lipofectin reagent complex was added to
the cells and incubated for 5 h at 37°C in 5% CO2. Then, 1 ml of
medium containing 15% (v/v) FCS was added. Twenty-four h af-
ter transfection, cells were washed once in phosphate-buffered
saline pH 7.4 (PBS) and luciferase activity was determined as
described below. In cotransfection experiments, 0.05 µg of the
expression vector pSG5VDR and 0.05 µg pSG5RXR were in-
cluded. pCMVluc (0.4 µg) was used as positive control.
Luciferase Assays 
Six hours (Mono Mac 6) and 24 h (HeLa) after transfection, cells
were washed once in PBS containing 0.5 mM MgCl2, 0.5 mM
CaCl2 and lysed in 100 µl lysis buffer (Luciferase Reporter Gene
5-Lipoxygenase Promoter and Histone Acetylation 783Assay constant light signal kit, Boehringer Mannheim, Ger-
many). Luciferase activity was determined by monitoring light
emission with a Microlumat Plus LB96V EG&G Berthold lumi-
nometer. Light emission signal was integrated for 5 seconds.
Transfection efficiency was monitored and normalized by co-
transfection with pCMVSEAP using the Phospha-Light™ kit
(Tropix) to determine the secreted placental alkaline phos-
phatase (SEAP) activity.
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